Form **990**

Department of the Treasury
Internal Revenue Service

Return of Organization Exempt From Income Tax

Under section 501(c), 527, or 4947(a)(1) of the Internal Revenue Code (except private foundations)

▶ **Do not enter social security numbers on this form as it may be made public.**

▶ **Go to www.irs.gov/Form990 for instructions and the latest information.**

OMB No. 1545-0047

2021

Open to Public Inspection

A For the 2021 calendar year, or tax year beginning APR 1, 2021 **and ending** MAR 31, 2022

B Check if applicable: Address change; Name change; Initial return; Final return/ terminated; Amended return; Application pending

C Name of organization
BRIGHTFOCUS FOUNDATION

Doing business as

Number and street (or P.O. box if mail is not delivered to street address) 22512 GATEWAY CENTER DRIVE

Room/suite

City or town, state or province, country, and ZIP or foreign postal code
CLARKSBURG, MD 20871

F Name and address of principal officer: STACY PAGOS HALLER
SAME AS C ABOVE

D Employer identification number
23-7337229

E Telephone number
(301) 948-3244

G Gross receipts $ 68,033,506.

H(a) Is this a group return for subordinates? Yes [X] No

H(b) Are all subordinates included? Yes No
If "No," attach a list. See instructions

H(c) Group exemption number ▶

I Tax-exempt status: [X] 501(c)(3) 501(c) ( ) ◀ (insert no.) 4947(a)(1) or 527

J Website: ▶ WWW.BRIGHTFOCUS.ORG

K Form of organization: [X] Corporation Trust Association Other ▶

L Year of formation: 1973 **M** State of legal domicile: DC

Part I Summary

Activities & Governance

1 Briefly describe the organization's mission or most significant activities: BRIGHTFOCUS FOUNDATION (BRIGHTFOCUS) SEEKS A WORLD FREE FROM DISEASES OF MIND AND SIGHT.

2 Check this box ▶ if the organization discontinued its operations or disposed of more than 25% of its net assets.

3	Number of voting members of the governing body (Part VI, line 1a)	3	11
4	Number of independent voting members of the governing body (Part VI, line 1b)	4	11
5	Total number of individuals employed in calendar year 2021 (Part V, line 2a)	5	66
6	Total number of volunteers (estimate if necessary)	6	70
7a	Total unrelated business revenue from Part VIII, column (C), line 12	7a	0.
b	Net unrelated business taxable income from Form 990-T, Part I, line 11	7b	0.

Revenue

		Prior Year	Current Year
8	Contributions and grants (Part VIII, line 1h)	48,502,473.	46,522,410.
9	Program service revenue (Part VIII, line 2g)	0.	0.
10	Investment income (Part VIII, column (A), lines 3, 4, and 7d)	1,768,676.	3,244,235.
11	Other revenue (Part VIII, column (A), lines 5, 6d, 8c, 9c, 10c, and 11e)	975,243.	991,083.
12	Total revenue - add lines 8 through 11 (must equal Part VIII, column (A), line 12)	51,246,392.	50,757,728.

Expenses

13	Grants and similar amounts paid (Part IX, column (A), lines 1-3)	25,256,371.	23,651,211.
14	Benefits paid to or for members (Part IX, column (A), line 4)	0.	0.
15	Salaries, other compensation, employee benefits (Part IX, column (A), lines 5-10)	5,801,548.	5,534,304.
16a	Professional fundraising fees (Part IX, column (A), line 11e)	738,435.	798,203.
b	Total fundraising expenses (Part IX, column (D), line 25) ▶ 9,847,110.		
17	Other expenses (Part IX, column (A), lines 11a-11d, 11f-24e)	20,436,021.	24,073,639.
18	Total expenses. Add lines 13-17 (must equal Part IX, column (A), line 25)	52,232,375.	54,057,357.
19	Revenue less expenses. Subtract line 18 from line 12	-985,983.	-3,299,629.

Net Assets or Fund Balances

		Beginning of Current Year	End of Year
20	Total assets (Part X, line 16)	66,476,749.	65,540,964.
21	Total liabilities (Part X, line 26)	33,442,032.	36,521,089.
22	Net assets or fund balances. Subtract line 21 from line 20	33,034,717.	29,019,875.

Part II Signature Block

Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete. Declaration of preparer (other than officer) is based on all information of which preparer has any knowledge.

Sign Here

Stacy Pagos Haller
Signature of officer — August 4, 2022 Date

STACY PAGOS HALLER, PRESIDENT/CEO
Type or print name and title

Paid Preparer Use Only

Print/Type preparer's name	Preparer's signature	Date	Check if self-employed	PTIN
FRANK H. SMITH	Frank H. Smith	08/04/22		P00639053

Firm's name ▶ MARCUM, LLP — Firm's EIN ▶ 11-1986323

Firm's address ▶ 1899 L STREET, NW, SUITE 850
WASHINGTON, DC 20036 — Phone no. (202) 227-4000

May the IRS discuss this return with the preparer shown above? See instructions [X] Yes No

SEE SCHEDULE O FOR ORGANIZATION MISSION STATEMENT CONTINUATION

Part III Statement of Program Service Accomplishments

Check if Schedule O contains a response or note to any line in this Part III X

1 Briefly describe the organization's mission:
BRIGHTFOCUS FUNDS EXCEPTIONAL SCIENTIFIC RESEARCH WORLDWIDE TO DEFEAT ALZHEIMER'S DISEASE, MACULAR DEGENERATION, AND GLAUCOMA AND PROVIDES EXPERT INFORMATION ON THESE HEARTBREAKING DISEASES. PLEASE REFER TO SCHEDULE O FOR A COMPLETE OVERVIEW OF OUR MISSION.

2 Did the organization undertake any significant program services during the year which were not listed on the prior Form 990 or 990-EZ? ..... Yes X No
If "Yes," describe these new services on Schedule O.

3 Did the organization cease conducting, or make significant changes in how it conducts, any program services? ..... Yes X No
If "Yes," describe these changes on Schedule O.

4 Describe the organization's program service accomplishments for each of its three largest program services, as measured by expenses. Section 501(c)(3) and 501(c)(4) organizations are required to report the amount of grants and allocations to others, the total expenses, and revenue, if any, for each program service reported.

4a (Code:) (Expenses $ 24,808,686. including grants of $ 13,577,827.) (Revenue $)
ALZHEIMER'S DISEASE RESEARCH (ADR)

PLEASE REFER TO SCHEDULE O FOR A COMPLETE DESCRIPTION OF THE ACCOMPLISHMENTS FOR ALZHEIMER'S DISEASE RESEARCH.

4b (Code:) (Expenses $ 10,835,704. including grants of $ 6,533,700.) (Revenue $)
MACULAR DEGENERATION RESEARCH (MDR)

PLEASE REFER TO SCHEDULE O FOR A COMPLETE DESCRIPTION OF THE ACCOMPLISHMENTS FOR MACULAR DEGENERATION RESEARCH.

4c (Code:) (Expenses $ 4,530,788. including grants of $ 3,539,684.) (Revenue $)
NATIONAL GLAUCOMA RESEARCH (NGR)

PLEASE REFER TO SCHEDULE O FOR A COMPLETE DESCRIPTION OF THE ACCOMPLISHMENTS FOR NATIONAL GLAUCOMA RESEARCH.

4d Other program services (Describe on Schedule O.)
(Expenses $ including grants of $) (Revenue $)

4e Total program service expenses ▶ 40,175,178.

SEE SCHEDULE O FOR CONTINUATIONS OF 4A, 4B, & 4C

Part IV Checklist of Required Schedules

			Yes	No
1	Is the organization described in section 501(c)(3) or 4947(a)(1) (other than a private foundation)? *If "Yes," complete Schedule A*	1	X	
2	Is the organization required to complete *Schedule B, Schedule of Contributors*? See instructions	2	X	
3	Did the organization engage in direct or indirect political campaign activities on behalf of or in opposition to candidates for public office? *If "Yes," complete Schedule C, Part I*	3		X
4	**Section 501(c)(3) organizations.** Did the organization engage in lobbying activities, or have a section 501(h) election in effect during the tax year? *If "Yes," complete Schedule C, Part II*	4	X	
5	Is the organization a section 501(c)(4), 501(c)(5), or 501(c)(6) organization that receives membership dues, assessments, or similar amounts as defined in Rev. Proc. 98-19? *If "Yes," complete Schedule C, Part III*	5		X
6	Did the organization maintain any donor advised funds or any similar funds or accounts for which donors have the right to provide advice on the distribution or investment of amounts in such funds or accounts? *If "Yes," complete Schedule D, Part I*	6		X
7	Did the organization receive or hold a conservation easement, including easements to preserve open space, the environment, historic land areas, or historic structures? *If "Yes," complete Schedule D, Part II*	7		X
8	Did the organization maintain collections of works of art, historical treasures, or other similar assets? *If "Yes," complete Schedule D, Part III*	8		X
9	Did the organization report an amount in Part X, line 21, for escrow or custodial account liability, serve as a custodian for amounts not listed in Part X; or provide credit counseling, debt management, credit repair, or debt negotiation services? *If "Yes," complete Schedule D, Part IV*	9		X
10	Did the organization, directly or through a related organization, hold assets in donor-restricted endowments or in quasi endowments? *If "Yes," complete Schedule D, Part V*	10	X	
11	If the organization's answer to any of the following questions is "Yes," then complete Schedule D, Parts VI, VII, VIII, IX, or X, as applicable.			
a	Did the organization report an amount for land, buildings, and equipment in Part X, line 10? *If "Yes," complete Schedule D, Part VI*	11a	X	
b	Did the organization report an amount for investments - other securities in Part X, line 12, that is 5% or more of its total assets reported in Part X, line 16? *If "Yes," complete Schedule D, Part VII*	11b		X
c	Did the organization report an amount for investments - program related in Part X, line 13, that is 5% or more of its total assets reported in Part X, line 16? *If "Yes," complete Schedule D, Part VIII*	11c		X
d	Did the organization report an amount for other assets in Part X, line 15, that is 5% or more of its total assets reported in Part X, line 16? *If "Yes," complete Schedule D, Part IX*	11d		X
e	Did the organization report an amount for other liabilities in Part X, line 25? *If "Yes," complete Schedule D, Part X*	11e	X	
f	Did the organization's separate or consolidated financial statements for the tax year include a footnote that addresses the organization's liability for uncertain tax positions under FIN 48 (ASC 740)? *If "Yes," complete Schedule D, Part X*	11f	X	
12a	Did the organization obtain separate, independent audited financial statements for the tax year? *If "Yes," complete Schedule D, Parts XI and XII*	12a		X
b	Was the organization included in consolidated, independent audited financial statements for the tax year? *If "Yes," and if the organization answered "No" to line 12a, then completing Schedule D, Parts XI and XII is optional*	12b	X	
13	Is the organization a school described in section 170(b)(1)(A)(ii)? *If "Yes," complete Schedule E*	13		X
14a	Did the organization maintain an office, employees, or agents outside of the United States?	14a		X
b	Did the organization have aggregate revenues or expenses of more than $10,000 from grantmaking, fundraising, business, investment, and program service activities outside the United States, or aggregate foreign investments valued at $100,000 or more? *If "Yes," complete Schedule F, Parts I and IV*	14b	X	
15	Did the organization report on Part IX, column (A), line 3, more than $5,000 of grants or other assistance to or for any foreign organization? *If "Yes," complete Schedule F, Parts II and IV*	15	X	
16	Did the organization report on Part IX, column (A), line 3, more than $5,000 of aggregate grants or other assistance to or for foreign individuals? *If "Yes," complete Schedule F, Parts III and IV*	16		X
17	Did the organization report a total of more than $15,000 of expenses for professional fundraising services on Part IX, column (A), lines 6 and 11e? *If "Yes," complete Schedule G, Part I.* See instructions	17	X	
18	Did the organization report more than $15,000 total of fundraising event gross income and contributions on Part VIII, lines 1c and 8a? *If "Yes," complete Schedule G, Part II*	18		X
19	Did the organization report more than $15,000 of gross income from gaming activities on Part VIII, line 9a? *If "Yes," complete Schedule G, Part III*	19		X
20a	Did the organization operate one or more hospital facilities? *If "Yes," complete Schedule H*	20a		X
b	If "Yes" to line 20a, did the organization attach a copy of its audited financial statements to this return?	20b		
21	Did the organization report more than $5,000 of grants or other assistance to any domestic organization or domestic government on Part IX, column (A), line 1? *If "Yes," complete Schedule I, Parts I and II*	21	X	

Part IV Checklist of Required Schedules *(continued)*

			Yes	No
22	Did the organization report more than $5,000 of grants or other assistance to or for domestic individuals on Part IX, column (A), line 2? *If "Yes," complete Schedule I, Parts I and III*	22		X
23	Did the organization answer "Yes" to Part VII, Section A, line 3, 4, or 5, about compensation of the organization's current and former officers, directors, trustees, key employees, and highest compensated employees? *If "Yes," complete Schedule J*	23	X	
24a	Did the organization have a tax-exempt bond issue with an outstanding principal amount of more than $100,000 as of the last day of the year, that was issued after December 31, 2002? *If "Yes," answer lines 24b through 24d and complete Schedule K. If "No," go to line 25a*	24a		X
b	Did the organization invest any proceeds of tax-exempt bonds beyond a temporary period exception?	24b		
c	Did the organization maintain an escrow account other than a refunding escrow at any time during the year to defease any tax-exempt bonds?	24c		
d	Did the organization act as an "on behalf of" issuer for bonds outstanding at any time during the year?	24d		
25a	**Section 501(c)(3), 501(c)(4), and 501(c)(29) organizations.** Did the organization engage in an excess benefit transaction with a disqualified person during the year? *If "Yes," complete Schedule L, Part I*	25a		X
b	Is the organization aware that it engaged in an excess benefit transaction with a disqualified person in a prior year, and that the transaction has not been reported on any of the organization's prior Forms 990 or 990-EZ? *If "Yes," complete Schedule L, Part I*	25b		X
26	Did the organization report any amount on Part X, line 5 or 22, for receivables from or payables to any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or 35% controlled entity or family member of any of these persons? *If "Yes," complete Schedule L, Part II*	26		X
27	Did the organization provide a grant or other assistance to any current or former officer, director, trustee, key employee, creator or founder, substantial contributor or employee thereof, a grant selection committee member, or to a 35% controlled entity (including an employee thereof) or family member of any of these persons? *If "Yes," complete Schedule L, Part III*	27		X
28	Was the organization a party to a business transaction with one of the following parties (see the Schedule L, Part IV, instructions for applicable filing thresholds, conditions, and exceptions):			
a	A current or former officer, director, trustee, key employee, creator or founder, or substantial contributor? *If "Yes," complete Schedule L, Part IV*	28a		X
b	A family member of any individual described in line 28a? *If "Yes," complete Schedule L, Part IV*	28b		X
c	A 35% controlled entity of one or more individuals and/or organizations described in line 28a or 28b? *If "Yes," complete Schedule L, Part IV*	28c		X
29	Did the organization receive more than $25,000 in non-cash contributions? *If "Yes," complete Schedule M*	29	X	
30	Did the organization receive contributions of art, historical treasures, or other similar assets, or qualified conservation contributions? *If "Yes," complete Schedule M*	30		X
31	Did the organization liquidate, terminate, or dissolve and cease operations? *If "Yes," complete Schedule N, Part I*	31		X
32	Did the organization sell, exchange, dispose of, or transfer more than 25% of its net assets? *If "Yes," complete Schedule N, Part II*	32		X
33	Did the organization own 100% of an entity disregarded as separate from the organization under Regulations sections 301.7701-2 and 301.7701-3? *If "Yes," complete Schedule R, Part I*	33	X	
34	Was the organization related to any tax-exempt or taxable entity? *If "Yes," complete Schedule R, Part II, III, or IV, and Part V, line 1*	34		X
35a	Did the organization have a controlled entity within the meaning of section 512(b)(13)?	35a		X
b	If "Yes" to line 35a, did the organization receive any payment from or engage in any transaction with a controlled entity within the meaning of section 512(b)(13)? *If "Yes," complete Schedule R, Part V, line 2*	35b		
36	**Section 501(c)(3) organizations.** Did the organization make any transfers to an exempt non-charitable related organization? *If "Yes," complete Schedule R, Part V, line 2*	36		X
37	Did the organization conduct more than 5% of its activities through an entity that is not a related organization and that is treated as a partnership for federal income tax purposes? *If "Yes," complete Schedule R, Part VI*	37		X
38	Did the organization complete Schedule O and provide explanations on Schedule O for Part VI, lines 11b and 19? **Note:** All Form 990 filers are required to complete Schedule O	38	X	

Part V Statements Regarding Other IRS Filings and Tax Compliance

Check if Schedule O contains a response or note to any line in this Part V ☐

				Yes	No
1a	Enter the number reported in box 3 of Form 1096. Enter -0- if not applicable	1a	176		
b	Enter the number of Forms W-2G included on line 1a. Enter -0- if not applicable	1b	0		
c	Did the organization comply with backup withholding rules for reportable payments to vendors and reportable gaming (gambling) winnings to prize winners?	1c		X	

Part V Statements Regarding Other IRS Filings and Tax Compliance *(continued)*

				Yes	No
2a	Enter the number of employees reported on Form W-3, Transmittal of Wage and Tax Statements, filed for the calendar year ending with or within the year covered by this return	2a	66		
b	If at least one is reported on line 2a, did the organization file all required federal employment tax returns?	2b		X	
	Note: If the sum of lines 1a and 2a is greater than 250, you may be required to *e-file.* See instructions.				
3a	Did the organization have unrelated business gross income of $1,000 or more during the year?	3a			X
b	If "Yes," has it filed a Form 990-T for this year? *If "No" to line 3b, provide an explanation on Schedule O*	3b			
4a	At any time during the calendar year, did the organization have an interest in, or a signature or other authority over, a financial account in a foreign country (such as a bank account, securities account, or other financial account)?	4a			X
b	If "Yes," enter the name of the foreign country ▶ _____ See instructions for filing requirements for FinCEN Form 114, Report of Foreign Bank and Financial Accounts (FBAR).				
5a	Was the organization a party to a prohibited tax shelter transaction at any time during the tax year?	5a			X
b	Did any taxable party notify the organization that it was or is a party to a prohibited tax shelter transaction?	5b			X
c	If "Yes" to line 5a or 5b, did the organization file Form 8886-T?	5c			
6a	Does the organization have annual gross receipts that are normally greater than $100,000, and did the organization solicit any contributions that were not tax deductible as charitable contributions?	6a			X
b	If "Yes," did the organization include with every solicitation an express statement that such contributions or gifts were not tax deductible?	6b			
7	**Organizations that may receive deductible contributions under section 170(c).**				
a	Did the organization receive a payment in excess of $75 made partly as a contribution and partly for goods and services provided to the payor?	7a			X
b	If "Yes," did the organization notify the donor of the value of the goods or services provided?	7b			
c	Did the organization sell, exchange, or otherwise dispose of tangible personal property for which it was required to file Form 8282?	7c		X	
d	If "Yes," indicate the number of Forms 8282 filed during the year	7d	1		
e	Did the organization receive any funds, directly or indirectly, to pay premiums on a personal benefit contract?	7e			X
f	Did the organization, during the year, pay premiums, directly or indirectly, on a personal benefit contract?	7f			X
g	If the organization received a contribution of qualified intellectual property, did the organization file Form 8899 as required?	7g			
h	If the organization received a contribution of cars, boats, airplanes, or other vehicles, did the organization file a Form 1098-C?	7h			
8	**Sponsoring organizations maintaining donor advised funds.** Did a donor advised fund maintained by the sponsoring organization have excess business holdings at any time during the year?	8			
9	**Sponsoring organizations maintaining donor advised funds.**				
a	Did the sponsoring organization make any taxable distributions under section 4966?	9a			
b	Did the sponsoring organization make a distribution to a donor, donor advisor, or related person?	9b			
10	**Section 501(c)(7) organizations.** Enter:				
a	Initiation fees and capital contributions included on Part VIII, line 12	10a			
b	Gross receipts, included on Form 990, Part VIII, line 12, for public use of club facilities	10b			
11	**Section 501(c)(12) organizations.** Enter:				
a	Gross income from members or shareholders	11a			
b	Gross income from other sources. (Do not net amounts due or paid to other sources against amounts due or received from them.)	11b			
12a	**Section 4947(a)(1) non-exempt charitable trusts.** Is the organization filing Form 990 in lieu of Form 1041?	12a			
b	If "Yes," enter the amount of tax-exempt interest received or accrued during the year	12b			
13	**Section 501(c)(29) qualified nonprofit health insurance issuers.**				
a	Is the organization licensed to issue qualified health plans in more than one state?	13a			
	Note: See the instructions for additional information the organization must report on Schedule O.				
b	Enter the amount of reserves the organization is required to maintain by the states in which the organization is licensed to issue qualified health plans	13b			
c	Enter the amount of reserves on hand	13c			
14a	Did the organization receive any payments for indoor tanning services during the tax year?	14a			X
b	If "Yes," has it filed a Form 720 to report these payments? *If "No," provide an explanation on Schedule O*	14b			
15	Is the organization subject to the section 4960 tax on payment(s) of more than $1,000,000 in remuneration or excess parachute payment(s) during the year? If "Yes," see the instructions and file Form 4720, Schedule N.	15			X
16	Is the organization an educational institution subject to the section 4968 excise tax on net investment income? If "Yes," complete Form 4720, Schedule O.	16			X
17	**Section 501(c)(21) organizations.** Did the trust, any disqualified person, or mine operator engage in any activities that would result in the imposition of an excise tax under section 4951, 4952 or 4953? If "Yes," complete Form 6069.	17			

Part VI Governance, Management, and Disclosure. *For each "Yes" response to lines 2 through 7b below, and for a "No" response to line 8a, 8b, or 10b below, describe the circumstances, processes, or changes on Schedule O. See instructions.*

Check if Schedule O contains a response or note to any line in this Part VI X

Section A. Governing Body and Management

				Yes	No
1a	Enter the number of voting members of the governing body at the end of the tax year	1a	11		
	If there are material differences in voting rights among members of the governing body, or if the governing body delegated broad authority to an executive committee or similar committee, explain on Schedule O.				
b	Enter the number of voting members included on line 1a, above, who are independent	1b	11		
2	Did any officer, director, trustee, or key employee have a family relationship or a business relationship with any other officer, director, trustee, or key employee?	2			X
3	Did the organization delegate control over management duties customarily performed by or under the direct supervision of officers, directors, trustees, or key employees to a management company or other person?	3			X
4	Did the organization make any significant changes to its governing documents since the prior Form 990 was filed?	4			X
5	Did the organization become aware during the year of a significant diversion of the organization's assets?	5			X
6	Did the organization have members or stockholders?	6			X
7a	Did the organization have members, stockholders, or other persons who had the power to elect or appoint one or more members of the governing body?	7a			X
b	Are any governance decisions of the organization reserved to (or subject to approval by) members, stockholders, or persons other than the governing body?	7b			X
8	Did the organization contemporaneously document the meetings held or written actions undertaken during the year by the following:				
a	The governing body?	8a		X	
b	Each committee with authority to act on behalf of the governing body?	8b		X	
9	Is there any officer, director, trustee, or key employee listed in Part VII, Section A, who cannot be reached at the organization's mailing address? *If "Yes," provide the names and addresses on Schedule O*	9			X

Section B. Policies *(This Section B requests information about policies not required by the Internal Revenue Code.)*

			Yes	No
10a	Did the organization have local chapters, branches, or affiliates?	10a		X
b	If "Yes," did the organization have written policies and procedures governing the activities of such chapters, affiliates, and branches to ensure their operations are consistent with the organization's exempt purposes?	10b		
11a	Has the organization provided a complete copy of this Form 990 to all members of its governing body before filing the form?	11a	X	
b	Describe on Schedule O the process, if any, used by the organization to review this Form 990.			
12a	Did the organization have a written conflict of interest policy? *If "No," go to line 13*	12a	X	
b	Were officers, directors, or trustees, and key employees required to disclose annually interests that could give rise to conflicts?	12b	X	
c	Did the organization regularly and consistently monitor and enforce compliance with the policy? *If "Yes," describe on Schedule O how this was done*	12c	X	
13	Did the organization have a written whistleblower policy?	13	X	
14	Did the organization have a written document retention and destruction policy?	14	X	
15	Did the process for determining compensation of the following persons include a review and approval by independent persons, comparability data, and contemporaneous substantiation of the deliberation and decision?			
a	The organization's CEO, Executive Director, or top management official	15a	X	
b	Other officers or key employees of the organization	15b	X	
	If "Yes" to line 15a or 15b, describe the process on Schedule O. See instructions.			
16a	Did the organization invest in, contribute assets to, or participate in a joint venture or similar arrangement with a taxable entity during the year?	16a		X
b	If "Yes," did the organization follow a written policy or procedure requiring the organization to evaluate its participation in joint venture arrangements under applicable federal tax law, and take steps to safeguard the organization's exempt status with respect to such arrangements?	16b		

Section C. Disclosure

17 List the states with which a copy of this Form 990 is required to be filed ▶AK,AL,AR,CA,CT,FL,GA,HI,IL,KS,KY,ME

18 Section 6104 requires an organization to make its Forms 1023 (1024 or 1024-A, if applicable), 990, and 990-T (section 501(c)(3)s only) available for public inspection. Indicate how you made these available. Check all that apply.

X Own website X Another's website X Upon request ☐ Other *(explain on Schedule O)*

19 Describe on Schedule O whether (and if so, how) the organization made its governing documents, conflict of interest policy, and financial statements available to the public during the tax year.

20 State the name, address, and telephone number of the person who possesses the organization's books and records ▶

DAVID F. MARKS, CPA, CMA - (301) 948-3244
22512 GATEWAY CENTER DRIVE, CLARKSBURG, MD 20871

SEE SCHEDULE O FOR FULL LIST OF STATES

Part VII Compensation of Officers, Directors, Trustees, Key Employees, Highest Compensated Employees, and Independent Contractors

Check if Schedule O contains a response or note to any line in this Part VII ☐

Section A. Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees

1a Complete this table for all persons required to be listed. Report compensation for the calendar year ending with or within the organization's tax year.

- List all of the organization's **current** officers, directors, trustees (whether individuals or organizations), regardless of amount of compensation. Enter -0- in columns (D), (E), and (F) if no compensation was paid.
- List all of the organization's **current** key employees, if any. See the instructions for definition of "key employee."
- List the organization's five **current** highest compensated employees (other than an officer, director, trustee, or key employee) who received reportable compensation (box 5 of Form W-2, Form 1099-MISC, and/or box 1 of Form 1099-NEC) of more than $100,000 from the organization and any related organizations.
- List all of the organization's **former** officers, key employees, and highest compensated employees who received more than $100,000 of reportable compensation from the organization and any related organizations.
- List all of the organization's **former directors or trustees** that received, in the capacity as a former director or trustee of the organization, more than $10,000 of reportable compensation from the organization and any related organizations.

See the instructions for the order in which to list the persons above.

☐ Check this box if neither the organization nor any related organization compensated any current officer, director, or trustee.

(A) Name and title	(B) Average hours per week (list any hours for related organizations below line)	(C) Position (do not check more than one box, unless person is both an officer and a director/trustee)						(D) Reportable compensation from the organization (W-2/1099-MISC/ 1099-NEC)	(E) Reportable compensation from related organizations (W-2/1099-MISC/ 1099-NEC)	(F) Estimated amount of other compensation from the organization and related organizations
		Individual trustee or director	Institutional trustee	Officer	Key employee	Highest compensated employee	Former			
(1) STACY PAGOS HALLER PRESIDENT/CEO	55.00			X				435,364.	0.	51,027.
(2) NANCY LYNN SR. VP STRATEGIC PARTNERSHIPS	45.00				X			246,054.	0.	53,950.
(3) R. BRIAN ELDERTON SR. VP, DEVELOPMENT	45.00				X			247,200.	0.	46,416.
(4) DAVID F. MARKS, CPA, CMA VP, FINANCE & ADMINISTRATION	45.00				X			165,137.	0.	56,529.
(5) DIANE BOVENKAMP, PHD VP, SCIENTIFIC AFFAIRS	45.00				X			179,717.	0.	20,889.
(6) MICHAEL BUCKLEY VP, PUBLIC AFFAIRS	45.00				X			163,018.	0.	18,661.
(7) AYO ABRAHAM, CPA CONTROLLER	40.00					X		140,557.	0.	8,353.
(8) JEFFREY HONAKER SR. MANAGER OPERATIONS & BUILDING	40.00					X		104,049.	0.	38,719.
(9) LISA MORGAN DIRECTOR OF ANNUAL GIVING	40.00					X		106,425.	0.	30,773.
(10) PREETI SUBRAMANIAN, DIR. OF SCIENT. PROGRAMS, VISION SCIENCE	40.00					X		111,447.	0.	10,629.
(11) PATRICIA M. STEWART CHAIR	10.00	X		X				0.	0.	0.
(12) CECILIA ARRADAZA VICE CHAIR	5.00	X		X				0.	0.	0.
(13) MADDY DYCHTWALD SECRETARY	5.00	X		X				0.	0.	0.
(14) ETHAN TREESE TREASURER	5.00	X		X				0.	0.	0.
(15) EDWARD FINLEY DIRECTOR	5.00	X						0.	0.	0.
(16) SHAWA GOTTLIEB DIRECTOR	5.00	X						0.	0.	0.
(17) DANA GRIFFIN DIRECTOR	5.00	X						0.	0.	0.

Part VII **Section A. Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees** *(continued)*

(A) Name and title	(B) Average hours per week (list any hours for related organizations below line)	(C) Position (do not check more than one box, unless person is both an officer and a director/trustee)						(D) Reportable compensation from the organization (W-2/1099-MISC/ 1099-NEC)	(E) Reportable compensation from related organizations (W-2/1099-MISC/ 1099-NEC)	(F) Estimated amount of other compensation from the organization and related organizations
		Individual trustee or director	Institutional trustee	Officer	Key employee	Highest compensated employee	Former			
(18) SCOTT KAISER, MD DIRECTOR	5.00	X						0.	0.	0.
(19) TONYA MATTHEWS, PHD DIRECTOR	5.00	X						0.	0.	0.
(20) BRIAN K. REGAN, PHD DIRECTOR - UNTIL 06/2021	5.00	X						0.	0.	0.
(21) SCOTT RODGVILLE, CPA DIRECTOR - UNTIL 06/2021	5.00	X						0.	0.	0.
(22) ERIC SIEMERS, MD DIRECTOR	5.00	X						0.	0.	0.
(23) JAN M. STOUFFER, PHD DIRECTOR	5.00	X						0.	0.	0.
1b Subtotal ▶								1,898,968.	0.	335,946.
c Total from continuation sheets to Part VII, Section A ▶								0.	0.	0.
d Total (add lines 1b and 1c) ▶								1,898,968.	0.	335,946.

2 Total number of individuals (including but not limited to those listed above) who received more than $100,000 of reportable compensation from the organization ▶ 10

		Yes	No
3 Did the organization list any **former** officer, director, trustee, key employee, or highest compensated employee on line 1a? *If "Yes," complete Schedule J for such individual*	3		X
4 For any individual listed on line 1a, is the sum of reportable compensation and other compensation from the organization and related organizations greater than $150,000? *If "Yes," complete Schedule J for such individual*	4	X	
5 Did any person listed on line 1a receive or accrue compensation from any unrelated organization or individual for services rendered to the organization? *If "Yes," complete Schedule J for such person*	5		X

Section B. Independent Contractors

1 Complete this table for your five highest compensated independent contractors that received more than $100,000 of compensation from the organization. Report compensation for the calendar year ending with or within the organization's tax year.

(A) Name and business address	(B) Description of services	(C) Compensation
RKD GROUP, 35 PARKWOOD DRIVE, SUITE 160, HOPKINTON, MA 01748	PUBLIC AWARENESS CONSUL. & MATERIALS	9,417,726.
ALLEGIANCE GROUP, 2300 CLARENDON BLVD., SUITE 925, ARLINGTON, VA 22201	ONLINE PUBLIC AWARENESS CONSULTING	628,947.
ADSTRA LLC, 750 COLLEGE ROAD EAST, SUITE 201, PRINCETON, NJ 08540	LIST RENTAL	505,173.
DATA MANAGEMENT, INC. 160 STONE STREET, STONEVILLE, NC 27048	DATABASE MANAGEMENT	294,513.
GOOGLE, 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW, CA 94043	PUBLIC AWARENESS ADVERTISING	277,994.

2 Total number of independent contractors (including but not limited to those listed above) who received more than $100,000 of compensation from the organization ▶ 17

Part VIII Statement of Revenue

Check if Schedule O contains a response or note to any line in this Part VIII ☐

				(A) Total revenue	(B) Related or exempt function revenue	(C) Unrelated business revenue	(D) Revenue excluded from tax under sections 512 - 514
Contributions, Gifts, Grants and Other Similar Amounts	1a Federated campaigns	1a	255,977.				
	b Membership dues	1b					
	c Fundraising events	1c					
	d Related organizations	1d					
	e Government grants (contributions)	1e					
	f All other contributions, gifts, grants, and similar amounts not included above	1f	46266433.				
	g Noncash contributions included in lines 1a-1f	1g	$ 337,480.				
	h **Total.** Add lines 1a-1f			46522410.			
Program Service Revenue		**Business Code**					
	2a						
	b						
	c						
	d						
	e						
	f All other program service revenue						
	g **Total.** Add lines 2a-2f						
Other Revenue	3 Investment income (including dividends, interest, and other similar amounts)			1,038,513.			1038513.
	4 Income from investment of tax-exempt bond proceeds						
	5 Royalties			440,595.			440,595.
		(i) Real	(ii) Personal				
	6a Gross rents 6a	595,253.					
	b Less: rental expenses 6b	52,265.					
	c Rental income or (loss) 6c	542,988.					
	d Net rental income or (loss)			542,988.			542,988.
		(i) Securities	(ii) Other				
	7a Gross amount from sales of assets other than inventory 7a	19429235					
	b Less: cost or other basis and sales expenses 7b	17223513					
	c Gain or (loss) 7c	2205722.					
	d Net gain or (loss)			2,205,722.			2205722.
	8a Gross income from fundraising events (not including $ _____ of contributions reported on line 1c). See Part IV, line 18 8a						
	b Less: direct expenses 8b						
	c Net income or (loss) from fundraising events						
	9a Gross income from gaming activities. See Part IV, line 19 9a						
	b Less: direct expenses 9b						
	c Net income or (loss) from gaming activities						
	10a Gross sales of inventory, less returns and allowances 10a						
	b Less: cost of goods sold 10b						
	c Net income or (loss) from sales of inventory						
Miscellaneous Revenue		**Business Code**					
	11a SAVINGS BOND PAYOUT	900099		7,500.			7,500.
	b						
	c						
	d All other revenue						
	e **Total.** Add lines 11a-11d			7,500.			
	12 **Total revenue.** See instructions			50757728.	0.	0.	4235318.

Part IX Statement of Functional Expenses

Section 501(c)(3) and 501(c)(4) organizations must complete all columns. All other organizations must complete column (A).

Check if Schedule O contains a response or note to any line in this Part IX ☐

Do not include amounts reported on lines 6b, 7b, 8b, 9b, and 10b of Part VIII.	(A) Total expenses	(B) Program service expenses	(C) Management and general expenses	(D) Fundraising expenses
1 Grants and other assistance to domestic organizations and domestic governments. See Part IV, line 21	18,193,252.	18,193,252.		
2 Grants and other assistance to domestic individuals. See Part IV, line 22				
3 Grants and other assistance to foreign organizations, foreign governments, and foreign individuals. See Part IV, lines 15 and 16	5,457,959.	5,457,959.		
4 Benefits paid to or for members				
5 Compensation of current officers, directors, trustees, and key employees	1,685,216.	1,079,340.	339,220.	266,656.
6 Compensation not included above to disqualified persons (as defined under section 4958(f)(1)) and persons described in section 4958(c)(3)(B)				
7 Other salaries and wages	2,758,048.	1,435,538.	890,977.	431,533.
8 Pension plan accruals and contributions (include section 401(k) and 403(b) employer contributions)	186,521.	97,082.	60,255.	29,184.
9 Other employee benefits	606,087.	315,463.	195,794.	94,830.
10 Payroll taxes	298,432.	155,331.	96,407.	46,694.
11 Fees for services (nonemployees):				
a Management				
b Legal	90,920.	47,447.	43,473.	
c Accounting	95,713.	57,550.	26,236.	11,927.
d Lobbying				
e Professional fundraising services. See Part IV, line 17	798,203.			798,203.
f Investment management fees	351,028.		351,028.	
g Other. (If line 11g amount exceeds 10% of line 25, column (A), amount, list line 11g expenses on Sch O.)	2,261,900.	2,002,855.	194,077.	64,968.
12 Advertising and promotion	672,932.	352,899.		320,033.
13 Office expenses	1,060,023.	464,160.	327,500.	268,363.
14 Information technology	1,162,877.	868,504.	200,947.	93,426.
15 Royalties				
16 Occupancy	434,794.	255,882.	137,124.	41,788.
17 Travel	67,731.	32,444.	21,805.	13,482.
18 Payments of travel or entertainment expenses for any federal, state, or local public officials				
19 Conferences, conventions, and meetings	414,029.	298,650.	3,800.	111,579.
20 Interest	2,448.	1,441.	772.	235.
21 Payments to affiliates				
22 Depreciation, depletion, and amortization	308,229.	177,938.	94,428.	35,863.
23 Insurance	97,527.	32,086.	56,840.	8,601.
24 Other expenses. Itemize expenses not covered above. (List miscellaneous expenses on line 24e. If line 24e amount exceeds 10% of line 25, column (A), amount, list line 24e expenses on Schedule O.)				
a PUB. AWARENESS POSTAGE	7,664,190.	3,958,244.	484,631.	3,221,315.
b PUB. AWARENESS PRINTING	5,671,895.	2,947,419.	324,318.	2,400,158.
c PUB. AWARENESS COMP.	2,017,247.	1,058,022.	102,867.	856,358.
d LIST RENTAL	1,700,156.	885,672.	82,570.	731,914.
e All other expenses				
25 **Total functional expenses.** Add lines 1 through 24e	54,057,357.	40,175,178.	4,035,069.	9,847,110.
26 **Joint costs.** Complete this line only if the organization reported in column (B) joint costs from a combined educational campaign and fundraising solicitation. Check here ▶ ☒ if following SOP 98-2 (ASC 958-720)	16,603,523.	7,872,444.	1,050,335.	7,680,744.

Part X Balance Sheet

Check if Schedule O contains a response or note to any line in this Part X ☐

				(A) Beginning of year		(B) End of year
Assets	1	Cash - non-interest-bearing		3,829,911.	1	138,432.
	2	Savings and temporary cash investments		621,981.	2	4,940,634.
	3	Pledges and grants receivable, net		10,272,457.	3	6,568,692.
	4	Accounts receivable, net			4	
	5	Loans and other receivables from any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or 35% controlled entity or family member of any of these persons			5	
	6	Loans and other receivables from other disqualified persons (as defined under section 4958(f)(1)), and persons described in section 4958(c)(3)(B)			6	
	7	Notes and loans receivable, net			7	
	8	Inventories for sale or use		44,354.	8	37,046.
	9	Prepaid expenses and deferred charges		204,913.	9	322,345.
	10a	Land, buildings, and equipment: cost or other basis. Complete Part VI of Schedule D	10a 12,764,795.			
	b	Less: accumulated depreciation	10b 4,603,680.	7,830,979.	10c	8,161,115.
	11	Investments - publicly traded securities		43,404,279.	11	45,203,665.
	12	Investments - other securities. See Part IV, line 11			12	
	13	Investments - program-related. See Part IV, line 11			13	
	14	Intangible assets			14	
	15	Other assets. See Part IV, line 11		267,875.	15	169,035.
	16	**Total assets.** Add lines 1 through 15 (must equal line 33)		66,476,749.	16	65,540,964.
Liabilities	17	Accounts payable and accrued expenses		871,196.	17	862,205.
	18	Grants payable		31,618,962.	18	34,865,851.
	19	Deferred revenue			19	
	20	Tax-exempt bond liabilities			20	
	21	Escrow or custodial account liability. Complete Part IV of Schedule D			21	
	22	Loans and other payables to any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or 35% controlled entity or family member of any of these persons			22	
	23	Secured mortgages and notes payable to unrelated third parties			23	
	24	Unsecured notes and loans payable to unrelated third parties			24	
	25	Other liabilities (including federal income tax, payables to related third parties, and other liabilities not included on lines 17-24). Complete Part X of Schedule D		951,874.	25	793,033.
	26	**Total liabilities.** Add lines 17 through 25		33,442,032.	26	36,521,089.
Net Assets or Fund Balances		**Organizations that follow FASB ASC 958, check here ▶ ☒ and complete lines 27, 28, 32, and 33.**				
	27	Net assets without donor restrictions		15,708,243.	27	13,864,090.
	28	Net assets with donor restrictions		17,326,474.	28	15,155,785.
		Organizations that do not follow FASB ASC 958, check here ▶ ☐ and complete lines 29 through 33.				
	29	Capital stock or trust principal, or current funds			29	
	30	Paid-in or capital surplus, or land, building, or equipment fund			30	
	31	Retained earnings, endowment, accumulated income, or other funds			31	
	32	Total net assets or fund balances		33,034,717.	32	29,019,875.
	33	Total liabilities and net assets/fund balances		66,476,749.	33	65,540,964.

Form **990** (2021)

132011 12-09-21

Part XI Reconciliation of Net Assets

Check if Schedule O contains a response or note to any line in this Part XI X

1	Total revenue (must equal Part VIII, column (A), line 12)	1	50,757,728.
2	Total expenses (must equal Part IX, column (A), line 25)	2	54,057,357.
3	Revenue less expenses. Subtract line 2 from line 1	3	-3,299,629.
4	Net assets or fund balances at beginning of year (must equal Part X, line 32, column (A))	4	33,034,717.
5	Net unrealized gains (losses) on investments	5	-1,605,810.
6	Donated services and use of facilities	6	
7	Investment expenses	7	
8	Prior period adjustments	8	
9	Other changes in net assets or fund balances (explain on Schedule O)	9	890,597.
10	Net assets or fund balances at end of year. Combine lines 3 through 9 (must equal Part X, line 32, column (B))	10	29,019,875.

Part XII Financial Statements and Reporting

Check if Schedule O contains a response or note to any line in this Part XII .....

			Yes	No
1	Accounting method used to prepare the Form 990: ☐ Cash ☒ Accrual ☐ Other _____ If the organization changed its method of accounting from a prior year or checked "Other," explain on Schedule O.			
2a	Were the organization's financial statements compiled or reviewed by an independent accountant?	2a		X
	If "Yes," check a box below to indicate whether the financial statements for the year were compiled or reviewed on a separate basis, consolidated basis, or both: ☐ Separate basis ☐ Consolidated basis ☐ Both consolidated and separate basis			
b	Were the organization's financial statements audited by an independent accountant?	2b	X	
	If "Yes," check a box below to indicate whether the financial statements for the year were audited on a separate basis, consolidated basis, or both: ☐ Separate basis ☒ Consolidated basis ☐ Both consolidated and separate basis			
c	If "Yes" to line 2a or 2b, does the organization have a committee that assumes responsibility for oversight of the audit, review, or compilation of its financial statements and selection of an independent accountant?	2c	X	
	If the organization changed either its oversight process or selection process during the tax year, explain on Schedule O.			
3a	As a result of a federal award, was the organization required to undergo an audit or audits as set forth in the Single Audit Act and OMB Circular A-133?	3a		X
b	If "Yes," did the organization undergo the required audit or audits? If the organization did not undergo the required audit or audits, explain why on Schedule O and describe any steps taken to undergo such audits	3b		

SCHEDULE A
(Form 990)

Department of the Treasury
Internal Revenue Service

Public Charity Status and Public Support

Complete if the organization is a section 501(c)(3) organization or a section 4947(a)(1) nonexempt charitable trust.
▶ Attach to Form 990 or Form 990-EZ.
▶ Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2021

Open to Public Inspection

Name of the organization
BRIGHTFOCUS FOUNDATION

Employer identification number
23-7337229

Part I Reason for Public Charity Status. (All organizations must complete this part.) See instructions.

The organization is not a private foundation because it is: (For lines 1 through 12, check only one box.)

1 ☐ A church, convention of churches, or association of churches described in **section 170(b)(1)(A)(i).**
2 ☐ A school described in **section 170(b)(1)(A)(ii).** (Attach Schedule E (Form 990).)
3 ☐ A hospital or a cooperative hospital service organization described in **section 170(b)(1)(A)(iii).**
4 ☐ A medical research organization operated in conjunction with a hospital described in **section 170(b)(1)(A)(iii).** Enter the hospital's name, city, and state: _____
5 ☐ An organization operated for the benefit of a college or university owned or operated by a governmental unit described in **section 170(b)(1)(A)(iv).** (Complete Part II.)
6 ☐ A federal, state, or local government or governmental unit described in **section 170(b)(1)(A)(v).**
7 ☒ An organization that normally receives a substantial part of its support from a governmental unit or from the general public described in **section 170(b)(1)(A)(vi).** (Complete Part II.)
8 ☐ A community trust described in **section 170(b)(1)(A)(vi).** (Complete Part II.)
9 ☐ An agricultural research organization described in **section 170(b)(1)(A)(ix)** operated in conjunction with a land-grant college or university or a non-land-grant college of agriculture (see instructions). Enter the name, city, and state of the college or university: _____
10 ☐ An organization that normally receives (1) more than 33 1/3% of its support from contributions, membership fees, and gross receipts from activities related to its exempt functions, subject to certain exceptions; and (2) no more than 33 1/3% of its support from gross investment income and unrelated business taxable income (less section 511 tax) from businesses acquired by the organization after June 30, 1975. See **section 509(a)(2).** (Complete Part III.)
11 ☐ An organization organized and operated exclusively to test for public safety. See **section 509(a)(4).**
12 ☐ An organization organized and operated exclusively for the benefit of, to perform the functions of, or to carry out the purposes of one or more publicly supported organizations described in **section 509(a)(1)** or **section 509(a)(2)**. See **section 509(a)(3).** Check the box on lines 12a through 12d that describes the type of supporting organization and complete lines 12e, 12f, and 12g.

a ☐ **Type I.** A supporting organization operated, supervised, or controlled by its supported organization(s), typically by giving the supported organization(s) the power to regularly appoint or elect a majority of the directors or trustees of the supporting organization. **You must complete Part IV, Sections A and B.**
b ☐ **Type II.** A supporting organization supervised or controlled in connection with its supported organization(s), by having control or management of the supporting organization vested in the same persons that control or manage the supported organization(s). **You must complete Part IV, Sections A and C.**
c ☐ **Type III functionally integrated.** A supporting organization operated in connection with, and functionally integrated with, its supported organization(s) (see instructions). **You must complete Part IV, Sections A, D, and E.**
d ☐ **Type III non-functionally integrated.** A supporting organization operated in connection with its supported organization(s) that is not functionally integrated. The organization generally must satisfy a distribution requirement and an attentiveness requirement (see instructions). **You must complete Part IV, Sections A and D, and Part V.**
e ☐ Check this box if the organization received a written determination from the IRS that it is a Type I, Type II, Type III functionally integrated, or Type III non-functionally integrated supporting organization.
f Enter the number of supported organizations .....
g Provide the following information about the supported organization(s).

(i) Name of supported organization	(ii) EIN	(iii) Type of organization (described on lines 1-10 above (see instructions))	(iv) Is the organization listed in your governing document? Yes	(iv) No	(v) Amount of monetary support (see instructions)	(vi) Amount of other support (see instructions)
Total						

Part II Support Schedule for Organizations Described in Sections 170(b)(1)(A)(iv) and 170(b)(1)(A)(vi)

(Complete only if you checked the box on line 5, 7, or 8 of Part I or if the organization failed to qualify under Part III. If the organization fails to qualify under the tests listed below, please complete Part III.)

Section A. Public Support

Calendar year (or fiscal year beginning in) ▶	(a) 2017	(b) 2018	(c) 2019	(d) 2020	(e) 2021	(f) Total
1 Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.")	32362197.	39635190.	35740875.	48502473.	46522410.	202763145
2 Tax revenues levied for the organization's benefit and either paid to or expended on its behalf						
3 The value of services or facilities furnished by a governmental unit to the organization without charge						
4 **Total.** Add lines 1 through 3	32362197.	39635190.	35740875.	48502473.	46522410.	202763145
5 The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f)						711,894.
6 **Public support.** Subtract line 5 from line 4.						202051251

Section B. Total Support

Calendar year (or fiscal year beginning in) ▶	(a) 2017	(b) 2018	(c) 2019	(d) 2020	(e) 2021	(f) Total
7 Amounts from line 4	32362197.	39635190.	35740875.	48502473.	46522410.	202763145
8 Gross income from interest, dividends, payments received on securities loans, rents, royalties, and income from similar sources	1641767.	1925519.	2176998.	1887633.	2074361.	9706278.
9 Net income from unrelated business activities, whether or not the business is regularly carried on						
10 Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.)					7,500.	7,500.
11 **Total support.** Add lines 7 through 10						212476923

12 Gross receipts from related activities, etc. (see instructions) ▶ 12

13 **First 5 years.** If the Form 990 is for the organization's first, second, third, fourth, or fifth tax year as a section 501(c)(3) organization, check this box and **stop here** ▶ ☐

Section C. Computation of Public Support Percentage

14 Public support percentage for 2021 (line 6, column (f), divided by line 11, column (f))	14	95.09 %
15 Public support percentage from 2020 Schedule A, Part II, line 14	15	95.24 %

16a **33 1/3% support test - 2021.** If the organization did not check the box on line 13, and line 14 is 33 1/3% or more, check this box and **stop here.** The organization qualifies as a publicly supported organization ▶ ☒

b **33 1/3% support test - 2020.** If the organization did not check a box on line 13 or 16a, and line 15 is 33 1/3% or more, check this box and **stop here.** The organization qualifies as a publicly supported organization ▶ ☐

17a **10% -facts-and-circumstances test - 2021.** If the organization did not check a box on line 13, 16a, or 16b, and line 14 is 10% or more, and if the organization meets the facts-and-circumstances test, check this box and **stop here.** Explain in Part VI how the organization meets the facts-and-circumstances test. The organization qualifies as a publicly supported organization ▶ ☐

b **10% -facts-and-circumstances test - 2020.** If the organization did not check a box on line 13, 16a, 16b, or 17a, and line 15 is 10% or more, and if the organization meets the facts-and-circumstances test, check this box and **stop here.** Explain in Part VI how the organization meets the facts-and-circumstances test. The organization qualifies as a publicly supported organization ▶ ☐

18 **Private foundation.** If the organization did not check a box on line 13, 16a, 16b, 17a, or 17b, check this box and see instructions ▶ ☐

Part III Support Schedule for Organizations Described in Section 509(a)(2)

(Complete only if you checked the box on line 10 of Part I or if the organization failed to qualify under Part II. If the organization fails to qualify under the tests listed below, please complete Part II.)

Section A. Public Support

Calendar year (or fiscal year beginning in) ▶	(a) 2017	(b) 2018	(c) 2019	(d) 2020	(e) 2021	(f) Total
1 Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.")						
2 Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose						
3 Gross receipts from activities that are not an unrelated trade or business under section 513						
4 Tax revenues levied for the organization's benefit and either paid to or expended on its behalf						
5 The value of services or facilities furnished by a governmental unit to the organization without charge						
6 **Total.** Add lines 1 through 5						
7a Amounts included on lines 1, 2, and 3 received from disqualified persons						
b Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year						
c Add lines 7a and 7b						
8 **Public support.** (Subtract line 7c from line 6.)						

Section B. Total Support

Calendar year (or fiscal year beginning in) ▶	(a) 2017	(b) 2018	(c) 2019	(d) 2020	(e) 2021	(f) Total
9 Amounts from line 6						
10a Gross income from interest, dividends, payments received on securities loans, rents, royalties, and income from similar sources						
b Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975						
c Add lines 10a and 10b						
11 Net income from unrelated business activities not included on line 10b, whether or not the business is regularly carried on						
12 Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.)						
13 **Total support.** (Add lines 9, 10c, 11, and 12.)						

14 **First 5 years.** If the Form 990 is for the organization's first, second, third, fourth, or fifth tax year as a section 501(c)(3) organization, check this box and **stop here** ▶ ☐

Section C. Computation of Public Support Percentage

15 Public support percentage for 2021 (line 8, column (f), divided by line 13, column (f))	15	%
16 Public support percentage from 2020 Schedule A, Part III, line 15	16	%

Section D. Computation of Investment Income Percentage

17 Investment income percentage for **2021** (line 10c, column (f), divided by line 13, column (f))	17	%
18 Investment income percentage from **2020** Schedule A, Part III, line 17	18	%

19a **33 1/3% support tests - 2021.** If the organization did not check the box on line 14, and line 15 is more than 33 1/3%, and line 17 is not more than 33 1/3%, check this box and **stop here.** The organization qualifies as a publicly supported organization ▶ ☐

b **33 1/3% support tests - 2020.** If the organization did not check a box on line 14 or line 19a, and line 16 is more than 33 1/3%, and line 18 is not more than 33 1/3%, check this box and **stop here.** The organization qualifies as a publicly supported organization ▶ ☐

20 **Private foundation.** If the organization did not check a box on line 14, 19a, or 19b, check this box and see instructions ▶ ☐

Part IV Supporting Organizations

(Complete only if you checked a box in line 12 on Part I. If you checked box 12a, Part I, complete Sections A and B. If you checked box 12b, Part I, complete Sections A and C. If you checked box 12c, Part I, complete Sections A, D, and E. If you checked box 12d, Part I, complete Sections A and D, and complete Part V.)

Section A. All Supporting Organizations

			Yes	No
1	Are all of the organization's supported organizations listed by name in the organization's governing documents? *If "No," describe in* **Part VI** *how the supported organizations are designated. If designated by class or purpose, describe the designation. If historic and continuing relationship, explain.*	1		
2	Did the organization have any supported organization that does not have an IRS determination of status under section 509(a)(1) or (2)? *If "Yes," explain in* **Part VI** *how the organization determined that the supported organization was described in section 509(a)(1) or (2).*	2		
3a	Did the organization have a supported organization described in section 501(c)(4), (5), or (6)? *If "Yes," answer lines 3b and 3c below.*	3a		
b	Did the organization confirm that each supported organization qualified under section 501(c)(4), (5), or (6) and satisfied the public support tests under section 509(a)(2)? *If "Yes," describe in* **Part VI** *when and how the organization made the determination.*	3b		
c	Did the organization ensure that all support to such organizations was used exclusively for section 170(c)(2)(B) purposes? *If "Yes," explain in* **Part VI** *what controls the organization put in place to ensure such use.*	3c		
4a	Was any supported organization not organized in the United States ("foreign supported organization")? *If "Yes," and if you checked box 12a or 12b in Part I, answer lines 4b and 4c below.*	4a		
b	Did the organization have ultimate control and discretion in deciding whether to make grants to the foreign supported organization? *If "Yes," describe in* **Part VI** *how the organization had such control and discretion despite being controlled or supervised by or in connection with its supported organizations.*	4b		
c	Did the organization support any foreign supported organization that does not have an IRS determination under sections 501(c)(3) and 509(a)(1) or (2)? *If "Yes," explain in* **Part VI** *what controls the organization used to ensure that all support to the foreign supported organization was used exclusively for section 170(c)(2)(B) purposes.*	4c		
5a	Did the organization add, substitute, or remove any supported organizations during the tax year? *If "Yes," answer lines 5b and 5c below (if applicable). Also, provide detail in* **Part VI,** *including (i) the names and EIN numbers of the supported organizations added, substituted, or removed; (ii) the reasons for each such action; (iii) the authority under the organization's organizing document authorizing such action; and (iv) how the action was accomplished (such as by amendment to the organizing document).*	5a		
b	**Type I or Type II only.** Was any added or substituted supported organization part of a class already designated in the organization's organizing document?	5b		
c	**Substitutions only.** Was the substitution the result of an event beyond the organization's control?	5c		
6	Did the organization provide support (whether in the form of grants or the provision of services or facilities) to anyone other than (i) its supported organizations, (ii) individuals that are part of the charitable class benefited by one or more of its supported organizations, or (iii) other supporting organizations that also support or benefit one or more of the filing organization's supported organizations? *If "Yes," provide detail in* **Part VI.**	6		
7	Did the organization provide a grant, loan, compensation, or other similar payment to a substantial contributor (as defined in section 4958(c)(3)(C)), a family member of a substantial contributor, or a 35% controlled entity with regard to a substantial contributor? *If "Yes," complete Part I of Schedule L (Form 990).*	7		
8	Did the organization make a loan to a disqualified person (as defined in section 4958) not described on line 7? *If "Yes," complete Part I of Schedule L (Form 990).*	8		
9a	Was the organization controlled directly or indirectly at any time during the tax year by one or more disqualified persons, as defined in section 4946 (other than foundation managers and organizations described in section 509(a)(1) or (2))? *If "Yes," provide detail in* **Part VI.**	9a		
b	Did one or more disqualified persons (as defined on line 9a) hold a controlling interest in any entity in which the supporting organization had an interest? *If "Yes," provide detail in* **Part VI.**	9b		
c	Did a disqualified person (as defined on line 9a) have an ownership interest in, or derive any personal benefit from, assets in which the supporting organization also had an interest? *If "Yes," provide detail in* **Part VI.**	9c		
10a	Was the organization subject to the excess business holdings rules of section 4943 because of section 4943(f) (regarding certain Type II supporting organizations, and all Type III non-functionally integrated supporting organizations)? *If "Yes," answer line 10b below.*	10a		
b	Did the organization have any excess business holdings in the tax year? *(Use Schedule C, Form 4720, to determine whether the organization had excess business holdings.)*	10b		

Part IV Supporting Organizations *(continued)*

			Yes	No
11	Has the organization accepted a gift or contribution from any of the following persons?			
a	A person who directly or indirectly controls, either alone or together with persons described on lines 11b and 11c below, the governing body of a supported organization?	**11a**		
b	A family member of a person described on line 11a above?	**11b**		
c	A 35% controlled entity of a person described on line 11a or 11b above? *If "Yes" to line 11a, 11b, or 11c, provide detail in* **Part VI.**	**11c**		

Section B. Type I Supporting Organizations

			Yes	No
1	Did the governing body, members of the governing body, officers acting in their official capacity, or membership of one or more supported organizations have the power to regularly appoint or elect at least a majority of the organization's officers, directors, or trustees at all times during the tax year? *If "No," describe in* **Part VI** *how the supported organization(s) effectively operated, supervised, or controlled the organization's activities. If the organization had more than one supported organization, describe how the powers to appoint and/or remove officers, directors, or trustees were allocated among the supported organizations and what conditions or restrictions, if any, applied to such powers during the tax year.*	**1**		
2	Did the organization operate for the benefit of any supported organization other than the supported organization(s) that operated, supervised, or controlled the supporting organization? *If "Yes," explain in* **Part VI** *how providing such benefit carried out the purposes of the supported organization(s) that operated, supervised, or controlled the supporting organization.*	**2**		

Section C. Type II Supporting Organizations

			Yes	No
1	Were a majority of the organization's directors or trustees during the tax year also a majority of the directors or trustees of each of the organization's supported organization(s)? *If "No," describe in* **Part VI** *how control or management of the supporting organization was vested in the same persons that controlled or managed the supported organization(s).*	**1**		

Section D. All Type III Supporting Organizations

			Yes	No
1	Did the organization provide to each of its supported organizations, by the last day of the fifth month of the organization's tax year, (i) a written notice describing the type and amount of support provided during the prior tax year, (ii) a copy of the Form 990 that was most recently filed as of the date of notification, and (iii) copies of the organization's governing documents in effect on the date of notification, to the extent not previously provided?	**1**		
2	Were any of the organization's officers, directors, or trustees either (i) appointed or elected by the supported organization(s) or (ii) serving on the governing body of a supported organization? *If "No," explain in* **Part VI** *how the organization maintained a close and continuous working relationship with the supported organization(s).*	**2**		
3	By reason of the relationship described on line 2, above, did the organization's supported organizations have a significant voice in the organization's investment policies and in directing the use of the organization's income or assets at all times during the tax year? *If "Yes," describe in* **Part VI** *the role the organization's supported organizations played in this regard.*	**3**		

Section E. Type III Functionally Integrated Supporting Organizations

1 *Check the box next to the method that the organization used to satisfy the Integral Part Test during the year* **(see instructions).**

- **a** ☐ The organization satisfied the Activities Test. *Complete* **line 2** *below.*
- **b** ☐ The organization is the parent of each of its supported organizations. *Complete* **line 3** *below.*
- **c** ☐ The organization supported a governmental entity. *Describe in* **Part VI** *how you supported a governmental entity (see instructions).*

			Yes	No
2	Activities Test. **Answer lines 2a and 2b below.**			
a	Did substantially all of the organization's activities during the tax year directly further the exempt purposes of the supported organization(s) to which the organization was responsive? *If "Yes," then in* **Part VI identify those supported organizations and explain** *how these activities directly furthered their exempt purposes, how the organization was responsive to those supported organizations, and how the organization determined that these activities constituted substantially all of its activities.*	**2a**		
b	Did the activities described on line 2a, above, constitute activities that, but for the organization's involvement, one or more of the organization's supported organization(s) would have been engaged in? *If "Yes," explain in* **Part VI** *the reasons for the organization's position that its supported organization(s) would have engaged in these activities but for the organization's involvement.*	**2b**		
3	Parent of Supported Organizations. **Answer lines 3a and 3b below.**			
a	Did the organization have the power to regularly appoint or elect a majority of the officers, directors, or trustees of each of the supported organizations? *If "Yes" or "No" provide details in* **Part VI.**	**3a**		
b	Did the organization exercise a substantial degree of direction over the policies, programs, and activities of each of its supported organizations? *If "Yes," describe in* **Part VI** *the role played by the organization in this regard.*	**3b**		

Part V Type III Non-Functionally Integrated 509(a)(3) Supporting Organizations

1 ☐ Check here if the organization satisfied the Integral Part Test as a qualifying trust on Nov. 20, 1970 (*explain in* **Part VI**). **See instructions.** All other Type III non-functionally integrated supporting organizations must complete Sections A through E.

Section A - Adjusted Net Income		(A) Prior Year	(B) Current Year (optional)
1 Net short-term capital gain	**1**		
2 Recoveries of prior-year distributions	**2**		
3 Other gross income (see instructions)	**3**		
4 Add lines 1 through 3.	**4**		
5 Depreciation and depletion	**5**		
6 Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions)	**6**		
7 Other expenses (see instructions)	**7**		
8 **Adjusted Net Income** (subtract lines 5, 6, and 7 from line 4)	**8**		

Section B - Minimum Asset Amount		(A) Prior Year	(B) Current Year (optional)
1 Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year):			
a Average monthly value of securities	**1a**		
b Average monthly cash balances	**1b**		
c Fair market value of other non-exempt-use assets	**1c**		
d **Total** (add lines 1a, 1b, and 1c)	**1d**		
e **Discount** claimed for blockage or other factors (*explain in detail in* **Part VI**):			
2 Acquisition indebtedness applicable to non-exempt-use assets	**2**		
3 Subtract line 2 from line 1d.	**3**		
4 Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions).	**4**		
5 Net value of non-exempt-use assets (subtract line 4 from line 3)	**5**		
6 Multiply line 5 by 0.035.	**6**		
7 Recoveries of prior-year distributions	**7**		
8 **Minimum Asset Amount** (add line 7 to line 6)	**8**		

Section C - Distributable Amount			Current Year
1 Adjusted net income for prior year (from Section A, line 8, column A)	**1**		
2 Enter 0.85 of line 1.	**2**		
3 Minimum asset amount for prior year (from Section B, line 8, column A)	**3**		
4 Enter greater of line 2 or line 3.	**4**		
5 Income tax imposed in prior year	**5**		
6 **Distributable Amount.** Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions).	**6**		

7 ☐ Check here if the current year is the organization's first as a non-functionally integrated Type III supporting organization (see instructions).

Part V Type III Non-Functionally Integrated 509(a)(3) Supporting Organizations *(continued)*

Section D - Distributions		**Current Year**
1 Amounts paid to supported organizations to accomplish exempt purposes	**1**	
2 Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity	**2**	
3 Administrative expenses paid to accomplish exempt purposes of supported organizations	**3**	
4 Amounts paid to acquire exempt-use assets	**4**	
5 Qualified set-aside amounts (prior IRS approval required - *provide details in* **Part VI**)	**5**	
6 Other distributions (*describe in* **Part VI**). See instructions.	**6**	
7 **Total annual distributions.** Add lines 1 through 6.	**7**	
8 Distributions to attentive supported organizations to which the organization is responsive (*provide details in* **Part VI**). See instructions.	**8**	
9 Distributable amount for 2021 from Section C, line 6	**9**	
10 Line 8 amount divided by line 9 amount	**10**	

Section E - Distribution Allocations (see instructions)	**(i) Excess Distributions**	**(ii) Underdistributions Pre-2021**	**(iii) Distributable Amount for 2021**
1 Distributable amount for 2021 from Section C, line 6			
2 Underdistributions, if any, for years prior to 2021 (reasonable cause required - *explain in* **Part VI**). See instructions.			
3 Excess distributions carryover, if any, to 2021			
a From 2016			
b From 2017			
c From 2018			
d From 2019			
e From 2020			
f **Total** of lines 3a through 3e			
g Applied to underdistributions of prior years			
h Applied to 2021 distributable amount			
i Carryover from 2016 not applied (see instructions)			
j Remainder. Subtract lines 3g, 3h, and 3i from line 3f.			
4 Distributions for 2021 from Section D, line 7: $			
a Applied to underdistributions of prior years			
b Applied to 2021 distributable amount			
c Remainder. Subtract lines 4a and 4b from line 4.			
5 Remaining underdistributions for years prior to 2021, if any. Subtract lines 3g and 4a from line 2. For result greater than zero, *explain in* **Part VI.** See instructions.			
6 Remaining underdistributions for 2021. Subtract lines 3h and 4b from line 1. For result greater than zero, *explain in* **Part VI**. See instructions.			
7 **Excess distributions carryover to 2022.** Add lines 3j and 4c.			
8 Breakdown of line 7:			
a Excess from 2017			
b Excess from 2018			
c Excess from 2019			
d Excess from 2020			
e Excess from 2021			

Part VI **Supplemental Information.** Provide the explanations required by Part II, line 10; Part II, line 17a or 17b; Part III, line 12; Part IV, Section A, lines 1, 2, 3b, 3c, 4b, 4c, 5a, 6, 9a, 9b, 9c, 11a, 11b, and 11c; Part IV, Section B, lines 1 and 2; Part IV, Section C, line 1; Part IV, Section D, lines 2 and 3; Part IV, Section E, lines 1c, 2a, 2b, 3a, and 3b; Part V, line 1; Part V, Section B, line 1e; Part V, Section D, lines 5, 6, and 8; and Part V, Section E, lines 2, 5, and 6. Also complete this part for any additional information. (See instructions.)

SCHEDULE A, PART II, LINE 10, EXPLANATION FOR OTHER INCOME:

SAVINGS BOND PAYOUT

2021 AMOUNT: $ 7,500.

Schedule B (Form 990)

Department of the Treasury
Internal Revenue Service

Schedule of Contributors

▶ Attach to Form 990 or Form 990-PF.
▶ Go to www.irs.gov/Form990 for the latest information.

OMB No. 1545-0047

2021

Name of the organization

BRIGHTFOCUS FOUNDATION

Employer identification number

23-7337229

Organization type (check one):

Filers of:	Section:
Form 990 or 990-EZ	[X] 501(c)(3) (enter number) organization
	[ ] 4947(a)(1) nonexempt charitable trust **not** treated as a private foundation
	[ ] 527 political organization
Form 990-PF	[ ] 501(c)(3) exempt private foundation
	[ ] 4947(a)(1) nonexempt charitable trust treated as a private foundation
	[ ] 501(c)(3) taxable private foundation

Check if your organization is covered by the **General Rule** or a **Special Rule.**
Note: Only a section 501(c)(7), (8), or (10) organization can check boxes for both the General Rule and a Special Rule. See instructions.

General Rule

[ ] For an organization filing Form 990, 990-EZ, or 990-PF that received, during the year, contributions totaling $5,000 or more (in money or property) from any one contributor. Complete Parts I and II. See instructions for determining a contributor's total contributions.

Special Rules

[X] For an organization described in section 501(c)(3) filing Form 990 or 990-EZ that met the 33 1/3% support test of the regulations under sections 509(a)(1) and 170(b)(1)(A)(vi), that checked Schedule A (Form 990), Part II, line 13, 16a, or 16b, and that received from any one contributor, during the year, total contributions of the greater of **(1)** $5,000; or **(2)** 2% of the amount on (i) Form 990, Part VIII, line 1h; or (ii) Form 990-EZ, line 1. Complete Parts I and II.

[ ] For an organization described in section 501(c)(7), (8), or (10) filing Form 990 or 990-EZ that received from any one contributor, during the year, total contributions of more than $1,000 exclusively for religious, charitable, scientific, literary, or educational purposes, or for the prevention of cruelty to children or animals. Complete Parts I (entering "N/A" in column (b) instead of the contributor name and address), II, and III.

[ ] For an organization described in section 501(c)(7), (8), or (10) filing Form 990 or 990-EZ that received from any one contributor, during the year, contributions *exclusively* for religious, charitable, etc., purposes, but no such contributions totaled more than $1,000. If this box is checked, enter here the total contributions that were received during the year for an *exclusively* religious, charitable, etc., purpose. Don't complete any of the parts unless the **General Rule** applies to this organization because it received *nonexclusively* religious, charitable, etc., contributions totaling $5,000 or more during the year ..... ▶ $ _____

Caution: An organization that isn't covered by the General Rule and/or the Special Rules doesn't file Schedule B (Form 990), but it **must** answer "No" on Part IV, line 2, of its Form 990; or check the box on line H of its Form 990-EZ or on its Form 990-PF, Part I, line 2, to certify that it doesn't meet the filing requirements of Schedule B (Form 990).

Name of organization

BRIGHTFOCUS FOUNDATION

Employer identification number

23-7337229

Part I **Contributors** (see instructions). Use duplicate copies of Part I if additional space is needed.

(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
1		$ 1,003,346.	Person [X] Payroll [ ] Noncash [ ] (Complete Part II for noncash contributions.)
2		$ 1,000,000.	Person [X] Payroll [ ] Noncash [ ] (Complete Part II for noncash contributions.)
3		$ 961,432.	Person [X] Payroll [ ] Noncash [ ] (Complete Part II for noncash contributions.)
		$	Person [ ] Payroll [ ] Noncash [ ] (Complete Part II for noncash contributions.)
		$	Person [ ] Payroll [ ] Noncash [ ] (Complete Part II for noncash contributions.)
		$	Person [ ] Payroll [ ] Noncash [ ] (Complete Part II for noncash contributions.)

Name of organization

BRIGHTFOCUS FOUNDATION

Employer identification number

23-7337229

Part II **Noncash Property** (see instructions). Use duplicate copies of Part II if additional space is needed.

(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions.)	(d) Date received
		$	
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions.)	(d) Date received
		$	
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions.)	(d) Date received
		$	
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions.)	(d) Date received
		$	
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions.)	(d) Date received
		$	
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions.)	(d) Date received
		$	

Name of organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

Part III **Exclusively religious, charitable, etc., contributions to organizations described in section 501(c)(7), (8), or (10) that total more than $1,000 for the year from any one contributor.** Complete columns **(a)** through **(e) and** the following line entry. For organizations completing Part III, enter the total of exclusively religious, charitable, etc., contributions of **$1,000 or less** for the year. (Enter this info. once.) ▶ $

Use duplicate copies of Part III if additional space is needed.

(a) No. from Part I	(b) Purpose of gift	(c) Use of gift	(d) Description of how gift is held

(e) Transfer of gift

Transferee's name, address, and ZIP + 4	Relationship of transferor to transferee

(a) No. from Part I	(b) Purpose of gift	(c) Use of gift	(d) Description of how gift is held

(e) Transfer of gift

Transferee's name, address, and ZIP + 4	Relationship of transferor to transferee

(a) No. from Part I	(b) Purpose of gift	(c) Use of gift	(d) Description of how gift is held

(e) Transfer of gift

Transferee's name, address, and ZIP + 4	Relationship of transferor to transferee

(a) No. from Part I	(b) Purpose of gift	(c) Use of gift	(d) Description of how gift is held

(e) Transfer of gift

Transferee's name, address, and ZIP + 4	Relationship of transferor to transferee

SCHEDULE C
(Form 990)

Department of the Treasury
Internal Revenue Service

Political Campaign and Lobbying Activities

For Organizations Exempt From Income Tax Under section 501(c) and section 527

▶ **Complete if the organization is described below.** ▶ **Attach to Form 990 or Form 990-EZ.**

▶ **Go to www.irs.gov/Form990 for instructions and the latest information.**

OMB No. 1545-0047

2021

Open to Public Inspection

If the organization answered "Yes," on Form 990, Part IV, line 3, or Form 990-EZ, Part V, line 46 (Political Campaign Activities), then

- Section 501(c)(3) organizations: Complete Parts I-A and B. Do not complete Part I-C.
- Section 501(c) (other than section 501(c)(3)) organizations: Complete Parts I-A and C below. Do not complete Part I-B.
- Section 527 organizations: Complete Part I-A only.

If the organization answered "Yes," on Form 990, Part IV, line 4, or Form 990-EZ, Part VI, line 47 (Lobbying Activities), then

- Section 501(c)(3) organizations that have filed Form 5768 (election under section 501(h)): Complete Part II-A. Do not complete Part II-B.
- Section 501(c)(3) organizations that have NOT filed Form 5768 (election under section 501(h)): Complete Part II-B. Do not complete Part II-A.

If the organization answered "Yes," on Form 990, Part IV, line 5 (Proxy Tax) (See separate instructions) or Form 990-EZ, Part V, line 35c (Proxy Tax) (See separate instructions), then

- Section 501(c)(4), (5), or (6) organizations: Complete Part III.

Name of organization	Employer identification number
BRIGHTFOCUS FOUNDATION	23-7337229

Part I-A Complete if the organization is exempt under section 501(c) or is a section 527 organization.

1 Provide a description of the organization's direct and indirect political campaign activities in Part IV.

2 Political campaign activity expenditures ▶ $

3 Volunteer hours for political campaign activities

Part I-B Complete if the organization is exempt under section 501(c)(3).

1 Enter the amount of any excise tax incurred by the organization under section 4955 ▶ $

2 Enter the amount of any excise tax incurred by organization managers under section 4955 ▶ $

3 If the organization incurred a section 4955 tax, did it file Form 4720 for this year? ☐ Yes ☐ No

4a Was a correction made? ☐ Yes ☐ No

b If "Yes," describe in Part IV.

Part I-C Complete if the organization is exempt under section 501(c), except section 501(c)(3).

1 Enter the amount directly expended by the filing organization for section 527 exempt function activities ▶ $

2 Enter the amount of the filing organization's funds contributed to other organizations for section 527 exempt function activities ▶ $

3 Total exempt function expenditures. Add lines 1 and 2. Enter here and on Form 1120-POL, line 17b ▶ $

4 Did the filing organization file **Form 1120-POL** for this year? ☐ Yes ☐ No

5 Enter the names, addresses and employer identification number (EIN) of all section 527 political organizations to which the filing organization made payments. For each organization listed, enter the amount paid from the filing organization's funds. Also enter the amount of political contributions received that were promptly and directly delivered to a separate political organization, such as a separate segregated fund or a political action committee (PAC). If additional space is needed, provide information in Part IV.

(a) Name	**(b)** Address	**(c)** EIN	**(d)** Amount paid from filing organization's funds. If none, enter -0-.	**(e)** Amount of political contributions received and promptly and directly delivered to a separate political organization. If none, enter -0-.

Part II-A **Complete if the organization is exempt under section 501(c)(3) and filed Form 5768 (election under section 501(h)).**

A Check ▶ ☐ if the filing organization belongs to an affiliated group (and list in Part IV each affiliated group member's name, address, EIN, expenses, and share of excess lobbying expenditures).

B Check ▶ ☐ if the filing organization checked box A and "limited control" provisions apply.

Limits on Lobbying Expenditures (The term "expenditures" means amounts paid or incurred.)	(a) Filing organization's totals	(b) Affiliated group totals
1a Total lobbying expenditures to influence public opinion (grassroots lobbying)	0.	
b Total lobbying expenditures to influence a legislative body (direct lobbying)	0.	
c Total lobbying expenditures (add lines 1a and 1b)	0.	
d Other exempt purpose expenditures	53,259,153.	
e Total exempt purpose expenditures (add lines 1c and 1d)	53,259,153.	
f Lobbying nontaxable amount. Enter the amount from the following table in both columns.	1,000,000.	
g Grassroots nontaxable amount (enter 25% of line 1f)	250,000.	
h Subtract line 1g from line 1a. If zero or less, enter -0-	0.	
i Subtract line 1f from line 1c. If zero or less, enter -0-	0.	

If the amount on line 1e, column (a) or (b) is:	The lobbying nontaxable amount is:
Not over $500,000	20% of the amount on line 1e.
Over $500,000 but not over $1,000,000	$100,000 plus 15% of the excess over $500,000.
Over $1,000,000 but not over $1,500,000	$175,000 plus 10% of the excess over $1,000,000.
Over $1,500,000 but not over $17,000,000	$225,000 plus 5% of the excess over $1,500,000.
Over $17,000,000	$1,000,000.

j If there is an amount other than zero on either line 1h or line 1i, did the organization file Form 4720 reporting section 4911 tax for this year? ☐ **Yes** ☐ **No**

4-Year Averaging Period Under Section 501(h)
(Some organizations that made a section 501(h) election do not have to complete all of the five columns below. See the separate instructions for lines 2a through 2f.)

Lobbying Expenditures During 4-Year Averaging Period

Calendar year (or fiscal year beginning in)	(a) 2018	(b) 2019	(c) 2020	(d) 2021	(e) Total
2a Lobbying nontaxable amount	1,000,000.	1,000,000.	1,000,000.	1,000,000.	4,000,000.
b Lobbying ceiling amount (150% of line 2a, column(e))					6,000,000.
c Total lobbying expenditures					
d Grassroots nontaxable amount	250,000.	250,000.	250,000.	250,000.	1,000,000.
e Grassroots ceiling amount (150% of line 2d, column (e))					1,500,000.
f Grassroots lobbying expenditures					

Schedule C (Form 990) 2021

132042 11-03-21

Part II-B Complete if the organization is exempt under section 501(c)(3) and has NOT filed Form 5768 (election under section 501(h)).

For each "Yes" response on lines 1a through 1i below, provide in Part IV a detailed description of the lobbying activity.	(a) Yes	(a) No	(b) Amount
1 During the year, did the filing organization attempt to influence foreign, national, state, or local legislation, including any attempt to influence public opinion on a legislative matter or referendum, through the use of:			
a Volunteers?			
b Paid staff or management (include compensation in expenses reported on lines 1c through 1i)?			
c Media advertisements?			
d Mailings to members, legislators, or the public?			
e Publications, or published or broadcast statements?			
f Grants to other organizations for lobbying purposes?			
g Direct contact with legislators, their staffs, government officials, or a legislative body?			
h Rallies, demonstrations, seminars, conventions, speeches, lectures, or any similar means?			
i Other activities?			
j Total. Add lines 1c through 1i			
2a Did the activities in line 1 cause the organization to be not described in section 501(c)(3)?			
b If "Yes," enter the amount of any tax incurred under section 4912			
c If "Yes," enter the amount of any tax incurred by organization managers under section 4912			
d If the filing organization incurred a section 4912 tax, did it file Form 4720 for this year?			

Part III-A Complete if the organization is exempt under section 501(c)(4), section 501(c)(5), or section 501(c)(6).

			Yes	No
1	Were substantially all (90% or more) dues received nondeductible by members?	1		
2	Did the organization make only in-house lobbying expenditures of $2,000 or less?	2		
3	Did the organization agree to carry over lobbying and political campaign activity expenditures from the prior year?	3		

Part III-B Complete if the organization is exempt under section 501(c)(4), section 501(c)(5), or section 501(c)(6) and if either (a) BOTH Part III-A, lines 1 and 2, are answered "No" OR (b) Part III-A, line 3, is answered "Yes."

1	Dues, assessments and similar amounts from members	1	
2	Section 162(e) nondeductible lobbying and political expenditures **(do not include amounts of political expenses for which the section 527(f) tax was paid).**		
a	Current year	2a	
b	Carryover from last year	2b	
c	Total	2c	
3	Aggregate amount reported in section 6033(e)(1)(A) notices of nondeductible section 162(e) dues	3	
4	If notices were sent and the amount on line 2c exceeds the amount on line 3, what portion of the excess does the organization agree to carryover to the reasonable estimate of nondeductible lobbying and political expenditure next year?	4	
5	Taxable amount of lobbying and political expenditures. See instructions	5	

Part IV Supplemental Information

Provide the descriptions required for Part I-A, line 1; Part I-B, line 4; Part I-C, line 5; Part II-A (affiliated group list); Part II-A, lines 1 and 2 (See instructions); and Part II-B, line 1. Also, complete this part for any additional information.

SCHEDULE D (Form 990)

Department of the Treasury
Internal Revenue Service

Supplemental Financial Statements

▶ Complete if the organization answered "Yes" on Form 990, Part IV, line 6, 7, 8, 9, 10, 11a, 11b, 11c, 11d, 11e, 11f, 12a, or 12b.
▶ Attach to Form 990.
▶ Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2021

Open to Public Inspection

Name of the organization
BRIGHTFOCUS FOUNDATION

Employer identification number
23-7337229

Part I Organizations Maintaining Donor Advised Funds or Other Similar Funds or Accounts.

Complete if the organization answered "Yes" on Form 990, Part IV, line 6.

		(a) Donor advised funds	(b) Funds and other accounts
1	Total number at end of year		
2	Aggregate value of contributions to (during year)		
3	Aggregate value of grants from (during year)		
4	Aggregate value at end of year		

5 Did the organization inform all donors and donor advisors in writing that the assets held in donor advised funds are the organization's property, subject to the organization's exclusive legal control? ☐ Yes ☐ No

6 Did the organization inform all grantees, donors, and donor advisors in writing that grant funds can be used only for charitable purposes and not for the benefit of the donor or donor advisor, or for any other purpose conferring impermissible private benefit? ☐ Yes ☐ No

Part II Conservation Easements.

Complete if the organization answered "Yes" on Form 990, Part IV, line 7.

1 Purpose(s) of conservation easements held by the organization (check all that apply).

☐ Preservation of land for public use (for example, recreation or education)
☐ Preservation of a historically important land area
☐ Protection of natural habitat
☐ Preservation of a certified historic structure
☐ Preservation of open space

2 Complete lines 2a through 2d if the organization held a qualified conservation contribution in the form of a conservation easement on the last day of the tax year.

			Held at the End of the Tax Year
a	Total number of conservation easements	2a	
b	Total acreage restricted by conservation easements	2b	
c	Number of conservation easements on a certified historic structure included in (a)	2c	
d	Number of conservation easements included in (c) acquired after 7/25/06, and not on a historic structure listed in the National Register	2d	

3 Number of conservation easements modified, transferred, released, extinguished, or terminated by the organization during the tax year ▶ _____

4 Number of states where property subject to conservation easement is located ▶ _____

5 Does the organization have a written policy regarding the periodic monitoring, inspection, handling of violations, and enforcement of the conservation easements it holds? ☐ Yes ☐ No

6 Staff and volunteer hours devoted to monitoring, inspecting, handling of violations, and enforcing conservation easements during the year ▶ _____

7 Amount of expenses incurred in monitoring, inspecting, handling of violations, and enforcing conservation easements during the year ▶ $ _____

8 Does each conservation easement reported on line 2(d) above satisfy the requirements of section 170(h)(4)(B)(i) and section 170(h)(4)(B)(ii)? ☐ Yes ☐ No

9 In Part XIII, describe how the organization reports conservation easements in its revenue and expense statement and balance sheet, and include, if applicable, the text of the footnote to the organization's financial statements that describes the organization's accounting for conservation easements.

Part III Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets.

Complete if the organization answered "Yes" on Form 990, Part IV, line 8.

1a If the organization elected, as permitted under FASB ASC 958, not to report in its revenue statement and balance sheet works of art, historical treasures, or other similar assets held for public exhibition, education, or research in furtherance of public service, provide in Part XIII the text of the footnote to its financial statements that describes these items.

b If the organization elected, as permitted under FASB ASC 958, to report in its revenue statement and balance sheet works of art, historical treasures, or other similar assets held for public exhibition, education, or research in furtherance of public service, provide the following amounts relating to these items:

(i) Revenue included on Form 990, Part VIII, line 1 ▶ $ _____

(ii) Assets included in Form 990, Part X ▶ $ _____

2 If the organization received or held works of art, historical treasures, or other similar assets for financial gain, provide the following amounts required to be reported under FASB ASC 958 relating to these items:

a Revenue included on Form 990, Part VIII, line 1 ▶ $ _____

b Assets included in Form 990, Part X ▶ $ _____

Part III Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets *(continued)*

3 Using the organization's acquisition, accession, and other records, check any of the following that make significant use of its collection items (check all that apply):

a ☐ Public exhibition
b ☐ Scholarly research
c ☐ Preservation for future generations
d ☐ Loan or exchange program
e ☐ Other _____

4 Provide a description of the organization's collections and explain how they further the organization's exempt purpose in Part XIII.

5 During the year, did the organization solicit or receive donations of art, historical treasures, or other similar assets to be sold to raise funds rather than to be maintained as part of the organization's collection? ☐ Yes ☐ No

Part IV Escrow and Custodial Arrangements. Complete if the organization answered "Yes" on Form 990, Part IV, line 9, or reported an amount on Form 990, Part X, line 21.

1a Is the organization an agent, trustee, custodian or other intermediary for contributions or other assets not included on Form 990, Part X? ☐ Yes ☐ No

b If "Yes," explain the arrangement in Part XIII and complete the following table:

		Amount
c Beginning balance	1c	
d Additions during the year	1d	
e Distributions during the year	1e	
f Ending balance	1f	

2a Did the organization include an amount on Form 990, Part X, line 21, for escrow or custodial account liability? ☐ Yes ☐ No

b If "Yes," explain the arrangement in Part XIII. Check here if the explanation has been provided on Part XIII ☐

Part V Endowment Funds. Complete if the organization answered "Yes" on Form 990, Part IV, line 10.

	(a) Current year	(b) Prior year	(c) Two years back	(d) Three years back	(e) Four years back
1a Beginning of year balance	302,000.	302,000.	302,000.	320,000.	90,000.
b Contributions	36,634.	14,744.	14,778.	14,385.	234,806.
c Net investment earnings, gains, and losses	23,000.			-18,000.	10,000.
d Grants or scholarships					
e Other expenditures for facilities and programs	36,634.	14,744.	14,778.	14,385.	14,806.
f Administrative expenses					
g End of year balance	325,000.	302,000.	302,000.	302,000.	320,000.

2 Provide the estimated percentage of the current year end balance (line 1g, column (a)) held as:

a Board designated or quasi-endowment ▶ .0000 %
b Permanent endowment ▶ 100 %
c Term endowment ▶ .0000 %

The percentages on lines 2a, 2b, and 2c should equal 100%.

3a Are there endowment funds not in the possession of the organization that are held and administered for the organization by:

		Yes	No
(i) Unrelated organizations	3a(i)	X	
(ii) Related organizations	3a(ii)		X
b If "Yes" on line 3a(ii), are the related organizations listed as required on Schedule R?	3b		

4 Describe in Part XIII the intended uses of the organization's endowment funds.

Part VI Land, Buildings, and Equipment.

Complete if the organization answered "Yes" on Form 990, Part IV, line 11a. See Form 990, Part X, line 10.

Description of property	(a) Cost or other basis (investment)	(b) Cost or other basis (other)	(c) Accumulated depreciation	(d) Book value
1a Land	2,800,000.	1,147,363.		3,947,363.
b Buildings	1,629,400.	5,271,548.	3,843,645.	3,057,303.
c Leasehold improvements				
d Equipment		1,699,731.	585,469.	1,114,262.
e Other		216,753.	174,566.	42,187.
Total. Add lines 1a through 1e. *(Column (d) must equal Form 990, Part X, column (B), line 10c.)* ▶				8,161,115.

Part VII Investments - Other Securities.

Complete if the organization answered "Yes" on Form 990, Part IV, line 11b. See Form 990, Part X, line 12.

(a) Description of security or category (including name of security)	(b) Book value	(c) Method of valuation: Cost or end-of-year market value
(1) Financial derivatives		
(2) Closely held equity interests		
(3) Other		
(A)		
(B)		
(C)		
(D)		
(E)		
(F)		
(G)		
(H)		
Total. (Col. (b) must equal Form 990, Part X, col. (B) line 12.) ▶		

Part VIII Investments - Program Related.

Complete if the organization answered "Yes" on Form 990, Part IV, line 11c. See Form 990, Part X, line 13.

(a) Description of investment	(b) Book value	(c) Method of valuation: Cost or end-of-year market value
(1)		
(2)		
(3)		
(4)		
(5)		
(6)		
(7)		
(8)		
(9)		
Total. (Col. (b) must equal Form 990, Part X, col. (B) line 13.) ▶		

Part IX Other Assets.

Complete if the organization answered "Yes" on Form 990, Part IV, line 11d. See Form 990, Part X, line 15.

(a) Description	(b) Book value
(1)	
(2)	
(3)	
(4)	
(5)	
(6)	
(7)	
(8)	
(9)	
Total. *(Column (b) must equal Form 990, Part X, col. (B) line 15.)* ▶	

Part X Other Liabilities.

Complete if the organization answered "Yes" on Form 990, Part IV, line 11e or 11f. See Form 990, Part X, line 25.

1. (a) Description of liability	(b) Book value
(1) Federal income taxes	
(2) CHARITABLE GIFT ANNUITIES	756,074.
(3) RENTAL DEPOSITS	25,000.
(4) CAPITAL LEASE OBLIGATIONS	11,959.
(5)	
(6)	
(7)	
(8)	
(9)	
Total. *(Column (b) must equal Form 990, Part X, col. (B) line 25.)* ▶	793,033.

2. Liability for uncertain tax positions. In Part XIII, provide the text of the footnote to the organization's financial statements that reports the organization's liability for uncertain tax positions under FASB ASC 740. Check here if the text of the footnote has been provided in Part XIII ... X

Part XI Reconciliation of Revenue per Audited Financial Statements With Revenue per Return.

Complete if the organization answered "Yes" on Form 990, Part IV, line 12a.

1	Total revenue, gains, and other support per audited financial statements			1	61,811,216.
2	Amounts included on line 1 but not on Form 990, Part VIII, line 12:				
a	Net unrealized gains (losses) on investments	2a	-1,605,810.		
b	Donated services and use of facilities	2b	12,439,938.		
c	Recoveries of prior year grants	2c	528,609.		
d	Other (Describe in Part XIII.)	2d			
e	Add lines **2a** through **2d**			2e	11,362,737.
3	Subtract line **2e** from line **1**			3	50,448,479.
4	Amounts included on Form 990, Part VIII, line 12, but not on line 1:				
a	Investment expenses not included on Form 990, Part VIII, line 7b	4a	351,028.		
b	Other (Describe in Part XIII.)	4b	-41,779.		
c	Add lines **4a** and **4b**			4c	309,249.
5	Total revenue. Add lines **3** and **4c.** *(This must equal Form 990, Part I, line 12.)*			5	50,757,728.

Part XII Reconciliation of Expenses per Audited Financial Statements With Expenses per Return.

Complete if the organization answered "Yes" on Form 990, Part IV, line 12a.

1	Total expenses and losses per audited financial statements			1	65,826,058.
2	Amounts included on line 1 but not on Form 990, Part IX, line 25:				
a	Donated services and use of facilities	2a	12,439,938.		
b	Prior year adjustments	2b			
c	Other losses	2c			
d	Other (Describe in Part XIII.)	2d			
e	Add lines **2a** through **2d**			2e	12,439,938.
3	Subtract line **2e** from line **1**			3	53,386,120.
4	Amounts included on Form 990, Part IX, line 25, but not on line 1:				
a	Investment expenses not included on Form 990, Part VIII, line 7b	4a	351,028.		
b	Other (Describe in Part XIII.)	4b	320,209.		
c	Add lines **4a** and **4b**			4c	671,237.
5	Total expenses. Add lines **3** and **4c.** *(This must equal Form 990, Part I, line 18.)*			5	54,057,357.

Part XIII Supplemental Information.

Provide the descriptions required for Part II, lines 3, 5, and 9; Part III, lines 1a and 4; Part IV, lines 1b and 2b; Part V, line 4; Part X, line 2; Part XI, lines 2d and 4b; and Part XII, lines 2d and 4b. Also complete this part to provide any additional information.

PART V, LINE 4:

THE EARNINGS ON THIS ENDOWMENT ARE AVAILABLE FOR THE ALZHEIMER'S DISEASE RESEARCH PROGRAM, ARE RECORDED AS TEMPORARILY RESTRICTED INVESTMENT INCOME, AND ARE RELEASED AS SPENT.

PART X, LINE 2:

BRIGHTFOCUS PERFORMED AN EVALUATION OF UNCERTAINTY IN INCOME TAXES FOR THE YEAR ENDED MARCH 31, 2022, AND DETERMINED THAT THERE WERE NO MATTERS THAT WOULD REQUIRE RECOGNITION IN THE CONSOLIDATED FINANCIAL STATEMENTS OR THAT MAY HAVE ANY EFFECT ON ITS TAX-EXEMPT STATUS.

PART XI, LINE 4B - OTHER ADJUSTMENTS:

Part XIII Supplemental Information *(continued)*

DEPRECIATION OF RENTAL PROPERTY	-41,779.

PART XII, LINE 4B - OTHER ADJUSTMENTS:

DEPRECIATION ON RENTAL PROPERTY	-41,779.
CHANGE IN PRESENT VALUE OF GRANTS	361,988.
TOTAL TO SCHEDULE D, PART XII, LINE 4B	320,209.

SCHEDULE F (Form 990)

Department of the Treasury
Internal Revenue Service

Statement of Activities Outside the United States

▶ **Complete if the organization answered "Yes" on Form 990, Part IV, line 14b, 15, or 16.**

▶ **Attach to Form 990.**

▶ **Go to www.irs.gov/Form990 for instructions and the latest information.**

OMB No. 1545-0047

2021

Open to Public Inspection

Name of the organization

BRIGHTFOCUS FOUNDATION

Employer identification number

23-7337229

Part I General Information on Activities Outside the United States. Complete if the organization answered "Yes" on Form 990, Part IV, line 14b.

1 **For grantmakers.** Does the organization maintain records to substantiate the amount of its grants and other assistance, the grantees' eligibility for the grants or assistance, and the selection criteria used to award the grants or assistance? ..... [X] **Yes** [ ] **No**

2 **For grantmakers.** Describe in Part V the organization's procedures for monitoring the use of its grants and other assistance outside the United States.

3 Activities per Region. (The following Part I, line 3 table can be duplicated if additional space is needed.)

(a) Region	**(b)** Number of offices in the region	**(c)** Number of employees, agents, and independent contractors in the region	**(d)** Activities conducted in the region (by type) (such as, fundraising, program services, investments, grants to recipients located in the region)	**(e)** If activity listed in (d) is a program service, describe specific type of service(s) in the region	**(f)** Total expenditures for and investments in the region
EAST ASIA AND THE PACIFIC	0	0	GRANTMAKING		347,083.
EUROPE	0	0	GRANTMAKING		3,167,829.
MIDDLE EAST AND NORTH AFRICA - ALGERIA, BAHRAIN, DJIBOUTI, EGYPT,	0	0	GRANTMAKING		600,000.
NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES	0	0	GRANTMAKING		1,343,047.
3 a Subtotal	0	0			5,457,959.
b Total from continuation sheets to Part I	0	0			0.
c **Totals** (add lines 3a and 3b)	0	0			5,457,959.

Part II **Grants and Other Assistance to Organizations or Entities Outside the United States.** Complete if the organization answered "Yes" on Form 990, Part IV, line 15, for any recipient who received more than $5,000. Part II can be duplicated if additional space is needed.

1 (a) Name of organization	(b) IRS code section and EIN (if applicable)	(c) Region	(d) Purpose of grant	(e) Amount of cash grant	(f) Manner of cash disbursement	(g) Amount of noncash assistance	(h) Description of noncash assistance	(i) Method of valuation (book, FMV, appraisal, other)
		EUROPE (INCLUDING ICELAND & GREENLAND)	ALZHEIMER'S DISEASE RESEARCH BY LAIA MONTOLIU-GAYA, PHD, ENTITLED: (A2022015F)	200,000.	WIRE TRANSFER	0.		
		NORTH AMERICA	ALZHEIMER'S DISEASE RES. BY CHRISTOPHER MORRONE, PHD, ENTITLED: (A2022016F)	200,000.	WIRE TRANSFER	0.		
		EUROPE (INCLUDING ICELAND & GREENLAND)	ALZHEIMER'S DISEASE RESEARCH BY SANDRA O. TOME, PHD, ENTITLED: (A2022019F)	200,000.	WIRE TRANSFER	0.		
		EAST ASIA AND THE PACIFIC	ALZHEIMER'S DISEASE RESEARCH BY KRISTIE STEFANOSKA, PHD, ENTITLED: (A2022022F)	199,034.	WIRE TRANSFER	0.		
		EUROPE (INCLUDING ICELAND & GREENLAND)	ALZHEIMER'S DISEASE RESEARCH BY LARISSA TRAXLER, PHD, ENTITLED: (A2022024F)	200,000.	WIRE TRANSFER	0.		
		MIDDLE EAST AND NORTH AFRICA	ALZHEIMER'S DISEASE RESEARCH BY URI ASHERY, PHD, ENTITLED: (A2022029S)	300,000.	WIRE TRANSFER	0.		
		EUROPE (INCLUDING ICELAND & GREENLAND)	ALZHEIMER'S DISEASE RESEARCH BY SAMUEL BARNES, PHD, ENTITLED: (A2022030S)	299,715.	WIRE TRANSFER	0.		
		EUROPE (INCLUDING ICELAND & GREENLAND)	ALZHEIMER'S DISEASE RES. BY MARTA CORTES-CANTELI, PHD, ENTITLED: (A2022034S)	300,000.	WIRE TRANSFER	0.		

2 Enter total number of recipient organizations listed above that are recognized as charities by the foreign country, recognized as a tax exempt 501(c)(3) organization by the IRS, or for which the grantee or counsel has provided a section 501(c)(3) equivalency letter ▶ 21

3 Enter total number of other organizations or entities ▶ 0

See Schedule O for continuation of Grant Purposes, item (d)

Part II **Continuation of Grants and Other Assistance to Organizations or Entities Outside the United States.** (Schedule F (Form 990), Part II, line 1)

1 (a) Name of organization	(b) IRS code section and EIN (if applicable)	(c) Region	(d) Purpose of grant	(e) Amount of cash grant	(f) Manner of cash disbursement	(g) Amount of non-cash assistance	(h) Description of non-cash assistance	(i) Method of valuation (book, FMV, appraisal, other)
		MIDDLE EAST AND NORTH AFRICA	ALZHEIMER'S DISEASE RESEARCH BY YUVAL DOR, PHD, ENTITLED: (A2022035S)	300,000.	WIRE TRANSFER	0.		
		NORTH AMERICA	ALZHEIMER'S DISEASE RESEARCH BY SUE-ANN MOK, PHD, ENTITLED: (A2022044S)	299,851.	WIRE TRANSFER	0.		
		EUROPE (INCLUDING ICELAND & GREENLAND)	ALZHEIMER'S DISEASE RESEARCH BY DOMINIK PAQUET, PHD, ENTITLED: (A2022045S)	300,000.	WIRE TRANSFER	0.		
		NORTH AMERICA	ALZHEIMER'S DISEASE RESEARCH BY CARLOS RONCERO, PHD, ENTITLED: (A2022046S)	243,196.	WIRE TRANSFER	0.		
		EUROPE (INCLUDING ICELAND & GREENLAND)	ALZHEIMER'S DISEASE RESEARCH BY CARLOS SAURA, PHD, ENTITLED: (A2022047S)	300,000.	WIRE TRANSFER	0.		
		EUROPE (INCLUDING ICELAND & GREENLAND)	ALZHEIMER'S DISEASE RESEARCH BY DR. GAELLE CHETELAT ENTITLED: (CA2021013)	68,278.	WIRE TRANSFER	0.		
		EAST ASIA AND THE PACIFIC	NATIONAL GLAUCOMA RES. BY EMMANUELLE SOUZEAU, PHD, ENTITLED: (G2022002F)	148,049.	WIRE TRANSFER	0.		
		EUROPE (INCLUDING ICELAND & GREENLAND)	NATIONAL GLAUCOMA RESEARCH BY MARCO FELIGIONI, PHD, ENTITLED: (G2022015S)	200,000.	WIRE TRANSFER	0.		
		EUROPE (INCLUDING ICELAND & GREENLAND)	MACULAR DEGENERATION RESEARCH BY NICOLE NOEL, PHD, ENTITLED: (M2022002F)	199,998.	WIRE TRANSFER	0.		

See Schedule O for continuation of Grant Purposes, item (d)

Part II **Continuation of Grants and Other Assistance to Organizations or Entities Outside the United States.** (Schedule F (Form 990), Part II, line 1)

1 (a) Name of organization	(b) IRS code section and EIN (if applicable)	(c) Region	(d) Purpose of grant	(e) Amount of cash grant	(f) Manner of cash disbursement	(g) Amount of non-cash assistance	(h) Description of non-cash assistance	(i) Method of valuation (book, FMV, appraisal, other)
		EUROPE (INCLUDING ICELAND & GREENLAND)	MACULAR DEGENERATION RESEARCH BY LUCIA CELKOVA, PHD, ENTITLED: (M2022004F)	200,000.	WIRE TRANSFER	0.		
		EUROPE (INCLUDING ICELAND & GREENLAND)	MACULAR DEGENERATION RESEARCH BY YARA LECHANTEUR, MD, PHD, ENTITLED: (M2022013N)	449,838.	WIRE TRANSFER	0.		
		NORTH AMERICA	MACULAR DEGENERATION RES. BY PRZEMYSLAW SAPIEHA, PHD, ENTITLED: (M2022015I)	600,000.	WIRE TRANSFER	0.		
		EUROPE (INCLUDING ICELAND & GREENLAND)	MACULAR DEGENERATION RESEARCH BY WEN HWA LEE, PHD, ENTITLED: (CM2022002)	250,000.	WIRE TRANSFER	0.		

See Schedule O for continuation of Grant Purposes, item (d)

Part III **Grants and Other Assistance to Individuals Outside the United States.** Complete if the organization answered "Yes" on Form 990, Part IV, line 16.
Part III can be duplicated if additional space is needed.

(a) Type of grant or assistance	**(b)** Region	**(c)** Number of recipients	**(d)** Amount of cash grant	**(e)** Manner of cash disbursement	**(f)** Amount of noncash assistance	**(g)** Description of noncash assistance	**(h)** Method of valuation (book, FMV, appraisal, other)

Part IV Foreign Forms

1	Was the organization a U.S. transferor of property to a foreign corporation during the tax year? *If "Yes," the organization may be required to file Form 926, Return by a U.S. Transferor of Property to a Foreign Corporation (see Instructions for Form 926)*	☐ Yes	☒ No
2	Did the organization have an interest in a foreign trust during the tax year? *If "Yes," the organization may be required to separately file Form 3520, Annual Return To Report Transactions With Foreign Trusts and Receipt of Certain Foreign Gifts, and/or Form 3520-A, Annual Information Return of Foreign Trust With a U.S. Owner (see Instructions for Forms 3520 and 3520-A; don't file with Form 990)*	☐ Yes	☒ No
3	Did the organization have an ownership interest in a foreign corporation during the tax year? *If "Yes," the organization may be required to file Form 5471, Information Return of U.S. Persons With Respect to Certain Foreign Corporations (see Instructions for Form 5471)*	☐ Yes	☒ No
4	Was the organization a direct or indirect shareholder of a passive foreign investment company or a qualified electing fund during the tax year? *If "Yes," the organization may be required to file Form 8621, Information Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund (see Instructions for Form 8621)*	☐ Yes	☒ No
5	Did the organization have an ownership interest in a foreign partnership during the tax year? *If "Yes," the organization may be required to file Form 8865, Return of U.S. Persons With Respect to Certain Foreign Partnerships (see Instructions for Form 8865)*	☐ Yes	☒ No
6	Did the organization have any operations in or related to any boycotting countries during the tax year? *If "Yes," the organization may be required to separately file Form 5713, International Boycott Report (see Instructions for Form 5713; don't file with Form 990)*	☐ Yes	☒ No

Part V Supplemental Information

Provide the information required by Part I, line 2 (monitoring of funds); Part I, line 3, column (f) (accounting method; amounts of investments vs. expenditures per region); Part II, line 1 (accounting method); Part III (accounting method); and Part III, column (c) (estimated number of recipients), as applicable. Also complete this part to provide any additional information. See instructions.

PART I, LINE 2:

BRIGHTFOCUS INTERACTS WITH ALL GRANTEES AT LEAST QUARTERLY BY E-MAIL OR AT SCIENTIFIC MEETINGS. IN ADDITION TO THESE INTERACTIONS, EACH GRANT RECIPIENT IS REQUIRED TO SUBMIT SEPARATE DETAILED ANNUAL SCIENTIFIC PROGRESS AND FINANCIAL REPORTS TO BRIGHTFOCUS. THESE ARE RECEIVED BY THE BRIGHTFOCUS SCIENTIFIC AFFAIRS DEPARTMENT, AND REVIEWED BY SCIENTIFIC STAFF WITH BROAD EXPERTISE, INCLUDING IMAGING, MOLECULAR BIOLOGY AND SIGNALING PATHWAYS, CELL BIOLOGY, ANGIOGENESIS, BIOCHEMISTRY, NEUROSCIENCE, AND GENETICS. SENIOR STAFF REVIEWS EACH PROGRESS REPORT AND EVALUATES THE PROJECT FOR SUFFICIENT PROGRESS TOWARDS THE SPECIFIC AIMS PROPOSED IN THE ORIGINAL APPLICATION OR ANY BUDGETARY CONCERNS. THIS EFFORT IS SUPPORTED BY ADDITIONAL SCIENTIFIC COUNSEL FROM MEMBERS OF THE BRIGHTFOCUS SCIENTIFIC REVIEW COMMITTEES, WHEN REQUIRED. IN ADDITION TO STATEMENTS OF EXPERIMENTAL PROGRESS, ALL GRANTEES ARE ASKED TO REPORT ANY TECHNICAL PUBLICATIONS, MEDIA REPORTS, OR PATENT APPLICATIONS IN WHICH BRIGHTFOCUS-SPONSORED RESEARCH IS DESCRIBED. IF SIGNIFICANT CONCERNS RELATED TO PROGRESS ON THE AWARDS ARE DISCOVERED, AND NOT RESOLVED AFTER INTERACTION WITH THE AWARD GRANTEE, THE BRIGHTFOCUS STAFF RECOMMENDS APPROPRIATE ACTIONS TO THE CHAIR OF THE SCIENTIFIC AFFAIRS COMMITTEE OF THE BOARD OF DIRECTORS. IN ACCORDANCE WITH THE GRANT AGREEMENT TERMS AND CONDITIONS, BRIGHTFOCUS MAY WITHHOLD FUNDING, OR DISCONTINUE AN AWARD, FOR ANY GRANTEE THAT FAILS TO ACHIEVE SUFFICIENT PROGRESS OR SUBMIT REQUIRED REPORTS.

AT THE CONCLUSION OF THE GRANT AWARD PERIOD, EACH GRANTEE MUST COMPLETE AND SUBMIT A FINAL REPORT THAT IS ALSO REVIEWED BY THE BRIGHTFOCUS SENIOR SCIENTIFIC STAFF. EVALUATION OF THE WORK OF EACH GRANTEE IS QUALITATIVELY

Part V Supplemental Information

Provide the information required by Part I, line 2 (monitoring of funds); Part I, line 3, column (f) (accounting method; amounts of investments vs. expenditures per region); Part II, line 1 (accounting method); Part III (accounting method); and Part III, column (c) (estimated number of recipients), as applicable. Also complete this part to provide any additional information. See instructions.

AND QUANTITATIVELY ASSESSED THROUGH VARIOUS METRICS RELATED TO THE IMPACT OF THE GRANT ON ITS TARGETED DISEASE FIELD. SUCH IMPACT METRICS HAVE REVEALED THAT 95% OF BRIGHTFOCUS-SUPPORTED RESEARCH RESULTS IN RESEARCH PUBLICATIONS THAT ADVANCE THE FIELDS SERVED BY BRIGHTFOCUS. THIS IMPACT IS FURTHER SUPPORTED BY ANNUAL CATEGORY NORMALIZED CITATION IMPACT ANALYSIS THAT COMPARES BRIGHTFOCUS-SUPPORTED WORKS TO AN UNBIASED COMPARISON OF IMPACT PERFORMANCE VERSUS THE WORLD AVERAGE. BRIGHTFOCUS-SUPPORTED PUBLICATIONS WERE RECENTLY CITED AT 2 TIMES THE FREQUENCY OF THE WORLD AVERAGE. A FINAL EXAMPLE OF IMPACT ASSESSMENT REVEALED THAT THE SUCCESSES OF BRIGHTFOCUS GRANTEES CONTINUE LONG AFTER THE GRANT EXPIRES. ON AVERAGE, EACH GRANTEE RECEIVES ADDITIONAL GRANTS FOR FOLLOW-ON PROJECTS SPAWNED BY THE BRIGHTFOCUS GRANT, WITH VALUES UP TO 10 TIMES THE LEVEL OF THE INITIAL BRIGHTFOCUS INVESTMENT.

BRIGHTFOCUS SOLICITS FEEDBACK FROM ITS GRANTEES, AND PROVIDES AN ANONYMOUS FORUM FOR COLLECTING SUCH INFORMATION. THROUGH THE BRIGHTFOCUS FOUNDATION WEBSITE AND WITHIN THE SCIENTIFIC PROGRESS REPORTS, THERE ARE DESIGNATED SECTIONS WHERE AWARDEES ARE ASKED TO PROVIDE FEEDBACK TO THE FOUNDATION. THROUGH THIS MECHANISM, THEY ARE GIVEN THE ABILITY TO ANONYMOUSLY PROVIDE FEEDBACK OR COMMUNICATE THEIR CONCERNS TO PROGRAM STAFF OR THE BRIGHTFOCUS' COMPLIANCE OFFICE. ANY SUGGESTIONS, CONCERNS, COMPLAINTS, OR POSITIVE EXPERIENCES CAN BE OUTLINED AND BROUGHT TO THE ATTENTION OF BRIGHTFOCUS IN THIS MANNER, SO THAT BRIGHTFOCUS CAN ADDRESS ANY AREAS NEEDING IMPROVEMENT, REAFFIRM PRAISE-WORTHY POLICIES, OR OTHERWISE ASSESS NEEDS FOR PROGRAMMATIC CHANGE. THE SENIOR LEADERSHIP PRESENTS AND SUMMARIZES THE STATUS AND PROGRESS ON GRANTS TO THE BRIGHTFOCUS BOARD OF DIRECTORS AT EACH OF THEIR QUARTERLY BOARD MEETINGS.

Part V **Supplemental Information**

Provide the information required by Part I, line 2 (monitoring of funds); Part I, line 3, column (f) (accounting method; amounts of investments vs. expenditures per region); Part II, line 1 (accounting method); Part III (accounting method); and Part III, column (c) (estimated number of recipients), as applicable. Also complete this part to provide any additional information. See instructions.

PART I, LINE 3:

BRIGHTFOCUS REPORTED THE EXPENDITURES BASED ON THE ACCOUNTING METHOD USED IN ITS AUDITED FINANCIAL STATEMENTS WHICH IS ON AN ACCRUAL BASIS.

PART II, LINE 1:

BRIGHTFOCUS REPORTED THE EXPENDITURES BASED ON THE ACCOUNTING METHOD USED IN ITS AUDITED FINANCIAL STATEMENTS WHICH IS ON AN ACCRUAL BASIS.

SCHEDULE G (Form 990)

Department of the Treasury
Internal Revenue Service

Supplemental Information Regarding Fundraising or Gaming Activities

Complete if the organization answered "Yes" on Form 990, Part IV, line 17, 18, or 19, or if the organization entered more than $15,000 on Form 990-EZ, line 6a.

▶ **Attach to Form 990 or Form 990-EZ.**

▶ **Go to www.irs.gov/Form990 for instructions and the latest information.**

OMB No. 1545-0047

2021

Open to Public Inspection

Name of the organization

BRIGHTFOCUS FOUNDATION

Employer identification number

23-7337229

Part I Fundraising Activities. Complete if the organization answered "Yes" on Form 990, Part IV, line 17. Form 990-EZ filers are not required to complete this part.

1 Indicate whether the organization raised funds through any of the following activities. Check all that apply.

- **a** [X] Mail solicitations
- **b** [X] Internet and email solicitations
- **c** [ ] Phone solicitations
- **d** [ ] In-person solicitations
- **e** [X] Solicitation of non-government grants
- **f** [ ] Solicitation of government grants
- **g** [ ] Special fundraising events

2 a Did the organization have a written or oral agreement with any individual (including officers, directors, trustees, or key employees listed in Form 990, Part VII) or entity in connection with professional fundraising services? [X] **Yes** [ ] **No**

b If "Yes," list the 10 highest paid individuals or entities (fundraisers) pursuant to agreements under which the fundraiser is to be compensated at least $5,000 by the organization.

(i) Name and address of individual or entity (fundraiser)	**(ii)** Activity	**(iii)** Did fundraiser have custody or control of contributions? Yes	No	**(iv)** Gross receipts from activity	**(v)** Amount paid to (or retained by) fundraiser listed in col. **(i)**	**(vi)** Amount paid to (or retained by) organization
RKD GROUP - 35 PARKWOOD DRIVE, STE. 160, HOPKINTON,	FUNDRAISING AND COMMUNICATIONS CONSULTANT		X	31,064,820.	471,000.	30,593,820.
ALLEGIANCE GROUP - 2300 CLARENDON BLVD., STE. 925,	FUNDRAISING AND COMMUNICATIONS CONSULTANT		X	2,158,912.	327,203.	1,831,709.
Total ▶				33,223,732.	798,203.	32,425,529.

3 List all states in which the organization is registered or licensed to solicit contributions or has been notified it is exempt from registration or licensing.

AK,AL,AR,AZ,CA,CO,CT,DC,FL,GA,HI,IL,KS,KY,LA,MA,MD,ME,MI,MN,MO,MS,NC,ND,NH
NJ,NM,NV,NY,OH,OK,OR,PA,RI,SC,TN,UT,VA,WA,WI,WV

SEE PART IV FOR CONTINUATIONS

Part II **Fundraising Events.** Complete if the organization answered "Yes" on Form 990, Part IV, line 18, or reported more than $15,000 of fundraising event contributions and gross income on Form 990-EZ, lines 1 and 6b. List events with gross receipts greater than $5,000.

		(a) Event #1 (event type)	(b) Event #2 (event type)	(c) Other events (total number)	(d) Total events (add col. (a) through col. (c))
Revenue	1 Gross receipts				
	2 Less: Contributions				
	3 Gross income (line 1 minus line 2)				
Direct Expenses	4 Cash prizes				
	5 Noncash prizes				
	6 Rent/facility costs				
	7 Food and beverages				
	8 Entertainment				
	9 Other direct expenses				
	10 Direct expense summary. Add lines 4 through 9 in column (d) ▶				
	11 Net income summary. Subtract line 10 from line 3, column (d) ▶				

Part III **Gaming.** Complete if the organization answered "Yes" on Form 990, Part IV, line 19, or reported more than $15,000 on Form 990-EZ, line 6a.

		(a) Bingo	(b) Pull tabs/instant bingo/progressive bingo	(c) Other gaming	(d) Total gaming (add col. (a) through col. (c))
Revenue	1 Gross revenue				
Direct Expenses	2 Cash prizes				
	3 Noncash prizes				
	4 Rent/facility costs				
	5 Other direct expenses				
	6 Volunteer labor	☐ Yes_____ % ☐ No	☐ Yes_____ % ☐ No	☐ Yes_____ % ☐ No	
	7 Direct expense summary. Add lines 2 through 5 in column (d) ▶				
	8 Net gaming income summary. Subtract line 7 from line 1, column (d) ▶				

9 Enter the state(s) in which the organization conducts gaming activities: _____

a Is the organization licensed to conduct gaming activities in each of these states? ☐ Yes ☐ No

b If "No," explain: _____

10a Were any of the organization's gaming licenses revoked, suspended, or terminated during the tax year? ☐ Yes ☐ No

b If "Yes," explain: _____

11 Does the organization conduct gaming activities with nonmembers? ☐ Yes ☐ No

12 Is the organization a grantor, beneficiary or trustee of a trust, or a member of a partnership or other entity formed to administer charitable gaming? ☐ Yes ☐ No

13 Indicate the percentage of gaming activity conducted in:

a The organization's facility	**13a**	%
b An outside facility	**13b**	%

14 Enter the name and address of the person who prepares the organization's gaming/special events books and records:

Name ▶

Address ▶

15a Does the organization have a contract with a third party from whom the organization receives gaming revenue? ☐ Yes ☐ No

b If "Yes," enter the amount of gaming revenue received by the organization ▶ $ _____ and the amount of gaming revenue retained by the third party ▶ $ _____

c If "Yes," enter name and address of the third party:

Name ▶

Address ▶

16 Gaming manager information:

Name ▶

Gaming manager compensation ▶ $ _____

Description of services provided ▶

☐ Director/officer ☐ Employee ☐ Independent contractor

17 Mandatory distributions:

a Is the organization required under state law to make charitable distributions from the gaming proceeds to retain the state gaming license? ☐ Yes ☐ No

b Enter the amount of distributions required under state law to be distributed to other exempt organizations or spent in the organization's own exempt activities during the tax year ▶ $

Part IV Supplemental Information. Provide the explanations required by Part I, line 2b, columns (iii) and (v); and Part III, lines 9, 9b, 10b, 15b, 15c, 16, and 17b, as applicable. Also provide any additional information. See instructions.

SCHEDULE G, PART I, LINE 2B, LIST OF TEN HIGHEST PAID FUNDRAISERS:

(I) NAME OF FUNDRAISER: RKD GROUP

(I) ADDRESS OF FUNDRAISER:

35 PARKWOOD DRIVE, STE. 160, HOPKINTON, MA 01748

(I) NAME OF FUNDRAISER: ALLEGIANCE GROUP

(I) ADDRESS OF FUNDRAISER:
2300 CLARENDON BLVD., STE. 925, ARLINGTON, VA 22201

Part IV **Supplemental Information** *(continued)*

PART I, LINE 2B, COLUMN (V):

IN THE CONTRACT WITH THE RKD GROUP, THE MANAGEMENTS FEES ARE FIXED AMOUNTS PER MONTH FOR IN-SCOPE SERVICES THAT TOTALS $1,106,496 PER YEAR, OF WHICH $635,496 HAS BEEN ALLOCATED UNDER PART XI, LINE 11(G) TO PROGRAM AND MANAGEMENT AND ARE NOT CONSIDERED TO BE THE PROFESSIONAL FUNDRAISING CONSULTANT FEE.

SCHEDULE I (Form 990)

Department of the Treasury
Internal Revenue Service

Grants and Other Assistance to Organizations, Governments, and Individuals in the United States

Complete if the organization answered "Yes" on Form 990, Part IV, line 21 or 22.

▶ **Attach to Form 990.**

▶ **Go to www.irs.gov/Form990 for the latest information.**

OMB No. 1545-0047

2021

Open to Public Inspection

Name of the organization
BRIGHTFOCUS FOUNDATION

Employer identification number
23-7337229

Part I General Information on Grants and Assistance

1 Does the organization maintain records to substantiate the amount of the grants or assistance, the grantees' eligibility for the grants or assistance, and the selection criteria used to award the grants or assistance? ..... [X] Yes [ ] No

2 Describe in Part IV the organization's procedures for monitoring the use of grant funds in the United States.

Part II Grants and Other Assistance to Domestic Organizations and Domestic Governments. Complete if the organization answered "Yes" on Form 990, Part IV, line 21, for any recipient that received more than $5,000. Part II can be duplicated if additional space is needed.

1 (a) Name and address of organization or government	(b) EIN	(c) IRC section (if applicable)	(d) Amount of cash grant	(e) Amount of noncash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of noncash assistance	(h) Purpose of grant or assistance
ALBANY MEDICAL COLLEGE 47 NEW SCOTLAND AVENUE ALBANY, NY 12208	14-1338310	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY CHARLY ABI GHANEM, PHD, ENTITLED: (A2022001F)
MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON, MA 02145	04-2697983	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY ANA RITA AGRA DE ALMEIDA QUADROS, PHD, ENTITLED: (A2022002F)
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY - 1300 YORK AVE - NEW YORK, NY 10065	13-1623978	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY ANTOINE ANFRAY, PHD, ENTITLED: (A2022003F)
STANFORD UNIVERSITY 450 JANE STANFORD WAY STANFORD, CA 94305	94-1156365	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY CHING-CHIEH CHOU, PHD, ENTITLED: (A2022004F)
UNIVERSITY OF CALIFORNIA, IRVINE 160 ALDRICH HALL IRVINE, CA 92697	95-2226406	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY CHRISTIAN CROUZET, PHD, ENTITLED: (A2022005F)
UNIVERSITY OF MASSACHUSETTS CHAN MEDICAL SCHOOL - OFFICE OF SPONSORED PROGRAMS, 55 LAKE AVENUE NORTH - WORCESTER, MA 01655	04-3167352	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY VIOLETA DURAN LAFORET, PHD, ENTITLED: (A2022006F)

2 Enter total number of section 501(c)(3) and government organizations listed in the line 1 table ..... ▶ 53.

3 Enter total number of other organizations listed in the line 1 table ..... ▶ 1.

See Schedule O for continuation of Grant Purposes, item (h)

Part II **Continuation of Grants and Other Assistance to Domestic Organizations and Domestic Governments** (Schedule I (Form 990), Part II.)

(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of noncash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI - ONE GUSTAVE L. LEVY PLACE, BOX 1075 - NEW YORK, NY 10029	13-6171197	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY GABRIELA FARIAS QUIPILDOR, PHD, ENTITLED: (A2022007F)
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO - 490 ILLINOIS STREET, 4TH FLOOR - SAN FRANCISCO, CA 94143	94-6036493	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY BRANDON HOLMES, PHD, ENTITLED: (A2022008F)
MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON, MA 02145	04-2697983	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY HOANG LE, PHD, ENTITLED: (A2022009F)
WASHINGTON UNIVERSITY IN ST. LOUIS ONE BROOKINGS DRIVE, CAMPUS BOX 105 ST. LOUIS, MO 63130	43-0653611	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY ALEXANDRA LITVINCHUK, PHD, ENTITLED: (A2022010F)
MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON, MA 02145	04-2697983	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY CHAO LIU, PHD, ENTITLED: (A2022011F)
UNIVERSITY OF PENNSYLVANIA 3451 WALNUT STREET PHILADELPHIA, PA 19104	23-1352685	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY COURTNEY MARSHALL, PHD, ENTITLED: (A2022012F)
WASHINGTON UNIVERSITY, SCHOOL OF MEDICINE - 660 S. EUCLID AVENUE, CAMPUS BOX 8233 - SAINT LOUIS, MO 63110	43-0653611	501(C)(3)	98,221.	0.			ALZHEIMER'S DISEASE RESEARCH BY NICOLE MCKAY, PHD, ENTITLED: (A2022013F)
WASHINGTON UNIVERSITY, SCHOOL OF MEDICINE - 660 S. EUCLID AVENUE, CAMPUS BOX 8233 - SAINT LOUIS, MO 63110	43-0653611	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY PETER MILLAR, PHD, ENTITLED: (A2022014F)
INDIANA UNIVERSITY 509 E 3RD STREET BLOOMINGTON, IN 47401	35-6001673	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY MIGUEL MOUTINHO, PHRMD,PHD, ENTITLED: (A2022017F)

See Schedule O for continuation of Grant Purposes, item (h)

Part II **Continuation of Grants and Other Assistance to Domestic Organizations and Domestic Governments** (Schedule I (Form 990), Part II.)

(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of noncash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
UNIVERSITY OF CALIFORNIA, IRVINE 160 ALDRICH HALL IRVINE, CA 92697	95-2226406	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY TATSUKI NAKAGAWA, PHD, ENTITLED: (A2022018F)
MEMORIAL SLOAN KETTERING CANCER CENTER - 1275 YORK AVENUE, BOX 701 - NEW YORK, NY 10065	13-1924236	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY SAHIL SHARMA, PHD, ENTITLED: (A2022020F)
UNIVERSITY OF CALIFORNIA, IRVINE 160 ALDRICH HALL IRVINE, CA 92697	95-2226406	501(C)(3)	199,396.	0.			ALZHEIMER'S DISEASE RESEARCH BY LORENA SORDO, PHD, ENTITLED: (A2022021F)
NORTHWESTERN UNIVERSITY - EVANSTON CAMPUS - 750 NORTH LAKE SHORE DRIVE - CHICAGO, IL 60611	36-2167817	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY XIAOJING SUI, PHD, ENTITLED: (A2022023F)
UNIVERSITY OF COLORADO, BOULDER 3100 MARINE STREET BOULDER, CO 80309	84-6000555	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY MEAGHAN VAN ALSTYNE, PHD, ENTITLED: (A2022025F)
BOSTON CHILDREN'S HOSPITAL 300 LONGWOOD AVENUE BOSTON, MA 02115	04-2774441	501(C)(3)	199,678.	0.			ALZHEIMER'S DISEASE RESEARCH BY HUIXIN XU, PHD, ENTITLED: (A2022026F)
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO - 490 ILLINOIS STREET, 4TH FLOOR - SAN FRANCISCO, CA 94143	94-6036493	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY ANDREW YANG, PHD, ENTITLED: (A2022027F)
MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON, MA 02145	04-2697983	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY QIUCHEN ZHAO, PHD, ENTITLED: (A2022028F)
UNIVERSITY OF CALIFORNIA, IRVINE 160 ALDRICH HALL IRVINE, CA 92697	95-2226406	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY KEVIN BEIER, PHD, ENTITLED: (A2022031S)

See Schedule O for continuation of Grant Purposes, item (h)

COPY

Part II **Continuation of Grants and Other Assistance to Domestic Organizations and Domestic Governments** (Schedule I (Form 990), Part II.)

(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of noncash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
WASHINGTON UNIVERSITY IN ST. LOUIS ONE BROOKINGS DRIVE ST. LOUIS, MO 63130	43-0653611	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY THOMAS BRETT, PHD, ENTITLED: (A2022032S)
NEW YORK UNIVERSITY SCHOOL OF MEDICINE - ONE PARK AVENUE, 6TH FLOOR - NEW YORK, NY 10016	13-5562308	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY OMONIGHO BUBU, MD, PHD, ENTITLED: (A2022033S)
UNIVERSITY OF KANSAS CENTER FOR RESEARCH, INC. - 2385 IRVING HILL ROAD - LAWRENCE, KS 66045	48-0680117	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY LAN GUO, PHD, ENTITLED: (A2022036S)
BRIGHAM YOUNG UNIVERSITY A-285 ASB CAMPUS DRIVE PROVO, UT 84602	87-0217280	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY DAVID HANSEN, PHD, ENTITLED: (A2022037S)
WASHINGTON UNIVERSITY IN ST. LOUIS ONE BROOKINGS DRIVE ST. LOUIS, MO 63130	43-0653611	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY KEITH HENGEN, PHD, ENTITLED: (A2022038S)
COLORADO STATE UNIVERSITY 2002 CAMPUS DELIVERY FORT COLLINS, CO 80523	84-6000545	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY SEONIL KIM, PHD, ENTITLED: (A2022039S)
RICE UNIVERSITY 6100 S. MAIN MS-16 HOUSTON, TX 77005	74-1109620	501(C)(3)	299,943.	0.			ALZHEIMER'S DISEASE RESEARCH BY STEPHANIE LEAL, PHD, ENTITLED: (A2022040S)
SEATTLE INSTITUTE FOR BIOMEDICAL AND CLINICAL RESEARCH - 1660 S. COLUMBIAN WAY - SEATTLE, WA 98108	91-1452438	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY NICOLE LIACHKO, PHD, ENTITLED: (A2022041S)
HEBREW REHABILITATION CENTER 1200 CENTRE STREET BOSTON, MA 02131	04-2104298	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY BRAD MANOR, PHD, ENTITLED: (A2022042S)

See Schedule O for continuation of Grant Purposes, item (h)

Part II **Continuation of Grants and Other Assistance to Domestic Organizations and Domestic Governments** (Schedule I (Form 990), Part II.)

(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of noncash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI - ONE GUSTAVE L. LEVY PLACE, BOX 1075 - NEW YORK, NY 10029	13-6171197	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY ALEJANDRO MARTIN TRUJILLO, PHD, ENTITLED: (A2022043S)
GEORGIA TECH RESEARCH CORPORATION 926 DALNEY STREET NW ATLANTA, GA 30332	58-0603146	501(C)(3)	299,993.	0.			ALZHEIMER'S DISEASE RESEARCH BY ANNABELLE SINGER, PHD, ENTITLED: (A2022048S)
TRUSTEES OF BOSTON UNIVERSITY 85 EAST NEWTON, M-921 BOSTON, MA 02218	04-2103547	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY JULIA TCW, PHD, ENTITLED: (A2022049S)
UNIVERSITY OF MICHIGAN 3003 S. STATE STREET ANN ARBOR, MI 48109	38-6006309	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY PETER TESSIER, PHD, ENTITLED: (A2022050S)
MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON, MA 02145	04-2697983	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY SUSANNE VAN VELUW, PHD, ENTITLED: (A2022051S)
PRESIDENT & FELLOWS OF HARVARD COLLEGE - 1033 MASSACHUSETTS AVE, 5TH FLOOR - CAMBRIDGE, MA 02138	04-2103580	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY LIMOR COHEN, PHD, ENTITLED: (A2022052F)
MAYO CLINIC, JACKSONVILLE 4500 SAN PABLO ROAD, ROOM 110 JACKSONVILLE, FL 32224	59-3337028	501(C)(3)	235,163.	0.			ALZHEIMER'S DISEASE RESEARCH, ENTITLED: (CA2021010)
INTERNATIONAL SOCIETY FOR MOLECULAR NEURODEGENERATION - 1001 MAYPORT RD - ATLANTIC BEACH, FL 32233	86-2907045	501(C)(3)	115,000.	0.			ALZHEIMER'S DISEASE RESEARCH, ENTITLED: (CA2021011)
MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET CHARLESTOWN, MA 02114	04-1564655	501(C)(3)	30,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY BECKY CARLYLE, PHD, ENTITLED: (A2019182S)

See Schedule O for continuation of Grant Purposes, item (h)

COPY

Part II **Continuation of Grants and Other Assistance to Domestic Organizations and Domestic Governments** (Schedule I (Form 990), Part II.)

(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of noncash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
JOHNS HOPKINS UNIVERSITY 733 NORTH BROADWAY, SUITE 117 BALTIMORE, MD 21205	52-0595110	501(C)(3)	67,582.	0.			ALZHEIMER'S DISEASE RESEARCH BY PETER ABADIR, PHD, ENTITLED: (A2019634S)
JOHNS HOPKINS UNIVERSITY 400 NORTH BROADWAY BALTIMORE, MD 21211	52-0595110	501(C)(3)	123,767.	0.			ALZHEIMER'S DISEASE RESEARCH BY QUINCY SAMUS, PHD, ENTITLED: (CA2021001)
FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH - 11400 ROCKVILLE PIKE, SUITE 600 - NORTH BETHESDA, MD 20852	52-1986675	501(C)(3)	100,000.	0.			ALZHEIMER'S DISEASE RESEARCH, ENTITLED: (CA2021012)
BOSTON UNIVERSITY SCHOOL OF MEDICINE - 72 EAST CONCORD STREET - BOSTON, MA 02215	04-2103547	501(C)(3)	317,298.	0.			ALZHEIMER'S DISEASE RESEARCH BY BENJAMIN WOLOZIN, MD, PHD ENTITLED: (CA2020002)
UNIVERSITY OF DENVER 2155 E. WESLEY AVENUE DENVER, CO 80208	84-0404231	501(C)(3)	81,710.	0.			ALZHEIMER'S DISEASE RESEARCH BY ANN CHARLOTTE GRANHOLM-BENTLEY, PHD, ENTITLED: (CA2018010)
INDIANA UNIVERSITY 509 E 3RD STREET BLOOMINGTON, IN 47401	35-6001673	501(C)(3)	147,339.	0.			NATIONAL GLAUCOMA RESEARCH BY ALESSANDRA CARMICHAEL-MARTINS, PHD, ENTITLED: (G2022001F)
INDIANA UNIVERSITY 509 E 3RD STREET BLOOMINGTON, IN 47401	35-6001673	501(C)(3)	150,000.	0.			NATIONAL GLAUCOMA RESEARCH BY CATIA GOMES, PHD, ENTITLED: (G2022003F)
UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH - 3500 CAMP BOWIE BLVD. - FORT WORTH, TX 76107	75-6064033	501(C)(3)	150,000.	0.			NATIONAL GLAUCOMA RESEARCH BY PRABHAVATHI MADDINENI, PHD, ENTITLED: (G2022004F)
JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE - 733 NORTH BROADWAY, SUITE 117 - BALTIMORE, MD 21205	52-0595110	501(C)(3)	200,000.	0.			NATIONAL GLAUCOMA RESEARCH BY THOMAS JOHNSON, MD, PHD, ENTITLED: (G2022005S)

See Schedule O for continuation of Grant Purposes, item (h)

COPY

Part II **Continuation of Grants and Other Assistance to Domestic Organizations and Domestic Governments** (Schedule I (Form 990), Part II.)

(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of noncash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
GOOD SAMARITAN FOUNDATION (LHS) 1015 NW 22ND AVENUE PORTLAND, OR 97210	23-7017276	501(C)(3)	200,000.	0.			NATIONAL GLAUCOMA RESEARCH BY KAZUHIRO KUROKAWA, PHD, ENTITLED: (G2022006S)
MICHIGAN STATE UNIVERSITY HANNAH ADMINISTRATION, 426 AUDITORIUM ROAD - EAST LANSING, MI 48824	38-6005984	501(C)(3)	199,992.	0.			NATIONAL GLAUCOMA RESEARCH BY ANDRAS KOMAROMY, DVM, PHD, ENTITLED: (G2022007S)
GOOD SAMARITAN FOUNDATION (LHS) 1015 NW 22ND AVENUE PORTLAND, OR 97210	23-7017276	501(C)(3)	199,992.	0.			NATIONAL GLAUCOMA RESEARCH BY HONGLI YANG, PHD, ENTITLED: (G2022008S)
CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BOULEVARD, SUITE 1800 LOS ANGELES, CA 90048	95-1644600	501(C)(3)	199,381.	0.			NATIONAL GLAUCOMA RESEARCH BY SHAOMEI WANG, MD, PHD, ENTITLED: (G2022009S)
DUKE UNIVERSITY SCHOOL OF MEDICINE 2200 WEST MAIN STREET, SUITE 820, E DURHAM, NC 27705	56-0532129	501(C)(3)	200,000.	0.			NATIONAL GLAUCOMA RESEARCH BY MYOUNGSUP SIM, PHD, ENTITLED: (G2022010S)
VANDERBILT UNIVERSITY MEDICAL CENTER - 3319 WEST END AVENUE, SUITE 970 - NASHVILLE, TN 37203	35-2528741	501(C)(3)	196,512.	0.			NATIONAL GLAUCOMA RESEARCH BY MICHAEL RISNER, PHD, ENTITLED: (G2022011S)
EMORY UNIVERSITY 1599 CLIFTON ROAD NE, 4TH FLOOR ATLANTA, GA 30322	58-0566256	501(C)(3)	200,000.	0.			NATIONAL GLAUCOMA RESEARCH BY JIAXING WANG, PHD, ENTITLED: (G2022012S)
TRUSTEES OF BOSTON UNIVERSITY 85 EAST NEWTON, M-921 BOSTON, MA 02218	04-2103547	501(C)(3)	200,000.	0.			NATIONAL GLAUCOMA RESEARCH BY HAIYAN GONG, MD, PHD, ENTITLED: (G2022013S)
INDIANA UNIVERSITY 509 E 3RD STREET BLOOMINGTON, IN 47401	35-6001673	501(C)(3)	200,000.	0.			NATIONAL GLAUCOMA RESEARCH BY JASON MEYER, PHD, ENTITLED: (G2022014S)

See Schedule O for continuation of Grant Purposes, item (h)

Part II **Continuation of Grants and Other Assistance to Domestic Organizations and Domestic Governments** (Schedule I (Form 990), Part II.)

(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of noncash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
UNIVERSITY OF CALIFORNIA DAVIS 1850 RESEARCH PARK DRIVE, SUITE 300 DAVIS, CA 95618	94-6036494	501(C)(3)	200,000.	0.			NATIONAL GLAUCOMA RESEARCH BY NICK MARSH-ARMSTRONG, PHD, ENTITLED: (G2022016S)
THE UNIVERSITY OF IOWA 2 GILMORE HALL IOWA CITY, IA 52242	42-6004813	501(C)(3)	200,000.	0.			NATIONAL GLAUCOMA RESEARCH BY MICHAEL ANDERSON, PHD, ENTITLED: (G2022017S)
INTERNATIONAL SOCIETY FOR EYE RESEARCH - 655 BEACH STREET - SAN FRANCISCO, CA 94109	51-0171667	501(C)(3)	5,900.	0.			TRAVEL GRANTS FOR CONFERENCE ATTENDANCE
STANFORD UNIVERSITY 2452 WATSON CT PALO ALTO, CA 94305	94-1156365	501(C)(3)	342,519.	0.			NATIONAL GLAUCOMA RESEARCH BY JEFFREY GOLDBERG, PHD, ENTITLED: (CG2022001)
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL - 104 AIRPORT DRIVE, SUITE 2200 - CHAPEL HILL, NC 27599	56-6001393	501(C)(3)	200,000.	0.			MACULAR DEGENERATION RESEARCH BY YONGSU KWON, PHD, ENTITLED: (M2022001F)
UNIVERSITY OF WASHINGTON 4333 BROOKLYN AVE, NE SEATTLE, WA 98195	91-6001537	501(C)(3)	200,000.	0.			MACULAR DEGENERATION RESEARCH BY DANIEL HASS, PHD, ENTITLED: (M2022003F)
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER - 5323 HARRY HINES BLVD. - DALLAS, TX 75390	75-6002868	501(C)(3)	200,000.	0.			MACULAR DEGENERATION RESEARCH BY STEFFI DANIEL, PHD, ENTITLED: (M2022005F)
SEATTLE CHILDREN'S HOSPITAL 1900 NINTH AVENUE, M/S: 818-S SEATTLE, WA 98101	91-0564748	501(C)(3)	200,000.	0.			MACULAR DEGENERATION RESEARCH BY LEAH VANDENBOSCH, PHD, ENTITLED: (M2022006F)
UNIVERSITY OF ROCHESTER 518 HYLAN BLDG. BOX 270140 ROCHESTER, NY 14627	16-0743209	501(C)(3)	200,000.	0.			MACULAR DEGENERATION RESEARCH BY KRISTEN BOWLES JOHNSON, PHD, OD, ENTITLED: (M2022007F)

See Schedule O for continuation of Grant Purposes, item (h)

Part II **Continuation of Grants and Other Assistance to Domestic Organizations and Domestic Governments** (Schedule I (Form 990), Part II.)

(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of noncash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
THE REGENTS OF THE UNIVERSITY OF MICHIGAN - 3003 S. STATE STREET - ANN ARBOR, MI 48109	38-6006309	501(C)(3)	450,000.	0.			MACULAR DEGENERATION RESEARCH BY THOMAS WUBBEN, PHD, ENTITLED: (M2022008N)
OREGON HEALTH & SCIENCE UNIVERSITY 3181 SW SAM JACKSON PARK RD. PORTLAND, OR 97239	93-1176109	501(C)(3)	449,323.	0.			MACULAR DEGENERATION RESEARCH BY YIFAN JIAN, PHD, ENTITLED: (M2022009N)
UNIVERSITY OF NEVADA, RENO 1664 N VIRGINIA ST, MAIL STOP 325 RENO, NV 89557	88-6000024	501(C)(3)	446,943.	0.			MACULAR DEGENERATION RESEARCH BY ALBERT GONZALES, PHD, ENTITLED: (M2022010N)
THE REGENTS OF THE UNIVERSITY OF MICHIGAN - 3003 S. STATE STREET - ANN ARBOR, MI 48109	38-6006309	501(C)(3)	450,000.	0.			MACULAR DEGENERATION RESEARCH BY LEV PRASOV, PHD, ENTITLED: (M2022011N)
UNIVERSITY OF SOUTH FLORIDA 3702 SPECTRUM BLVD, SUITE 165 TAMPA, FL 33612	59-3102112	501(C)(3)	450,000.	0.			MACULAR DEGENERATION RESEARCH BY MANAS BISWAL, PHD, ENTITLED: (M2022012N)
JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE - 733 NORTH BROADWAY, SUITE 117 - BALTIMORE, MD 21205	52-0595110	501(C)(3)	450,000.	0.			MACULAR DEGENERATION RESEARCH BY SRINIVASA RAO SRIPATHI, PHD, ENTITLED: (M2022014N)
THE JACKSON LABORATORY 600 MAIN STREET BAR HARBOR, ME 04609	01-0211513	501(C)(3)	600,000.	0.			MACULAR DEGENERATION RESEARCH BY PATSY NISHINA, PHD, ENTITLED: (M2022016I)
DRUSOLV THERAPUTICS, INC 1425 LOCUST STREET, UNIT 7C PHILADELPHIA, PA 19102	82-2704169		500,000.	0.			MACULAR DEGENERATION RESEARCH BY JOHN G. EDWARDS, MS/MBA, ENTITLED: (CM2022001)
RD MEETING, INC. 5200 NW 43RD STREET, SUITE 102-279 GAINESVILLE, FL 32606	84-1992631	501(C)(3)	12,358.	0.			TRAVEL GRANTS FOR MACULAR DEGENERATION FAST TRACK MEETING

See Schedule O for continuation of Grant Purposes, item (h)

Part II **Continuation of Grants and Other Assistance to Domestic Organizations and Domestic Governments** (Schedule I (Form 990), Part II.)

(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of noncash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
ARVO FOUNDATION FOR EYE RESEARCH 1801 ROCKVILLE PIKE, SUITE 400 ROCKVILLE, MD 20852	52-2322462	501(C)(3)	10,000.	0.			2022 EYEFIND RESEARCH GRANT SPONSORSHIP
ARVO FOUNDATION FOR EYE RESEARCH 1801 ROCKVILLE PIKE, SUITE 400 ROCKVILLE, MD 20852	52-2322462	501(C)(3)	15,240.	0.			2022 TRAVEL GRANTS FOR CONFERENCE ATTENDEES

Part III **Grants and Other Assistance to Domestic Individuals.** Complete if the organization answered "Yes" on Form 990, Part IV, line 22. Part III can be duplicated if additional space is needed.

(a) Type of grant or assistance	(b) Number of recipients	(c) Amount of cash grant	(d) Amount of non-cash assistance	(e) Method of valuation (book, FMV, appraisal, other)	(f) Description of noncash assistance

Part IV **Supplemental Information.** Provide the information required in Part I, line 2; Part III, column (b); and any other additional information.

PART I, LINE 2:

BRIGHTFOCUS INTERACTS WITH ALL GRANTEES AT LEAST QUARTERLY BY E-MAIL OR AT SCIENTIFIC MEETINGS. IN ADDITION TO THESE INTERACTIONS, EACH GRANT RECIPIENT IS REQUIRED TO SUBMIT SEPARATE DETAILED ANNUAL SCIENTIFIC PROGRESS AND FINANCIAL REPORTS TO BRIGHTFOCUS. THESE ARE RECEIVED BY THE BRIGHTFOCUS SCIENTIFIC AFFAIRS DEPARTMENT, AND REVIEWED BY SCIENTIFIC STAFF WITH BROAD EXPERTISE, INCLUDING IMAGING, MOLECULAR BIOLOGY AND SIGNALING PATHWAYS, CELL BIOLOGY, ANGIOGENESIS, BIOCHEMISTRY, NEUROSCIENCE, AND GENETICS. SENIOR STAFF REVIEWS EACH PROGRESS REPORT AND EVALUATES THE

Part IV Supplemental Information

PROJECT FOR SUFFICIENT PROGRESS TOWARDS THE SPECIFIC AIMS PROPOSED IN THE ORIGINAL APPLICATION OR ANY BUDGETARY CONCERNS. THIS EFFORT IS SUPPORTED BY ADDITIONAL SCIENTIFIC COUNSEL FROM MEMBERS OF THE BRIGHTFOCUS SCIENTIFIC REVIEW COMMITTEES, WHEN REQUIRED. IN ADDITION TO STATEMENTS OF EXPERIMENTAL PROGRESS, ALL GRANTEES ARE ASKED TO REPORT ANY TECHNICAL PUBLICATIONS, MEDIA REPORTS, OR PATENT APPLICATIONS IN WHICH BRIGHTFOCUS-SPONSORED RESEARCH IS DESCRIBED. IF SIGNIFICANT CONCERNS RELATED TO PROGRESS ON THE AWARDS ARE DISCOVERED, AND NOT RESOLVED AFTER INTERACTION WITH THE AWARD GRANTEE, THE BRIGHTFOCUS STAFF RECOMMENDS APPROPRIATE ACTIONS TO THE CHAIR OF THE SCIENTIFIC AFFAIRS COMMITTEE OF THE BOARD OF DIRECTORS. IN ACCORDANCE WITH THE GRANT AGREEMENT TERMS AND CONDITIONS, BRIGHTFOCUS MAY WITHHOLD FUNDING, OR DISCONTINUE AN AWARD, FOR ANY GRANTEE THAT FAILS TO ACHIEVE SUFFICIENT PROGRESS OR SUBMIT REQUIRED REPORTS.

AT THE CONCLUSION OF THE GRANT AWARD PERIOD, EACH GRANTEE MUST COMPLETE AND SUBMIT A FINAL REPORT THAT IS ALSO REVIEWED BY THE BRIGHTFOCUS SENIOR SCIENTIFIC STAFF. EVALUATION OF THE WORK OF EACH GRANTEE IS QUALITATIVELY AND QUANTITATIVELY ASSESSED THROUGH VARIOUS METRICS RELATED TO THE IMPACT OF THE GRANT ON ITS TARGETED DISEASE FIELD. SUCH IMPACT METRICS HAVE REVEALED THAT 95% OF BRIGHTFOCUS-SUPPORTED RESEARCH RESULTS IN RESEARCH PUBLICATIONS THAT ADVANCE THE FIELDS SERVED BY BRIGHTFOCUS. THIS IMPACT IS FURTHER SUPPORTED BY ANNUAL CATEGORY NORMALIZED CITATION IMPACT ANALYSIS THAT COMPARES BRIGHTFOCUS-SUPPORTED WORKS TO AN UNBIASED COMPARISON OF IMPACT PERFORMANCE VERSUS THE WORLD AVERAGE. BRIGHTFOCUS-SUPPORTED PUBLICATIONS WERE RECENTLY CITED AT 2 TIMES THE FREQUENCY OF THE WORLD AVERAGE. A FINAL EXAMPLE OF IMPACT ASSESSMENT REVEALED THAT THE SUCCESSES OF BRIGHTFOCUS GRANTEES CONTINUE LONG AFTER THE GRANT EXPIRES. ON AVERAGE, EACH GRANTEE RECEIVES ADDITIONAL GRANTS FOR FOLLOW-ON PROJECTS SPAWNED BY

Part IV Supplemental Information

THE BRIGHTFOCUS GRANT, WITH VALUES UP TO 10 TIMES THE LEVEL OF THE INITIAL BRIGHTFOCUS INVESTMENT.

BRIGHTFOCUS SOLICITS FEEDBACK FROM ITS GRANTEES, AND PROVIDES AN ANONYMOUS FORUM FOR COLLECTING SUCH INFORMATION. THROUGH THE BRIGHTFOCUS FOUNDATION WEBSITE AND WITHIN THE SCIENTIFIC PROGRESS REPORTS, THERE ARE DESIGNATED SECTIONS WHERE AWARDEES ARE ASKED TO PROVIDE FEEDBACK TO THE FOUNDATION. THROUGH THIS MECHANISM, THEY ARE GIVEN THE ABILITY TO ANONYMOUSLY PROVIDE FEEDBACK OR COMMUNICATE THEIR CONCERNS TO PROGRAM STAFF OR THE BRIGHTFOCUS' COMPLIANCE OFFICE. ANY SUGGESTIONS, CONCERNS, COMPLAINTS, OR POSITIVE EXPERIENCES CAN BE OUTLINED AND BROUGHT TO THE ATTENTION OF BRIGHTFOCUS IN THIS MANNER, SO THAT BRIGHTFOCUS CAN ADDRESS ANY AREAS NEEDING IMPROVEMENT, REAFFIRM PRAISE-WORTHY POLICIES, OR OTHERWISE ASSESS NEEDS FOR PROGRAMMATIC CHANGE. THE SENIOR LEADERSHIP PRESENTS AND SUMMARIZES THE STATUS AND PROGRESS ON GRANTS TO THE BRIGHTFOCUS BOARD OF DIRECTORS AT EACH OF THEIR QUARTERLY BOARD MEETINGS.

SCHEDULE J (Form 990)

Department of the Treasury
Internal Revenue Service

Compensation Information

For certain Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees

▶ **Complete if the organization answered "Yes" on Form 990, Part IV, line 23.**

▶ **Attach to Form 990.**

▶ **Go to www.irs.gov/Form990 for instructions and the latest information.**

OMB No. 1545-0047

2021

Open to Public Inspection

Name of the organization

BRIGHTFOCUS FOUNDATION

Employer identification number

23-7337229

Part I Questions Regarding Compensation

			Yes	No
1a	Check the appropriate box(es) if the organization provided any of the following to or for a person listed on Form 990, Part VII, Section A, line 1a. Complete Part III to provide any relevant information regarding these items.			
	☐ First-class or charter travel	☐ Housing allowance or residence for personal use		
	☐ Travel for companions	☐ Payments for business use of personal residence		
	☐ Tax indemnification and gross-up payments	☐ Health or social club dues or initiation fees		
	☐ Discretionary spending account	☐ Personal services (such as maid, chauffeur, chef)		
b	If any of the boxes on line 1a are checked, did the organization follow a written policy regarding payment or reimbursement or provision of all of the expenses described above? If "No," complete Part III to explain	**1b**		
2	Did the organization require substantiation prior to reimbursing or allowing expenses incurred by all directors, trustees, and officers, including the CEO/Executive Director, regarding the items checked on line 1a?	**2**		
3	Indicate which, if any, of the following the organization used to establish the compensation of the organization's CEO/Executive Director. Check all that apply. Do not check any boxes for methods used by a related organization to establish compensation of the CEO/Executive Director, but explain in Part III.			
	☒ Compensation committee	☐ Written employment contract		
	☒ Independent compensation consultant	☒ Compensation survey or study		
	☒ Form 990 of other organizations	☒ Approval by the board or compensation committee		
4	During the year, did any person listed on Form 990, Part VII, Section A, line 1a, with respect to the filing organization or a related organization:			
a	Receive a severance payment or change-of-control payment?	**4a**		X
b	Participate in or receive payment from a supplemental nonqualified retirement plan?	**4b**		X
c	Participate in or receive payment from an equity-based compensation arrangement?	**4c**		X
	If "Yes" to any of lines 4a-c, list the persons and provide the applicable amounts for each item in Part III.			
	Only section 501(c)(3), 501(c)(4), and 501(c)(29) organizations must complete lines 5-9.			
5	For persons listed on Form 990, Part VII, Section A, line 1a, did the organization pay or accrue any compensation contingent on the revenues of:			
a	The organization?	**5a**		X
b	Any related organization?	**5b**		X
	If "Yes" on line 5a or 5b, describe in Part III.			
6	For persons listed on Form 990, Part VII, Section A, line 1a, did the organization pay or accrue any compensation contingent on the net earnings of:			
a	The organization?	**6a**		X
b	Any related organization?	**6b**		X
	If "Yes" on line 6a or 6b, describe in Part III.			
7	For persons listed on Form 990, Part VII, Section A, line 1a, did the organization provide any nonfixed payments not described on lines 5 and 6? If "Yes," describe in Part III	**7**		X
8	Were any amounts reported on Form 990, Part VII, paid or accrued pursuant to a contract that was subject to the initial contract exception described in Regulations section 53.4958-4(a)(3)? If "Yes," describe in Part III	**8**		X
9	If "Yes" on line 8, did the organization also follow the rebuttable presumption procedure described in Regulations section 53.4958-6(c)?	**9**		

Part II **Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees.** Use duplicate copies if additional space is needed.

For each individual whose compensation must be reported on Schedule J, report compensation from the organization on row (i) and from related organizations, described in the instructions, on row (ii). Do not list any individuals that aren't listed on Form 990, Part VII.

Note: The sum of columns (B)(i)-(iii) for each listed individual must equal the total amount of Form 990, Part VII, Section A, line 1a, applicable column (D) and (E) amounts for that individual.

(A) Name and Title		(B) Breakdown of W-2 and/or 1099-MISC and/or 1099-NEC compensation			(C) Retirement and other deferred compensation	(D) Nontaxable benefits	(E) Total of columns (B)(i)-(D)	(F) Compensation in column (B) reported as deferred on prior Form 990
		(i) Base compensation	(ii) Bonus & incentive compensation	(iii) Other reportable compensation				
(1) STACY PAGOS HALLER	(i)	388,780.	45,000.	1,584.	26,100.	24,927.	486,391.	0.
PRESIDENT/CEO	(ii)	0.	0.	0.	0.	0.	0.	0.
(2) NANCY LYNN	(i)	241,970.	2,500.	1,584.	23,006.	30,944.	300,004.	0.
SR. VP STRATEGIC PARTNERSHIPS	(ii)	0.	0.	0.	0.	0.	0.	0.
(3) R. BRIAN ELDERTON	(i)	235,152.	10,000.	2,048.	22,654.	23,762.	293,616.	0.
SR. VP, DEVELOPMENT	(ii)	0.	0.	0.	0.	0.	0.	0.
(4) DAVID F. MARKS, CPA, CMA	(i)	161,053.	2,500.	1,584.	15,876.	40,653.	221,666.	0.
VP, FINANCE & ADMINISTRATION	(ii)	0.	0.	0.	0.	0.	0.	0.
(5) DIANE BOVENKAMP, PHD	(i)	176,665.	2,500.	552.	16,125.	4,764.	200,606.	0.
VP, SCIENTIFIC AFFAIRS	(ii)	0.	0.	0.	0.	0.	0.	0.
(6) MICHAEL BUCKLEY	(i)	159,966.	2,500.	552.	14,622.	4,039.	181,679.	0.
VP, PUBLIC AFFAIRS	(ii)	0.	0.	0.	0.	0.	0.	0.
	(i)							
	(ii)							
	(i)							
	(ii)							
	(i)							
	(ii)							
	(i)							
	(ii)							
	(i)							
	(ii)							
	(i)							
	(ii)							
	(i)							
	(ii)							
	(i)							
	(ii)							
	(i)							
	(ii)							
	(i)							
	(ii)							

Part III Supplemental Information

Provide the information, explanation, or descriptions required for Part I, lines 1a, 1b, 3, 4a, 4b, 4c, 5a, 5b, 6a, 6b, 7, and 8, and for Part II. Also complete this part for any additional information.

SCHEDULE M (Form 990)

Department of the Treasury
Internal Revenue Service

Noncash Contributions

▶ **Complete if the organizations answered "Yes" on Form 990, Part IV, lines 29 or 30.**
▶ **Attach to Form 990.**
▶ **Go to www.irs.gov/Form990 for instructions and the latest information.**

OMB No. 1545-0047

2021

Open to Public Inspection

Name of the organization

BRIGHTFOCUS FOUNDATION

Employer identification number

23-7337229

Part I Types of Property

		(a) Check if applicable	(b) Number of contributions or items contributed	(c) Noncash contribution amounts reported on Form 990, Part VIII, line 1g	(d) Method of determining noncash contribution amounts
1	Art - Works of art				
2	Art - Historical treasures				
3	Art - Fractional interests				
4	Books and publications				
5	Clothing and household goods				
6	Cars and other vehicles				
7	Boats and planes				
8	Intellectual property				
9	Securities - Publicly traded	X	29	203,467.	FMV
10	Securities - Closely held stock				
11	Securities - Partnership, LLC, or trust interests				
12	Securities - Miscellaneous				
13	Qualified conservation contribution - Historic structures				
14	Qualified conservation contribution - Other				
15	Real estate - Residential	X	1	134,013.	DISPOSITION PRICE
16	Real estate - Commercial				
17	Real estate - Other				
18	Collectibles				
19	Food inventory				
20	Drugs and medical supplies				
21	Taxidermy				
22	Historical artifacts				
23	Scientific specimens				
24	Archeological artifacts				
25	Other ▶ ( )				
26	Other ▶ ( )				
27	Other ▶ ( )				
28	Other ▶ ( )				

29 Number of Forms 8283 received by the organization during the tax year for contributions for which the organization completed Form 8283, Part V, Donee Acknowledgement 29

			Yes	No
30a	During the year, did the organization receive by contribution any property reported in Part I, lines 1 through 28, that it must hold for at least three years from the date of the initial contribution, and which isn't required to be used for exempt purposes for the entire holding period?	30a		X
b	If "Yes," describe the arrangement in Part II.			
31	Does the organization have a gift acceptance policy that requires the review of any nonstandard contributions?	31	X	
32a	Does the organization hire or use third parties or related organizations to solicit, process, or sell noncash contributions?	32a	X	
b	If "Yes," describe in Part II.			
33	If the organization didn't report an amount in column (c) for a type of property for which column (a) is checked, describe in Part II.			

Part II **Supplemental Information.** Provide the information required by Part I, lines 30b, 32b, and 33, and whether the organization is reporting in Part I, column (b), the number of contributions, the number of items received, or a combination of both. Also complete this part for any additional information.

SCHEDULE M, PART I, COLUMN (B):

BRIGHTFOCUS REPORTS THE NUMBER OF CONTRIBUTIONS IN PART I, COLUMN (B).

SCHEDULE M, LINE 32B:

BRIGHTFOCUS RECEIVED DONATED RESIDENTIAL REAL ESTATE IN APRIL 2021. IN JUNE 2021, BRIGHTFOCUS SOLD THE REAL ESTATE WITH THE ASSISTANCE OF A REAL ESTATE AGENT.

SCHEDULE O (Form 990)

Department of the Treasury
Internal Revenue Service

Supplemental Information to Form 990 or 990-EZ

Complete to provide information for responses to specific questions on Form 990 or 990-EZ or to provide any additional information.
▶ Attach to Form 990 or Form 990-EZ.
▶ Go to www.irs.gov/Form990 for the latest information.

OMB No. 1545-0047

2021

Open to Public Inspection

Name of the organization
BRIGHTFOCUS FOUNDATION

Employer identification number
23-7337229

FORM 990, PART III, LINE 1, DESCRIPTION OF ORGANIZATION MISSION:

BRIGHTFOCUS FUNDS EXCEPTIONAL SCIENTIFIC RESEARCH WORLDWIDE TO DEFEAT ALZHEIMER'S DISEASE, MACULAR DEGENERATION, AND GLAUCOMA AND PROVIDES EXPERT INFORMATION ON THESE HEARTBREAKING DISEASES. OUR VISION IS: A WORLD FREE FROM DISEASES OF MIND AND SIGHT. COLLECTIVELY, 1 IN 16 PEOPLE OVER THE AGE OF 40 IN THE U.S. HAS ONE OF THESE DISEASES.

BRIGHTFOCUS HAS A PROVEN TRACK RECORD OF SUPPORTING THE MOST INNOVATIVE, EARLY-STAGE RESEARCH SEEKING BETTER UNDERSTANDING, TREATMENTS, OR, ULTIMATELY, A CURE FOR THESE DISEASES. SINCE 1973, BRIGHTFOCUS HAS AWARDED OVER $270 MILLION IN RESEARCH GRANTS TO THOUSANDS OF SCIENTISTS AROUND THE WORLD. OUR RESEARCH FUNDING HAS LED TO MAJOR CONTRIBUTIONS TO THE UNDERSTANDING OF THESE DISEASES AND SUPPORT FOR SCIENTISTS WHO HAVE RECEIVED PRESTIGIOUS AWARDS, INCLUDING TWO NOBEL PRIZES. AN INDICATOR OF OUR ABILITY TO PUSH NEW BOUNDARIES OF KNOWLEDGE IS THAT BRIGHTFOCUS-SUPPORTED RESEARCH WAS RECENTLY FOUND TO HAVE HAD TWICE THE IMPACT ON DRIVING FUTURE SCIENCE THAN WORK SUPPORTED BY MANY OTHER ORGANIZATIONS.

THE WORLD-CLASS RESEARCH IDENTIFIED AND SUPPORTED BY BRIGHTFOCUS IS ON THE CUTTING-EDGE OF THE FIGHT TO SAVE MIND AND SIGHT. OUR FUNDING ACTS AS A CATALYST IN EARLY-STAGE RESEARCH. THE BRIGHTFOCUS RESEARCH PROGRAMS ARE DESIGNED TO PROVIDE INITIAL FUNDING FOR HIGHLY INNOVATIVE EXPERIMENTAL IDEAS. DUE TO THE STRUCTURED GRANT REVIEW AND APPROVAL PROCESS, THE RESEARCH IMPACT OF BRIGHTFOCUS IS VERY HIGH. MOST RECIPIENTS OF BRIGHTFOCUS FUNDING GO ON TO RECEIVE FUTURE GRANTS FROM

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

OTHER SOURCES THAT ARE UP TO 10 TIMES LARGER THAN THE ORIGINAL BRIGHTFOCUS AWARD. THIS HIGH RETURN ON BRIGHTFOCUS INVESTMENT SPEAKS TO OUR ABILITY TO IDENTIFY PROMISING RESEARCH IN ITS EARLIEST STAGES AND SPAWN FUTURE SCIENTIFIC DISCOVERIES. IT IS OUR FIRM BELIEF THAT HAVING THE COURAGE TO INVEST IN INNOVATIVE IDEAS WILL LEAD TO REVOLUTIONARY APPROACHES AND LIFE-SAVING BREAKTHROUGHS.

ALONG WITH FUNDING CUTTING-EDGE RESEARCH TO FIND CURES TO SOME OF THE WORLD'S COSTLIEST DISEASES, BRIGHTFOCUS ALSO PROVIDES FREE EDUCATIONAL MATERIALS AND SUPPORT TO HUNDREDS OF THOUSANDS OF THOSE IMPACTED BY THESE DISEASES NATIONWIDE. WE ROOT THESE EDUCATIONAL MATERIALS IN THE LATEST RESEARCH FINDINGS.

BRIGHTFOCUS INCREASES PUBLIC AWARENESS OF ALZHEIMER'S, MACULAR DEGENERATION, AND GLAUCOMA, AND COMMUNICATES WITH THOUGHT LEADERS AND ELECTED OFFICIALS ABOUT THE IMPORTANCE OF SCIENTIFIC RESEARCH IN THESE AREAS.

BRIGHTFOCUS' AWARD-WINNING PUBLIC SERVICE ANNOUNCEMENTS (PSA) HAVE APPEARED ON TELEVISION, RADIO, AND IN PRINT THROUGHOUT THE NATION. THE IMPACT OF ALZHEIMER'S. MAKE A PLAN TODAY: GET YOUR EYES CHECKED AND NOW IS THE MOMENT TO STOP ALZHEIMER'S DISEASE POWERFULLY SEEK TO RAISE AWARENESS AND EARLY DETECTION, AND SIMILAR MESSAGES HAVE BEEN DELIVERED THROUGH DONATED PRINT PSA SPACE IN AIRPORTS AND TRAIN STATIONS, AS WELL AS AT PHARMACIES, SUPERMARKETS AND DIGITALLY. IN FISCAL YEAR 2022, THESE PSA MESSAGES GENERATED $12,439,938 IN DONATED MEDIA SERVICES AND GARNERED OVER 693 MILLION IMPRESSIONS.

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

SINCE 2014, THE BRIGHTFOCUS CHATS HAVE BROUGHT TOGETHER PATIENTS AND CAREGIVERS FOR FREE, INTERACTIVE MONTHLY TELEPHONE FORUMS TO LEARN FROM, AND ASK QUESTIONS OF, LEADING RESEARCHERS AND SPECIALISTS ON VISION DISEASES. THE CHATS ARE ARCHIVED ON OUR WEB SITE, WITH AUDIO AND PRINT TRANSCRIPTS AVAILABLE IN A NUMBER OF ACCESSIBLE FORMATS.

WE CONTINUE TO INCREASE OUR PRINT PUBLICATIONS, MANY IN SPANISH, THAT PROVIDE HELPFUL INFORMATION TO PATIENTS AND CAREGIVERS, AND REGULARLY UNVEIL NEW VIDEO AND AUDIO RESOURCES IN CONJUNCTION WITH ALLIES IN THE MEDICAL AND SCIENTIFIC COMMUNITIES.

PARTNERING WITH SEVERAL HIGH-PROFILE PUBLIC AND PRIVATE ORGANIZATIONS, BRIGHTFOCUS IS HELPING BETTER EDUCATE THE PUBLIC ON THE IMPORTANCE OF EQUITABLE PARTICIPATION IN CLINICAL RESEARCH AS A WAY TO ACCELERATE THE PATH TO CURES FOR NEURODEGENERATIVE DISEASES.

SPECIFICALLY, BRIGHTFOCUS IS PRODUCING AND DISSEMINATING BRAIN INFO LIVE, A SUSTAINED, EPISODIC VIRTUAL EDUCATION SERIES TAILORED TO DIVERSE COMMUNITIES ACROSS THE US. BRIGHTFOCUS IS PREPARING TO ALSO PRESENT AN UPCOMING DOCUMENTARY, "WILDER: HIS LIFE, LEGACY AND BATTLE WITH ALZHEIMER'S DISEASE," AND WILL EXECUTE AN ASSOCIATED EDUCATIONAL IMPACT CAMPAIGN. THE FILM WILL BE SHOWN IN COMMUNITY SETTINGS ACROSS THE COUNTRY TO INCREASE THE AWARENESS OF, AND PARTICIPATION IN, ALZHEIMER'S CLINICAL RESEARCH.

WE HAVE EXPANDED OUR WRITTEN CONTENT OF KEY RESEARCH FINDINGS, PROMOTING AND SHARING THIS INFORMATION THROUGH OUR WEB SITE AND SOCIAL MEDIA PLATFORMS. BRIGHTFOCUS INFOGRAPHICS EASILY AND VISUALLY

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

COMMUNICATE INFORMATION ON ALZHEIMER'S, MACULAR DEGENERATION, AND GLAUCOMA. IN THE SPRING OF 2020, WE LAUNCHED A FULL SECTION OF OUR WEBSITE DEDICATED TO SHARING EXCLUSIVE CONTENT ON COVID-19 FOR FAMILIES IMPACTED BY DISEASES OF MIND AND SIGHT.

MORE SPECIFICALLY, EACH OF THESE PROGRAM AREAS MAIL AWARENESS-RAISING MATERIALS TO HUNDREDS OF THOUSANDS OF HOUSEHOLDS, WITH MESSAGES FOCUSING ON:

- RISK FACTORS AND SYMPTOM RECOGNITION THROUGH PUBLIC AWARENESS AND STEPS THE PUBLIC SHOULD TAKE THAT MAY HELP REDUCE THEIR RISK.
- LIFESTYLE CHOICES THAT PROMOTE GOOD HEALTH, ENCOURAGING READERS TO TAKE ACTION TO REDUCE THE LIKELIHOOD OF THE ONSET OF THE DISEASE.
- RESEARCH RESULTS AND TREATMENTS AVAILABLE TO ADDRESS THE DISEASE.

BRIGHTFOCUS REGULARLY INTERACTS WITH ADVOCACY ORGANIZATIONS, GOVERNMENTS AT ALL LEVELS, AND MEMBERS OF THE MEDIA TO CALL GREATER ATTENTION TO DISEASES OF MIND AND SIGHT AND SHARE THE LATEST RESEARCH AND BEST PRACTICES WITH THE PUBLIC FIGURES AND KEY STAKEHOLDERS. THROUGH OUR OWN OUTREACH EFFORTS, AS WELL AS ACTIVE ROLES IN ADVOCACY COALITIONS WE HELP ADVANCE THE CAUSE OF PIONEERING SCIENCE AND BETTER POSITION BRIGHTFOCUS AS A RESOURCE FOR THOSE STRUGGLING WITH, AND SEARCHING FOR CURES FOR, THESE TERRIBLE DISEASES.

BRIGHTFOCUS IS THE PRESENTING SPONSOR OF THE HELEN KELLER PRIZE FOR VISION RESEARCH, ONE OF THE MOST PRESTIGIOUS RECOGNITIONS IN THE FIELD. SELECTED BY A PANEL OF THE WORLD'S FOREMOST VISION SCIENTISTS, EACH YEAR'S LAUREATE IS HONORED FOR A GROUNDBREAKING CONTRIBUTION OR

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

DISCOVERY TO SAVE SIGHT. BRIGHTFOCUS BEGAN ITS SPONSORSHIP IN 2015 TO CALL GREATER ATTENTION TO VISION RESEARCH ACROSS THE PRIVATE AND PUBLIC SECTORS.

FORM 990, PART III, LINE 4A, DESCRIPTION OF PROGRAM SERVICE:

ALZHEIMER'S DISEASE RESEARCH (ADR) -

ALZHEIMER'S DISEASE IS THE ONLY CAUSE OF DEATH AMONG THE TOP 10 IN AMERICA WITHOUT A WAY TO PREVENT, CURE, OR EVEN SLOW ITS PROGRESSION. IT IS AN IRREVERSIBLE DEGENERATION OF THE BRAIN THAT CAUSES DISRUPTIONS IN MEMORY, COGNITION, PERSONALITY, AND OTHER FUNCTIONS AND INEVITABLY LEADS TO DEATH. AN ESTIMATED 5.5 MILLION AMERICANS HAVE ALZHEIMER'S DISEASE, ABOUT TWO-THIRDS ARE WOMEN.

BRIGHTFOCUS' ADR PROGRAM FUNDS RESEARCH FOCUSED ON UNDERSTANDING THE CAUSES OF ALZHEIMER'S DISEASE, ITS EARLY DETECTION, AND TREATMENTS TO HELP SLOW OR STOP ITS PROGRESSION, AND ULTIMATELY TO PREVENT THE DISEASE ALTOGETHER. ADR ANNUALLY AWARDS PEER-REVIEWED GRANTS TO SCIENTISTS FROM INSTITUTIONS WORLDWIDE WHO ARE CONDUCTING BIOMEDICAL AND CLINICAL RESEARCH ON ALZHEIMER'S DISEASE.

SINCE INCEPTION, BRIGHTFOCUS HAS CONTRIBUTED MORE THAN $167 MILLION TO THE CONQUERING OF ALZHEIMER'S DISEASE. DURING THE FISCAL YEAR ENDED MARCH 31, 2022, ADR AWARDED $12,439,027 IN PEER-REVIEWED GRANT AWARDS TO 52 NEW RESEARCH PROJECTS AND THREE OTHER NEW SCIENTIFIC AWARDS TO MAKE A TOTAL OF $13,577,827 IN FUNDING.

NOTABLE PROJECTS INCLUDE: USING THE EYE AND VARIOUS IMAGING METHODS TO DETECT DEMENTIA; HYPERTENSION AND LIFESTYLE EFFECTS ON RISK OF ALZHEIMER'S (INCLUDING LIPIDS); DRUG DISCOVERY AND BIOMARKERS; THE ROLE OF INFLAMMATION, MICROGLIA AND VASCULAR HEALTH IN DISEASE RISK; LOOKING AT THE MITOCHONDRIA AND CELL ENERGY DEFICIENCIES; ROLE OF SLEEP DISTURBANCES CAUSING INCREASED RISK OF COGNITIVE ISSUES; DIFFERENCES IN GENETICS AND DISEASE RISK FOR UNDERREPRESENTED POPULATIONS; AND BETTER USE OF MODERN TECHNOLOGIES, INCLUDING BIG DATA/AI AND SYSTEMS GENETICS ANALYSIS FOR INCREASED AND DECREASED RISKS. ADDITIONAL INFORMATION ABOUT SPECIFIC PROJECTS IS INCLUDED IN SCHEDULES F & I.

BRIGHTFOCUS IS HONORED TO HAVE SUPPORTED THE EARLY RESEARCH OF TWO NOBEL PRIZE WINNERS: DR. STANLEY PRUSINER AND DR. PAUL GREENGARD, WHOSE WORK HAS BEEN INSTRUMENTAL TO OUR CURRENT UNDERSTANDING OF ALZHEIMER'S DISEASE.

BRIGHTFOCUS CONTINUES ITS PARTNERSHIP WITH THE ACADEMIC JOURNAL "MOLECULAR NEURODEGENERATION" AS THE OFFICIAL JOURNAL OF THE BRIGHTFOCUS FOUNDATION. THE JOURNAL PUBLISHES TECHNICAL PAPERS RELATED TO NEURODEGENERATION IN THE THREE DISEASE AREAS. TO ACCELERATE SCIENTIFIC PROGRESS, IT IS AN "OPEN ACCESS" JOURNAL, AND ALL CONTENT IS FREE OF CHARGE. THIS OPEN ACCESS ENSURES MAXIMAL REACH OF JOURNAL CONTENTS TO SCIENTISTS AND CARE PROVIDERS WORLDWIDE. MOLECULAR NEURODEGENERATION IS CURRENTLY THE HIGHEST IMPACT OPEN ACCESS JOURNAL IN THE NEUROSCIENCES.

IN ADDITION TO SUPPORTING CUTTING-EDGE RESEARCH, ALZHEIMER'S DISEASE RESEARCH PROVIDES EXCELLENT RESOURCES ON DETECTING, TREATING, AND

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

LIVING WITH THE DISEASE. THESE ARE AVAILABLE IN BOTH PRINT AS WELL AS ON OUR WEBSITE, WWW.BRIGHTFOCUS.ORG.

FORM 990, PART III, LINE 4B, DESCRIPTION OF PROGRAM SERVICE:

MACULAR DEGENERATION RESEARCH (MDR) -

AGE-RELATED MACULAR DEGENERATION IS A LEADING CAUSE OF VISION LOSS IN THE UNITED STATES. IT DESTROYS THE MACULA, THE PART OF THE EYE THAT PROVIDES SHARP, CENTRAL VISION NEEDED FOR SEEING OBJECTS CLEARLY. THE MOST COMMON EYE CONDITION IN PEOPLE AGE 60 AND OLDER, IT CAN LEAD TO VISION LOSS IN ONE OR BOTH EYES, MAKING IT DIFFICULT TO RECOGNIZE FACES, DRIVE A CAR, OR READ. AS MANY AS 11 MILLION AMERICANS HAVE SOME TYPE OF MACULAR DEGENERATION, INCLUDING BOTH THE EARLY AND LATER STAGES OF THE WET AND DRY TYPES. THIS NUMBER IS EXPECTED TO DOUBLE TO NEARLY 22 MILLION BY 2050.

MACULAR DEGENERATION RESEARCH (MDR), A PROGRAM OF BRIGHTFOCUS, HAS AWARDED MORE THAN $45 MILLION TO SCIENTISTS STUDYING THE DISEASE. THE LATEST RESEARCH IS FOCUSED ON NOVEL TREATMENTS FOR THE DISEASE, UNDERSTANDING ITS CAUSES AND PROGRESSION, PREDICTION METHODS AND DISEASE MODELING, DRUG THERAPIES, THE ROLE OF THE METABOLISM IN DISEASE RISK, GENES, THE ROLE OF THE IMMUNE RESPONSE IN DISEASE RISK, AND NEW IMAGING, MACHINE LEARNING AND SCREENING TECHNIQUES.

MDR GRANTS ARE AVAILABLE TO MACULAR DEGENERATION RESEARCHERS WORLDWIDE. MDR PLACES SPECIAL EMPHASIS ON ENCOURAGING APPLICATIONS FROM YOUNG SCIENTISTS AND THOSE WITH CUTTING-EDGE IDEAS. ANNUAL GRANT

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

APPLICATIONS ARE PEER-REVIEWED, AND RECIPIENT SELECTIONS ARE BASED ON SCIENTIFIC MERIT.

DURING THE FISCAL YEAR ENDING MARCH 31, 2022, MDR AWARDED $5,746,102 IN PEER-REVIEWED GRANT AWARDS TO 16 NEW RESEARCH PROJECTS, WITH 5 ADDITIONAL SCIENTIFIC PROJECTS THAT TAKE THE TOTAL FUNDING TO $6,533,701. DETAILS ABOUT SPECIFIC PROJECTS ARE INCLUDED IN SCHEDULES F & I.

IN ADDITION TO SUPPORTING CUTTING-EDGE RESEARCH, MACULAR DEGENERATION RESEARCH PROVIDES EXCELLENT RESOURCES ON DETECTING, TREATING, AND LIVING WITH THIS DISEASE. THESE ARE AVAILABLE IN BOTH PRINT AS WELL AS ON OUR WEBSITE, WWW.BRIGHTFOCUS.ORG.

FORM 990, PART III, LINE 4C, DESCRIPTION OF PROGRAM SERVICE:

NATIONAL GLAUCOMA RESEARCH (NGR) -

GLAUCOMA IS THE SECOND LEADING CAUSE OF BLINDNESS WORLDWIDE, ACCORDING TO A RECENT REPORT FROM THE WORLD HEALTH ORGANIZATION, APPROXIMATELY 80 MILLION PEOPLE AROUND THE WORLD HAVE GLAUCOMA. MORE THAN THREE MILLION AMERICANS, OVER THE AGE OF 40 ARE LIVING WITH GLAUCOMA, WITH AN ESTIMATED 2.7 MILLION HAVE OPEN-ANGLE GLAUCOMA, THE MOST COMMON TYPE. IN THE UNITED STATES, GLAUCOMA IS A LEADING CAUSE OF BLINDNESS AMONG BLACK AND HISPANIC AMERICANS. WITH EARLY DETECTION AND TREATMENT, GLAUCOMA OFTEN CAN BE MANAGED TO PROTECT EYES FROM MORE SERIOUS VISION LOSS. IT IS ESTIMATED THAT ONLY HALF OF THE PEOPLE LIVING WITH GLAUCOMA ARE AWARE THAT THEY HAVE THE DISEASE.

Name of the organization
BRIGHTFOCUS FOUNDATION

Employer identification number
23-7337229

BRIGHTFOCUS' NGR PROGRAM HAS AWARDED MORE THAN $46 MILLION WORLDWIDE FOR THE STUDY OF GLAUCOMA. NGR-SUPPORTED RESEARCH HAS BEEN FOCUSED ON THE EYE-BRAIN CONNECTION, HOW PRESSURE BUILDUP IN THE EYE CAN AFFECT SYNAPTIC NERVE COMMUNICATIONS, NEUROPROTECTION AND OPTIC NERVE REGENERATION, DISCOVERING GLAUCOMA RISK GENES, AI/DEEP LEARNING AND ADAPTIVE OPTICS, SLEEP DISTURBANCE AND RISK OF DEVELOPING GLAUCOMA, DEVELOPING EARLY GLAUCOMA SCREENING, AND PURSUING NOVEL GENETIC COUNSELING AND COMMUNICATION STRATEGIES, AMONGST OTHER INNOVATIVE PURSUITS.

NGR GRANTS ARE AVAILABLE TO GLAUCOMA RESEARCHERS WORLDWIDE. NGR PLACES SPECIAL EMPHASIS ON ENCOURAGING APPLICATIONS FROM YOUNG SCIENTISTS AND THOSE WITH CUTTING-EDGE IDEAS. ANNUAL GRANT APPLICATIONS ARE PEER-REVIEWED, AND RECIPIENT SELECTIONS ARE BASED ON SCIENTIFIC MERIT.

DURING THE FISCAL YEAR ENDING MARCH 31, 2022, NGR AWARDED $3,191,265 IN PEER-REVIEWED GRANT AWARDS FOR 17 NEW PROJECTS AND 2 OTHER SCIENTIFIC AWARDS TO MAKE A TOTAL OF $3,539,684 IN FUNDING. DETAILS ABOUT SPECIFIC PROJECTS ARE INCLUDED IN SCHEDULES F & I.

IN ADDITION TO SUPPORTING CUTTING-EDGE RESEARCH, NATIONAL GLAUCOMA RESEARCH PROVIDES EXCELLENT RESOURCES ON DETECTING, TREATING, AND LIVING WITH THE DISEASE. THESE ARE AVAILABLE IN BOTH PRINT AS WELL AS ON OUR WEBSITE, WWW.BRIGHTFOCUS.ORG.

FORM 990, PART VI, SECTION B, LINE 11B:

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

A DRAFT OF THE FEDERAL FORM 990 IS DISTRIBUTED TO THE AUDIT COMMITTEE FOR REVIEW PRIOR TO BEING SUBMITTED TO THE INTERNAL REVENUE SERVICE. THE DRAFT FEDERAL FORM 990 IS DISTRIBUTED EARLY ENOUGH TO PROVIDE EACH COMMITTEE MEMBER WITH A REASONABLE AMOUNT OF TIME FOR REVIEW AND SUBMISSION OF QUESTIONS OR COMMENTS PRIOR TO THE FILING DEADLINE. THE FINAL FEDERAL FORM 990 IS DISTRIBUTED TO EACH MEMBER OF THE FULL BOARD OF DIRECTORS PRIOR TO BEING FILED WITH THE INTERNAL REVENUE SERVICE. THE DRAFT OR FINAL FEDERAL FORM 990 MAY BE DISTRIBUTED IN PERSON, BY REGULAR MAIL, E-MAIL, OR FAX.

FORM 990, PART VI, SECTION B, LINE 12C:
BRIGHTFOCUS HAS ALL EMPLOYEES, OFFICERS, AND DIRECTORS AGREE TO THE CODE OF CONDUCT THAT INCLUDES ADHERENCE TO THE CONFLICT OF INTEREST AND IMPLEMENTATION POLICY. EACH BOARD DIRECTOR, OFFICER, AND EMPLOYEE IS REQUIRED TO COMPLETE A CONFLICT OF INTEREST DISCLOSURE STATEMENT ANNUALLY.

EMPLOYEES MEET ANNUALLY WITH THE BRIGHTFOCUS' CHIEF COMPLIANCE OFFICER TO REVIEW THEIR CONFLICT OF INTEREST STATEMENTS, AND GIVE AN ANNUAL CONFLICT OF INTEREST COMPLIANCE REPORT TO THE BOARD CHAIR AND VICE CHAIR. IF A CONFLICT IS REPORTED, IT IS THEN REFERRED TO THE PRESIDENT/CEO AND/OR BRIGHTFOCUS' LEGAL COUNSEL AND, IF APPROPRIATE AND NECESSARY, THEN TO THE BOARD OF DIRECTORS OR ITS APPOINTED COMMITTEE FOR FURTHER ACTION.

THE DIRECTOR'S AND OFFICER'S STATEMENTS ARE REVIEWED BY THE BRIGHTFOCUS LEGAL COUNSEL. IF A CONFLICT IS REPORTED, IT IS THEN REFERRED TO THE BOARD OF DIRECTORS OR ITS APPOINTED COMMITTEE FOR FURTHER ACTION.

AT THE TIME OF THE BRIGHTFOCUS DISCUSSION AND DECISION CONCERNING A CONFLICT OF INTEREST, THE CONFLICTED PARTY IS NOT PRESENT IN THE MEETING.

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

FORM 990, PART VI, SECTION B, LINE 15:

BRIGHTFOCUS' BOARD OF DIRECTORS HAS OVERALL AUTHORITY AND RESPONSIBILITY FOR APPROVING THE ANNUAL BUDGET WHICH INCLUDES SALARY AND BENEFITS FOR ALL EMPLOYEES AT EVERY LEVEL INCLUDING NON-DIRECTOR OFFICERS AND KEY EMPLOYEES. ALL PAY ADJUSTMENTS ARE MADE ON A YEARLY BASIS EFFECTIVE APRIL 1ST, THE BEGINNING OF THE BRIGHTFOCUS FISCAL YEAR.

BEFORE APPROVING THE COMPENSATION OF THE PRESIDENT/CEO, THE BOARD DETERMINES THE TOTAL COMPENSATION TO BE PROVIDED BY BRIGHTFOCUS TO THE PRESIDENT/CEO IS REASONABLE IN LIGHT OF THE POSITION, RESPONSIBILITY AND QUALIFICATION OF THE POSITION HELD INCLUDING THE RESULT OF AN EVALUATION OF PRIOR PERFORMANCE FOR BRIGHTFOCUS, IF APPLICABLE. THE PRESIDENT/CEO IS EVALUATED ANNUALLY BY THE BOARD OF DIRECTORS THROUGH THE USE OF AN IN-DEPTH GOAL ATTAINMENT STRUCTURE, (DEVELOPED WITH ADVICE FROM BOARD SOURCE) THAT INCLUDES A SELF ASSESSMENT AND A BOARD OF DIRECTORS ASSESSMENT AND EVALUATION AGAINST SET GOALS, OUTCOMES AND DELIVERABLES. IN ADDITION, THE BOARD OF DIRECTORS PERIODICALLY ENGAGES AN OUTSIDE CONSULTANT TO OBTAIN AND CONSIDER APPROPRIATE DATA, INCLUDING A SALARY SURVEY, WHICH INCLUDES INFORMATION COMPILED FROM THE FEDERAL FORM 990 OF OTHER ORGANIZATIONS, CONCERNING COMPENSATION PAID TO CEOS IN LIKE CIRCUMSTANCES. IN MAKING THE DETERMINATION, THE BOARD OF DIRECTORS SHALL CONSIDER TOTAL COMPENSATION TO INCLUDE THE SALARY AND VALUE OF ALL BENEFITS PROVIDED BY BRIGHTFOCUS TO THE INDIVIDUAL IN PAYMENT FOR SERVICES. AT THE TIME OF THE BRIGHTFOCUS BOARD DISCUSSION AND DECISION CONCERNING THE PRESIDENT/CEO'S COMPENSATION, THE PRESIDENT/CEO IS NOT PRESENT IN THE MEETING.

THE BOARD SHALL SET FORTH THE BASIS FOR ITS DECISIONS WITH RESPECT TO

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

COMPENSATION IN THE MINUTES OF THE MEETING AT WHICH THE DECISIONS ARE MADE, INCLUDING THE CONCLUSIONS OF THE EVALUATION AND THE BASIS FOR DETERMINING THAT THE INDIVIDUAL'S COMPENSATION WAS REASONABLE IN LIGHT OF THE EVALUATION AND COMPARABILITY DATA.

THE PRESIDENT/CEO IS CHARGED WITH THE SETTING OF SALARIES OF ALL OTHER EMPLOYEES IN ACCORDANCE WITH A COMPENSATION STRUCTURE AND BUDGET APPROVED BY THE BOARD OF DIRECTORS. THE PRESIDENT/CEO AND HUMAN RESOURCES REVIEW EMPLOYEE COMPENSATION AND BENEFITS THAT INCLUDE KEY EMPLOYEES, BY PERIODICALLY ENGAGING AN OUTSIDE CONSULTANT TO CONDUCT COMPENSATION AND BENEFIT BENCHMARKING STUDIES THAT INCLUDE VARIOUS REGIONAL AND NATIONAL NON-PROFIT COMPENSATION REPORTS AND SURVEYS. COMPENSATION DELIBERATIONS AND DECISIONS INCLUDE THE REVIEW OF SELF AND SUPERVISORY EVALUATIONS OF EMPLOYEE PERFORMANCE COMPARED TO SET INDIVIDUAL AND ORGANIZATIONAL GOALS.

FORM 990, PART VI, LINE 17, LIST OF STATES RECEIVING COPY OF FORM 990:
AK,AL,AR,CA,CT,FL,GA,HI,IL,KS,KY,ME,MD,MA,MI,MN,MO,MS,NC,ND,NH,NJ,NM,NY,OH OK,OR,PA,RI,SC,TN,UT,VA,WA,WI,WV

FORM 990, PART VI, SECTION C, LINE 19:
BRIGHTFOCUS MAKES ITS GOVERNING DOCUMENTS INCLUDING ITS ARTICLES OF INCORPORATION AND BYLAWS, THE FEDERAL FORM 1023, THE 501(C)(3) LETTER OF DETERMINATION FROM THE INTERNAL REVENUE SERVICE, CONFLICT OF INTEREST POLICY, AUDITED FINANCIAL STATEMENTS AND FEDERAL FORM 990 AVAILABLE TO THE PUBLIC UPON REQUEST. IN ADDITION, THE PUBLIC ALSO HAS ACCESS TO THE ANNUAL REPORT, AUDITED FINANCIAL STATEMENTS, THE 501(C)(3) LETTER OF DETERMINATION FROM THE INTERNAL REVENUE SERVICE, AND FEDERAL FORM 990 ON OUR WEBSITE.

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

FORM 990, PART XI, LINE 9, CHANGES IN NET ASSETS:

RECOVERIES OF PRIOR YEAR GRANTS	528,609.
CHANGE IN PRESENT VALUE OF GRANTS	361,988.
TOTAL TO FORM 990, PART XI, LINE 9	890,597.

SCHEDULE F, PART II, LINE 1, COLUMN D:

REGION: EUROPE (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY LAIA MONTOLIU-GAYA, PHD, ENTITLED: (A2022015F) SIMULTANEOUS MEASUREMENT OF SIX TAU PHOSPHORYLATIONS IN BLOOD TO STAGE ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: A RELIABLE BLOOD TEST WOULD HAVE A GREAT POTENTIAL FOR DIAGNOSIS OF ALZHEIMERS DISEASE (AD). IN THE RECENT YEARS, MANY ASSAYS HAVE BEEN DEVELOPED TO MEASURE DIFFERENT PATHOLOGICAL VARIANTS OF A PROTEIN CALLED TAU IN BLOOD. WHEN TRYING TO DETERMINE WHICH VARIANT IS THE BEST BIOMARKER, STUDIES CAN ONLY COMPARE THE ASSAYS, BUT NOT THE LEVELS OF THE VARIANTS BECAUSE THEY ARE MEASURED DIFFERENTLY. WE HAVE DEVELOPED A NOVEL METHOD THAT CAN COMPARE ALL THESE VARIANTS AT THE SAME TIME IN THE SAME SAMPLE. WE AIM TO USE THIS METHOD TO DETERMINE THE BEST BLOOD BIOMARKER FOR THE DIFFERENT STAGES OF AD. GRANT AWARDED: $200,000, UNIVERSITY OF GOTHENBURG, INSTITUTE FOR NEUROSCIENCE AND PHYSIOLOGY, GOTHENBURG, SWEDEN. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022015F

REGION: NORTH AMERICA (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY CHRISTOPHER MORRONE, PHD, ENTITLED: (A2022016F) IMPAIRMENTS IN SLEEP AND PROTEOSTASIS ACCELERATE ALZHEIMER'S DISEASE PROGRESSION. INVESTIGATOR'S SUMMARY: I HYPOTHESIZE THAT SLEEP LOSS AND PROTEIN RECYCLING FAILURE ARE INTERACTIVE EVENTS IN ALZHEIMER'S DISEASE (AD),

THAT PRECEDE MEMORY LOSS AND PREDICT DISEASE PROGRESSION. TO TEST THIS, I WILL LOOK AT SLEEP AND MEMORY, NEURONAL FUNCTION, AND MARKERS OF PROTEIN RECYCLING AND PATHOLOGY IN AN AD MOUSE MODEL TO SEE IF IMPROVING PROTEIN RECYCLING CAN RESCUE BEHAVIOR. ARTIFICIAL INTELLIGENCE MODELS WILL BE USED TO ASSESS THE CONTRIBUTION OF THESE BIOLOGICAL EVENTS TO PREDICT MEMORY LOSS AND DISEASE RISK, FACILITATING THE DISCOVERY OF NOVEL BIOMARKERS AND TREATMENTS FOR AD. GRANT AWARDED: $200,000, CENTRE FOR ADDICTION AND MENTAL HEALTH, TORONTO, ONTARIO, CANADA. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022016F

REGION: EUROPE (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY SANDRA O. TOME, PHD, ENTITLED: (A2022019F) INVESTIGATING TDP-43 BIOLOGY IN ALZHEIMER'S DISEASE AND LATE: IMPACT ON THE CLINICAL DIAGNOSIS. INVESTIGATOR'S SUMMARY: DEMENTIA AFFECTS AROUND 50 MILLION PEOPLE WORLDWIDE, CAUSING DEVASTATING CONSEQUENCES TO THESE PATIENTS, THEIR FAMILIES AND SOCIETY. ALZHEIMER'S DISEASE (AD) AND LATE ARE THE MOST COMMON DEMENTIAS IN THE ELDERLY. A LINK BETWEEN THESE DISEASES IS THE PRESENCE OF PATHOLOGICAL AGGREGATES WITH TDP-43 PROTEIN. IN LATE, IT IS THE MAJOR CAUSE OF THE DISEASE WHILE IN AD IT ACCUMULATES ALONGSIDE AMYLOID-BETA AND TAU PROTEINS, WORSENING COGNITION. A RELEVANT QUESTION IS WHETHER THE TDP-43 PATHOLOGY OBSERVED IN AD AND LATE IS MOLECULARLY SIMILAR AND HOW IT IMPACTS THE CLINICAL DIAGNOSIS OF THESE PATIENTS. GRANT AWARDED: $200,000, CATHOLIC UNIVERSITY OF LEUVEN, BELGIUM. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022019F

REGION: EAST ASIA & PACIFIC (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE

RESEARCH BY KRISTIE STEFANOSKA, PHD, ENTITLED: (A2022022F) MASTER SITES OF TAU PHOSPHORYLATION AS TREATMENT TARGETS FOR ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: THE PROGRESSION OF ALZHEIMER'S DISEASE CORRELATES WITH THE ABNORMAL ACCUMULATION OF A BRAIN MOLECULE CALLED TAU. TAU UNDERGOES MODIFICATION, WHICH SUBSEQUENTLY CAUSES IT TO COLLECT WITH OTHER TAU PROTEINS AND FORM LARGER, ABNORMAL STRUCTURES IN THE BRAIN. I MADE THE DISCOVERY THAT TAU CONTAINS DISEASE-PROMOTING SITES, WHICH ARE ESSENTIAL IN DRIVING MODIFICATION IN THIS PROTEIN AND I AIM TO INVESTIGATE HOW REMOVING THE DISEASE-PROMOTING SITES ON TAU COULD REDUCE ABNORMAL MODIFICATION OF TAU, AND THUS BE USED AS A NOVEL THERAPEUTIC APPROACH TO MITIGATE PROCESSES UNDERLYING ALZHEIMER'S DISEASE. GRANT AWARDED: $199,034, THE FLINDERS UNIVERSITY OF SOUTH AUSTRALIA, BEDFORD PARK, ADELAIDE, AUSTRALIA. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022022F

REGION: EUROPE (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY LARISSA TRAXLER, PHD, ENTITLED: (A2022024F) ASSESSMENT OF THE PYRUVATE KINASE ISOFORM IMBALANCE IN THE LOSS OF CELL IDENTITY IN ALZHEIMER'S DISEASE NEURONS AND NEUROINFLAMMATION. INVESTIGATOR'S SUMMARY: ALZHEIMER'S DISEASE (AD) IS A FATAL NEURODEGENERATIVE DISEASE WITH NO CURE IN SIGHT. BY GENERATING PATIENT-SPECIFIC INDUCED NEURONS (INS), WE FOUND THAT ALZHEIMER NEURONS BEHAVE SIMILARLY TO CANCER CELLS, AS THEY DE-DIFFERENTIATE TOWARDS A PRECURSOR STATE. HOWEVER, INSTEAD OF INITIATING PROLIFERATION, NEURONS GET VULNERABLE TO STRESS-INDUCED PROGRAMMED CELL DEATH. IN THIS PROJECT, WE WILL DEEPLY CHARACTERIZE PYRUVATE KINASE M (PKM) IN THIS PROCESS IN POST-MITOTIC NEURONS, AND ASSESS PKM AS A THERAPEUTIC TARGET FOR REVERSING THE AD PHENOTYPE. GRANT AWARDED: $200,000, UNIVERSITAT INNSBRUCK, AUSTRIA. FOR MORE

INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:

WWW.BRIGHTFOCUS.ORG/GRANT/A2022024F

REGION: MIDDLE EAST (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY URI ASHERY, PHD, ENTITLED: (A2022029S) TOWARDS NANOSCALE BLUEPRINTS OF EARLY MOLECULAR, SYNAPTIC AND PHYSIOLOGICAL CHANGES IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: DEGENERATION OF SYNAPTIC CONTACTS BETWEEN NEURONS IN THE BRAIN IS ONE OF THE FIRST PROCESSES THAT LEAD TO ALZHEIMER'S DISEASE (AD). THIS OCCURS NEAR AMYLOID DEPOSITS, WHICH ARE THE MAIN HALLMARKS OF AD. HOWEVER, WHAT CAUSES SYNAPTIC LOSS IS NOT KNOWN. WE WILL USE, FIRST TIME IN AD, A NOVEL PLATFORM WE DEVELOPED, TO DETECT MOLECULAR CHANGES OF HUNDREDS OF GENES IN INTACT BRAIN TISSUES AT EARLY DISEASE STAGES, RELATE THEM TO SPECIFIC CELL TYPES, PROXIMITY TO AMYLOID DEPOSITS, AND SEX DIFFERENCES. UNDERSTANDING THESE MECHANISMS WILL HELP DEVELOP THERAPEUTICS TO HINDER AND PREVENT THESE PROCESSES. GRANT AWARDED: $300,000, TEL AVIV UNIVERSITY, ISRAEL. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:

WWW.BRIGHTFOCUS.ORG/GRANT/A2022029S

REGION: EUROPE (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY SAMUEL BARNES, PHD, ENTITLED: (A2022030S) FUNCTIONAL AND MOLECULAR MAPPING OF VULNERABLE GABAERGIC SYNAPSES IN EARLY-STAGE AD PATHOPHYSIOLOGY. INVESTIGATOR'S SUMMARY: LOSS OF SYNAPTIC CONNECTION POINTS BETWEEN BRAIN CELLS HAS BEEN LINKED TO MEMORY LOSS IN ALZHEIMER'S DISEASE (AD). HOWEVER, NOT ALL SYNAPSES ARE LOST DURING THE DISEASE, WITH SOME REPORTS FINDING APPROXIMATELY 60% SYNAPTIC SURVIVAL. WE AIM TO UNDERSTAND THE MOLECULES AND RESPONSE PROPERTIES THAT MAKE SOME SYNAPSES VULNERABLE AND OTHERS RESILIENT. TO DO THIS, WE WILL USE

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

MOUSE MODELS AND HUMAN AD BRAIN TISSUE TO IDENTIFY KEY MOLECULES AT SYNAPSES WITH NORMAL AND ABNORMAL RESPONSES DURING DISEASE PROGRESSION. WE WILL USE THIS INFORMATION TO DEVELOP NEW MEDICAL APPROACHES TO BOOST SYNAPSE SURVIVAL IN AD. GRANT AWARDED: $299,715, IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE, LONDON, UNITED KINGDOM. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022030S

REGION: EUROPE (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY MARTA CORTES-CANTELI, PHD, ENTITLED: (A2022034S) UNDERSTANDING THE IMPACT OF MIDLIFE CARDIOVASCULAR RISK FACTORS & SUBCLINICAL ATHEROSCLEROSIS ON BRAINS HEALTH: A ROLE ON ALZHEIMERS PATHOLOGY. INVESTIGATOR'S SUMMARY: CARDIOVASCULAR RISK FACTORS INCREASE THE LIKELIHOOD OF DEVELOPING MEMORY PROBLEMS IN THE ELDERLY AND, INDEED, CARDIOVASCULAR DISORDERS AND ALZHEIMER'S DISEASE APPEAR TOGETHER IN SYMPTOMATIC STAGES. AS BOTH DISEASES SHARE RISK FACTORS AND HAVE LONG SUBCLINICAL PHASES, WE PROPOSE TO ANALYZE WHAT IS HAPPENING DURING THE 10-20 YEARS BEFORE THE SYMPTOMS OF BOTH PATHOLOGIES APPEAR. OUR STUDIES WILL DECIPHER WHETHER NOT MAINTAINING A HEALTHY LIFESTYLE WHEN YOU ARE IN YOUR 50'S COULD START HAVING NEGATIVE CONSEQUENCES FOR YOUR BRAIN AT THAT MOMENT AND CONTRIBUTE TO MEMORY PROBLEMS A DECADE LATER. GRANT AWARDED: $300,000, CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III (F.S.P.), MADRID, SPAIN. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022034S

SCHEDULE F, PART II, LINE 1, COLUMN D, CONTINUED:

REGION: MIDDLE EAST (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY YUVAL DOR, PHD, ENTITLED: (A2022035S) LIQUID BIOPSY FOR DETECTION OF

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

CELL DEATH IN ALZHEIMER'S DISEASE BASED ON CFDNA METHYLATION PATTERNS. INVESTIGATOR'S SUMMARY: WE PROPOSE TO ESTABLISH A NOVEL TYPE OF BLOOD TEST A LIQUID BIOPSY - TO IDENTIFY AND MONITOR CELL DEATH IN THE BRAIN AND IN OTHER KEY TISSUES IN PATIENTS DEVELOPING ALZHEIMER'S DISEASE (AD). THE APPROACH IS BASED ON A NEW TECHNOLOGY THAT ALLOWS TO DETERMINE THE TISSUE SOURCES OF DNA MOLECULES RELEASED FROM DYING CELLS TO THE BLOOD, USING CELL TYPE-SPECIFIC DNA METHYLATION PATTERNS. THE ASSAY WILL BE APPLIED TO BLOOD SAMPLES OBTAINED FROM HEALTHY INDIVIDUALS, PEOPLE WITH MILD COGNITIVE IMPAIRMENT THAT GO ON TO DEVELOP AD, AND PATIENTS WITH ESTABLISHED DISEASE. GRANT AWARDED: $300,000, HEBREW UNIVERSITY OF JERUSALEM, ISRAEL. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022035S

REGION: NORTH AMERICA (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY SUE-ANN MOK, PHD, ENTITLED: (A2022044S) DISSECTING HOW PTMS REGULATE TAU AGGREGATE STRAIN FORMATION. INVESTIGATOR'S SUMMARY: IN ALZHEIMER'S DISEASE, MOLECULES OF TAU PROTEIN FORM VERY SPECIFIC SHAPES AS THEY STACK TOGETHER TO CREATE LARGE STRUCTURES CALLED AGGREGATES THAT ARE THOUGHT TO CONTRIBUTE TO DEVELOPMENT AND PROGRESSION OF DISEASE. IF WE COULD FIGURE OUT THE FACTORS THAT CAUSE TAU TO TAKE ON THE SPECIFIC SHAPES WE OBSERVE IN DISEASE, WE MAY BE ABLE TO PREVENT THIS PATHOLOGICAL PROCESS. WE ARE USING ADVANCED BIOCHEMICAL TECHNOLOGIES TO STUDY HUNDREDS OF POTENTIAL FACTORS, CALLED POST-TRANSLATIONAL MODIFICATIONS, AND IDENTIFY THE KEY FACTORS LEADING TO THE TAU SHAPES OBSERVED IN ALZHEIMER'S. GRANT AWARDED: $299,851, UNIVERSITY OF ALBERTA, EDMONTON, CANADA. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022044S

REGION: EUROPE (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY DOMINIK PAQUET, PHD, ENTITLED: (A2022045S) DEVELOPMENT OF A HUMAN IPSC-BASED TAUOPATHY MODEL SHOWING ADVANCED PHENOTYPES. INVESTIGATOR'S SUMMARY: INVESTIGATING THE MECHANISMS LEADING TO NERVE CELL DECLINE IN DEMENTIAS REQUIRES EXPERIMENTAL DISEASE MODELS. WE WILL DEVELOP A HUMAN MODEL OF TAU-RELATED DEMENTIAS, SUCH AS ALZHEIMER'S AND FTD. THE TAU PROTEIN PLAYS A CENTRAL ROLE IN DEMENTIA FORMATION AND NERVE CELL DEATH. BUT ITS REGULATION IN HUMAN NERVE CELLS DIFFERS FROM MICE, WHICH ARE CURRENTLY USED AS MODELS. USING BRAIN CELLS DERIVED FROM HUMAN STEM CELLS AND GENOME EDITING WITH CRISPR, WE AIM TO GENERATE BRAIN TISSUE WITH GENETIC ALTERATIONS IN THE TAU GENE LEADING TO DEMENTIA IN PATIENTS, TO INVESTIGATE HUMAN DISEASE MECHANISMS. GRANT AWARDED: $300,000, HOSPITAL OF THE LUDWIG MAXIMILIAN, UNIVERSITY OF MUNICH, GERMANY. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022045S

REGION: NORTH AMERICA (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY CARLOS RONCERO, PHD, ENTITLED: (A2022046S) UNDERSTANDING HOW ALZHEIMER'S DISEASE IMPACTS THE THERAPEUTIC RESPONSE TO TRANSCRANIAL DIRECT CURRENT STIMULATION. INVESTIGATOR'S SUMMARY: TRANSCRANIAL DIRECT CURRENT STIMULATION (TDCS) IS A NEW POTENTIAL THERAPY FOR IMPROVING THE QUALITY OF LIFE FOR PEOPLE LIVING WITH ALZHEIMER'S DISEASE (AD). FURTHER WORK IS NEEDED FOR UNDERSTANDING HOW TDCS COULD BE OPTIMIZED AND WHICH INDIVIDUALS ARE THE BEST CANDIDATES FOR RECEIVING THIS FORM OF THERAPY. THE PROPOSED PROJECT WILL TEST A NEW INTENSITY LEVEL OF TDCS THAT MAY PRODUCE STRONGER RESULTS IN PEOPLE WITH AD AND COLLECT PARTICIPANT INFORMATION TO IDENTIFY WHO BEST

RESPONDS TO TDCS. THESE RESULTS WILL HELP US OPTIMIZE AND TAILOR TDCS FOR PEOPLE WITH AD. GRANT AWARDED: $243,196, BAYCREST CENTRE FOR GERIATRIC CARE, TORONTO, CANADA. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022046S

REGION: EUROPE (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY CARLOS SAURA, PHD, ENTITLED: (A2022047S) TARGETING EXCITATORY NEURAL CIRCUITS IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: COMMUNICATION OF NEURONS IS FUNDAMENTAL FOR BRAIN FUNCTION DURING COGNITION, MEMORY AND MENTAL PROCESSES. DISRUPTION OF MEMORY NEURAL CIRCUITS CONTRIBUTES TO PATHOLOGY, NEURODEGENERATION AND MEMORY LOSS EARLY IN ALZHEIMER'S DISEASE (AD), BUT THE MECHANISMS INVOLVED REMAIN UNKNOWN. THIS PROJECT WILL EMPLOY NOVEL STATE-OF-THE ART MOUSE MODELS AND TECHNIQUES TO UNRAVEL THE MECHANISMS UNDERLYING MEMORY CIRCUIT DISRUPTION AND HOW IT CONTRIBUTES TO MEMORY LOSS EARLY IN AD. FINALLY, WE WILL DEVELOP NOVEL PHARMACOGENETIC AND GENE THERAPY APPROACHES TO ACTIVATE NEURAL CIRCUITS AND MEMORY IN AD. GRANT AWARDED: $300,000, UNIVERSITY AUTONOMA OF BARCELONA, BELLATERRA, SPAIN. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022047S

REGION: EUROPE (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY DR. GAELLE CHETELAT ENTITLED: (CA2021013) SEX DIFFERENCES IN RISK PROFILES ACROSS THE ALZHEIMER'S DISEASE CONTINUUM. INVESTIGATOR'S SUMMARY: THIS PROJECT, WHICH WILL TAKE PLACE AT UNIVERSITY OF CAEN NORMANDIE. BASED ON TWO EXISTING COHORTS OF PEOPLE AT DIFFERENT STAGES OF ALZHEIMER'S DISEASE, DR. CHETELAT'S TEAM WILL HIGHLIGHT GENDER-SPECIFIC RISK PROFILES AND ASSESS THEIR ABILITY TO PREDICT THE CLINICAL COURSE OF PATIENTS. NEXT, THE TEAM WILL INVESTIGATE WHETHER

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

THESE RISK PROFILES CAN BE REDUCED BY AN INTERVENTION BASED ON MENTAL TRAINING (THROUGH MEDITATION OR LEARNING ENGLISH). IDENTIFYING AND DISTINGUISHING THE RISK FACTORS THAT ARE SPECIFIC TO MEN AND WOMEN SHOULD ALLOW BETTER CONSIDERATION OF SEX-RELATED DIFFERENCES AND THUS LEAD TO AN EARLIER DIAGNOSIS OF THE DISEASE. THE RESULTS OF THIS PROJECT WILL ALSO HELP IN THE DEVELOPMENT OF PERSONALIZED MANAGEMENT OF THE DISEASE, TAKING INTO ACCOUNT THE SPECIFICITIES OF MEN AND WOMEN. GRANT AWARDED: $68,278, FONDATION VAINCRE ALZHEIMER, PARIS, FRANCE. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/CA2021013

REGION: EAST ASIA & PACIFIC (D) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY EMMANUELLE SOUZEAU, PHD, ENTITLED: (G2022002F) INVESTIGATING NOVEL GENETIC COUNSELING AND COMMUNICATION STRATEGIES FOR POLYGENIC RISK TESTING IN GLAUCOMA. INVESTIGATOR'S SUMMARY: THE RECENT DEVELOPMENT OF POLYGENIC RISK SCORES (PRS) FOR GLAUCOMA MAKES GENETIC TESTING AN IDEAL STRATEGY TO IDENTIFY AT-RISK INDIVIDUALS WHO CAN BENEFIT FROM EARLY MANAGEMENT TO REDUCE PREVENTABLE BLINDNESS. HOWEVER, THE CURRENT LACK IN REPORTING STRATEGIES TO EFFICIENTLY COMMUNICATE PRS TO PATIENTS IMPEDES THE IMPLEMENTATION OF TESTING IN CLINICAL PRACTICE. THIS PROPOSAL AIMS TO DEVELOP THE FIRST PATIENT-FRIENDLY REPORTS AND ASSESS DELIVERY METHODS FOR RISK COMMUNICATION OF PRS FOR GLAUCOMA, WHICH WILL ULTIMATELY BENEFIT AT-RISK INDIVIDUALS GLOBALLY. GRANT AWARDED: $148,049, THE FLINDERS UNIVERSITY OF SOUTH AUSTRALIA, BEDFORD PARK, ADELAIDE, AUSTRALIA. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2022002F

REGION: EUROPE (D) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

MARCO FELIGIONI, PHD, ENTITLED: (G2022015S) SPECIFICALLY TARGETING GLUTAMATE RELEASE TO TACKLE RETINAL GANGLION CELL DEGENERATION IN GLAUCOMA. INVESTIGATOR'S SUMMARY: GLAUCOMA IS A PROGRESSIVE AND NEURODEGENERATIVE DISORDER AFFECTING RETINAL CELLS VIABILITY WHICH PROGRESSIVELY BRINGS TO BLINDNESS. DESPITE THE PHARMACOLOGICAL TREATMENTS AVAILABLE ON THE MARKET, NORMALLY LIMITED TO ANTIHYPERTENSIVE DRUGS, THERE ARE NO TREATMENTS TO PROTECT THE RETINA AND OPTIC NERVE FROM THE PROGRESSIVE DAMAGE. THEREFORE NEUROPROTECTION IS AN UNMET MEDICAL NEED FOR WHICH THE RESEARCH IS TRYING TO GIVE NEW ANSWER. IN THIS CONTEXT, THIS PROJECT AIMS AT INVESTIGATING THE PROPERTIES OF OUR NEW DRUG AGAINST DEGENERATION OF RETINAL GANGLIAL CELLS GRANT AWARDED: $200,000, FONDAZIONE EBRI "RITA LEVI-MONTALCINI", ROME, ITALY. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2022015S

REGION: EUROPE (D) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY NICOLE NOEL, PHD, ENTITLED: (M2022002F) ASSESSING RETINAL DISEASE MANIFESTATION AND NEUROPROTECTION IN THE KILLIFISH MODEL OF AGE-RELATED MACULAR DEGENERATION. INVESTIGATOR'S SUMMARY: THIS WORK PROVIDES THE UNIQUE OPPORTUNITY TO DEVELOP KILLIFISH AS A RETINAL AGEING MODEL, DETERMINE THE CELLULAR MECHANISMS THAT LEAD TO AMD, AND ASSESS HOW HEALTHY RETINAL AGEING CAN BE PROMOTED IN A MODEL OF AGE-RELATED RETINAL DEGENERATION. GRANT AWARDED: $199,998, UNIVERSITY COLLEGE LONDON, UNITED KINGDOM. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2022002F

SCHEDULE F, PART II, LINE 1, COLUMN D, CONTINUED:

REGION: EUROPE (D) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY

LUCIA CELKOVA, PHD, ENTITLED: (M2022004F) AN INVESTIGATION INTO THE ROLE OF PANOPTOSIS IN GEOGRAPHIC ATROPHY. INVESTIGATOR'S SUMMARY: THE RESEARCH PROPOSED HERE AIMS TO EXPLORE A MASTER "DECISION MAKER" WHICH COULD INTEGRATE AND PROCESS THESE TRIGGERS AND GUIDE THE FATE OF RPE CELLS EITHER TOWARDS SURVIVAL OR DEATH. THROUGH THIS, WE WILL NOT ONLY GAIN A BETTER UNDERSTANDING OF THE COMPLEX PROCESS UNDERLYING RPE CELL DEATH, BUT WILL ALSO IDENTIFY POTENTIAL NEW TARGETS AND STRATEGIES FOR THERAPEUTIC INTERVENTION IN DRY AMD. GRANT AWARDED: $200,000, COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, DUBLIN, IRELAND. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2022004F

REGION: EUROPE (D) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY YARA LECHANTEUR, MD, PHD, ENTITLED: (M2022013N) CLINICAL AND MOLECULAR CHARACTERIZATION OF EARLY ONSET DRUSEN MACULOPATHY. INVESTIGATOR'S SUMMARY: AGE-RELATED MACULAR DEGENERATION IS THE MOST COMMON CAUSE OF BLINDNESS. IT USUALLY STARTS AT AN AFTER THE AGE OF 65 BUT SOME PATIENTS DEVELOP A SIMILAR PHENOTYPE ALREADY BEFORE THEY TURN 50. WE AIM TO STUDY THESE YOUNG ONSET CASES BY STUDYING THEIR FAMILY MEMBERS AND BY LOOKING AT GENETIC FACTORS AND SPECIFIC MARKERS IN BLOODSAMPLES. OUR AIM IS TO IDENTIFY NEW FACTORS THAT ARE INVOLVED IN THIS DISEASE. BETTER KNOWLEDGE ABOUT THE DISEASE CAN AID IN DEVELOPMENT OF FUTURE THERAPIES AND MAY BRING US A STEP CLOSER TOWARDS TREATMENT. GRANT AWARDED: $449,838, RADBOUD UNIVERSITY NIJMEGEN MEDICAL CENTRE, NIJMEGEN, NETHERLANDS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2022013N

REGION: NORTH AMERICA (D) PURPOSE OF GRANT: MACULAR DEGENERATION

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

RESEARCH BY PRZEMYSLAW SAPIEHA, PHD, ENTITLED: (M2022015I) EARLY LIFE METABOLIC EVENTS INFLUENCE AGE-RELATED MACULAR DEGENERATION. INVESTIGATOR'S SUMMARY: IMMUNE CELLS, WHICH PLAY A KEY ROLE IN THE ABERRANT BLOOD VESSEL GROWTH DURING AMD, ARE ALTERED FOLLOWING ENCOUNTERS WITH PATHOGENS, AS WELL AS DURING PERSISTENT EVENTS SUCH AS OBESITY, POTENTIALLY IMPACTING DISEASE DEVELOPMENT. IN THIS PROPOSAL, WE WILL ASSESS WHETHER IMMUNE CELLS ARE MODIFIED IN A WAY THAT INCREASES THE RISK OF AMD FOLLOWING WEIGHT GAIN AND SUBSEQUENT WEIGHT LOSS. UNDERSTANDING HOW IMMUNE CELLS RESPOND IN THE CONTEXT OF PAST OBESITY WILL ALLOW US TO GAIN INSIGHT ON MECHANISMS THAT CAUSE AMD AND POTENTIALLY LEAD THE WAY TO DEVELOPING TARGETED INTERVENTIONS. GRANT AWARDED: $600,000, HOSPITAL MAISONNEUVE-ROSEMONT, MONTREAL, QUEBEC, CANADA. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2022015I

REGION: EUROPE (D) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY WEN HWA LEE, PHD, ENTITLED: (M2022002) CREATING FORESIGHT: CHARITY-LED BIG DATA RESOURCE FOR DISCOVERY OF NOVEL BIOMARKERS FOR MULTIPLE CONDITIONS USING EYE SCANS. INVESTIGATOR'S SUMMARY: THE GOAL OF THIS PROJECT IS TO BUILD A PROSPECTIVE DATASET OF HIGH-CONTENT IMAGES AND 3D SUB-TISSUE RETINAL SCANS OF 500,000 PARTICIPANTS WITH CONSENT FOR SECONDARY USE AND LINKAGE TO OTHER HEALTH DATASETS. PARTICIPANTS AND DATA COLLECTION WILL BE DISEASE AGNOSTIC AND WILL INCLUDE HEALTHY PARTICIPANTS; 500,000 MILESTONE TO BE REACHED BY YEAR 3; ETHICAL, TRANSPARENT, AND PUBLICLY SUPPORTED DATA ACCESS MODEL; PARTICIPANTS' EYE SCANS CAN BE LINKED TO GENOTYPING DATA TO BE GENERATED BY UK'S OUR FUTURE HEALTH INITIATIVE. FURTHER THIS DATASET WILL BE MADE AVAILABLE FOR RESEARCH VIA COLLABORATION WITH SCIENTISTS FROM ACADEMIA AND/OR

SMES. GRANT AWARDED: $250,000, ACTION AGAINST AMD, LONDON, UNITED KINGDOM. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/CM2022002

SCHEDULE I, PART II, LINE 1, COLUMN (H):
NAME OF ORGANIZATION OR GOVERNMENT: ALBANY MEDICAL COLLEGE. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY CHARLY ABI GHANEM, PHD, ENTITLED: (A2022001F) INFLUENCE OF ANDROGENS ON MULTI-ETIOLOGY DEMENTIA. INVESTIGATOR'S SUMMARY: LOW TESTOSTERONE LEVELS IN MEN ARE A RISK FACTOR FOR DEMENTIA AND ARE ASSOCIATED WITH COGNITIVE DECLINE. THIS STUDY WILL INVESTIGATE THE EFFECTS OF TESTOSTERONE REMOVAL AND TREATMENT ON COGNITIVE DECLINE AND PATHOLOGY IN A NEW MOUSE MODEL OF MULTI-ETIOLOGY DEMENTIA. THIS ADDRESSES A MAJOR BRAIN HEALTH ISSUE IN MEN (DEMENTIA) AND CONTRIBUTES TO THE DEVELOPMENT OF NEW TREATMENTS AND PREVENTIONS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022001F

NAME OF ORGANIZATION OR GOVERNMENT: MASSACHUSETTS GENERAL HOSPITAL. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY ANA RITA AGRA DE ALMEIDA QUADROS, PHD, ENTITLED: (A2022002F) TDP-43-DEPENDENT TRUNCATION OF STATHMIN-2 MRNA AS A NOVEL TARGET IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: ACCUMULATION OF TOXIC PROTEINS IN THE BRAIN FROM PATIENTS WITH ALZHEIMER'S DISEASE (AD) CONTRIBUTES TO NEURODEGENERATION. TDP-43 IS ONE OF THE PROTEINS THAT ABNORMALLY ACCUMULATES IN UP TO 50% OF AD PATIENTS. RECENTLY, MY LABORATORY AND OTHERS SHOWED THAT STATHMIN-2, A PROTEIN CRUCIAL FOR NEURONAL FUNCTION, IS LOST IN NEURONS WITH ABNORMAL TDP-43. I WILL DETERMINE WHETHER STATHMIN-2 IS ALTERED IN ALZHEIMER'S DISEASE PATIENTS AND REPRESENTS A

NEW POTENTIAL THERAPEUTIC TARGETS FOR PATIENTS WITH TDP-43 PATHOLOGY. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022002F

NAME OF ORGANIZATION OR GOVERNMENT: WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY ANTOINE ANFRAY, PHD, ENTITLED: (A2022003F) ROLE OF PERIVASCULAR MACROPHAGES IN APOE4-INDUCED NEUROVASCULAR DYSFUNCTION. INVESTIGATOR'S SUMMARY: ACCUMULATING EVIDENCE SUGGEST THAT EARLY ALTERATION IN THE BLOOD FLOW IN THE BRAIN IS AN IMPORTANT CONTRIBUTING FACTOR TO ALZHEIMER'S DISEASE (AD). INDIVIDUALS WITH APOLIPOPROTEIN E E4 (APOE4), A LEADING GENETIC RISK FACTOR FOR AD, HAVE REDUCED BLOOD FLOW TO THE BRAIN; HOWEVER, THE UNDERLYING MECHANISMS ARE UNKNOWN. THEREFORE, THE AIM OF THIS PROJECT IS TO STUDY THE BRAIN BLOOD FLOW DYSFUNCTION CAUSED BY APOE4 WITH THE ULTIMATE GOAL OF IDENTIFYING NEW PATHWAYS THAT COULD BE USED TO DEVELOP NEW DRUGS FOR THE PREVENTION AND TREATMENT OF DEMENTIA. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022003F

NAME OF ORGANIZATION OR GOVERNMENT: STANFORD UNIVERSITY. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY CHING-CHIEH CHOU, PHD, ENTITLED: (A2022004F) ROLE OF AGE-RELATED LYSOSOMAL VULNERABILITY IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: LYSOSOMAL VULNERABILITY IS CRITICAL TO THE DEVELOPMENT OF ALZHEIMER'S DISEASE (AD), WHEREAS THE MOLECULAR BASIS OF THE DEFICIT IN HUMAN NEURONS IS NOT FULLY UNDERSTOOD. I HARNESS THE LINEAGE REPROGRAMMING TECHNOLOGY TO TRANSDIFFERENTIATE HUMAN SOMATIC CELLS INTO NEURONS (TNEURONS) TO FACILITATE THE LEARNING OF DISEASE BIOLOGY AND TEST THERAPEUTIC

STRATEGIES FOR AD. THE OUTCOMES WILL ADVANCE OUR UNDERSTANDING OF LYSOSOMAL DYSFUNCTION AND LYSOSOME-TARGETING COMPOUNDS FOR AD AND POTENTIALLY AND OTHER DEMENTIAS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022004F

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA (IRVINE). (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY CHRISTIAN CROUZET, PHD, ENTITLED: (A2022005F) THE EFFECT OF HYPERTENSION ON NEUROVASCULAR DYSFUNCTION AND ALZHEIMER'S DISEASE PROGRESSION DURING MIDLIFE. INVESTIGATOR'S SUMMARY: MIDLIFE HYPERTENSION IS AN INCREASINGLY IMPORTANT RISK FACTOR FOR ALZHEIMER'S DISEASE (AD) AND RELATED DEMENTIAS. WE WILL INVESTIGATE HOW HYPERTENSION AFFECTS THE PROGRESSION OF ALZHEIMER'S DISEASE FROM A BLOOD FLOW, COGNITIVE, AND PATHOLOGICAL PERSPECTIVE THROUGH MIDLIFE. WE WILL TEST IF ANTI-HYPERTENSIVE MEDICATION CAN SLOW THE PROGRESSION OF AD AND IMPROVE COGNITIVE FUNCTION. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022005F

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF MASSACHUSETTS CHAN MEDICAL SCHOOL. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY VIOLETA DURAN LAFORET, PHD, ENTITLED: (A2022006F) HARNESSING SPATIAL TRANSCRIPTOMICS TO INVESTIGATE THE INTERSECTION OF SENESCENCE AND INFLAMMATION IN NEURODEGENERATION. INVESTIGATOR'S SUMMARY: AGING IS THE MAJOR RISK FACTOR FOR ALZHEIMER'S DISEASE (AD). SENESCENCE, A HALLMARK OF AGING, IS A PROCESS BY WHICH A CELL NO LONGER CAN PROLIFERATE. SINCE MICROGLIA, THE PRIMARY IMMUNE CELL OF THE CENTRAL NERVOUS SYSTEM, BECOME SENESCENT IN AD, I WILL INVESTIGATE IF THEY INITIATE THE INFLAMMATORY PROCESS IN THE AGING BRAIN AND STUDY IF

SENESCENT CELLS ARE PRESENT IN SPECIFIC LOCATIONS WITHIN THE BRAIN IN AD. TO DO SO, I WILL IMPLEMENT AN INNOVATIVE APPROACH CALLED MERFISH TO LOOK AT 100'S OF GENES DIRECTLY IN TISSUE. ULTIMATELY, THIS STUDY COULD RESULT IN IDENTIFYING NEW THERAPEUTIC TARGETS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022006F

NAME OF ORGANIZATION OR GOVERNMENT: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY GABRIELA FARIAS QUIPILDOR, PHD, ENTITLED: (A2022007F) SCRUTINIZING THE FUNCTION OF TREM2 AND TYROBP IN MICROGLIAL HOMEOSTASIS AND ACTIVATION. INVESTIGATOR'S SUMMARY: DURING NORMAL AGING AND ALZHEIMER'S DISEASE (AD), MICROGLIA, THE PRIMARY IMMUNE CELL IN THE BRAIN, HAVE SHOWN TO HAVE A DIFFERENT PHENOTYPE, MORPHOLOGY, AND FUNCTION UPON ACTIVATION. HOWEVER, THERE ARE STILL MANY UNKNOWNS IN RELATION TO THE MECHANISMS INVOLVED IN THE DIFFERENT ACTIVATION STATES OF MICROGLIA. THEREFORE, THIS STUDY PROPOSES TO DISSECT THE INVOLVEMENT OF KEY REGULATORS OF MICROGLIAL ACTIVATION IN NORMAL PHYSIOLOGY AND DISEASE AND TO PROVIDE NEW INSIGHTS ON THE ROLE OF MICROGLIA IN AD PATHOGENESIS WITH THE POTENTIAL TO UNEARTH NEW THERAPEUTIC TARGETS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022007F

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY BRANDON HOLMES, PHD, ENTITLED: (A2022008F) INTERROGATING AND TARGETING THE MICROGLIA CELL-SURFACE IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: THE MICROGLIA SURFACEOME SERVES AS A CRITICAL CELLULAR HUB THAT ENABLES NEUROPROTECTIVE, NEUROTOXIC, AND NEUROINFLAMMATORY SIGNALING IN THE DISEASED BRAIN. THE ABILITY TO PRECISELY TARGET AND

MANIPULATE DIVERSE MICROGLIA STATES THEREFORE HOLDS TREMENDOUS EXPERIMENTAL, DIAGNOSTIC, AND THERAPEUTIC POTENTIAL. THE PROPOSED PROJECT WILL USE INNOVATIVE TECHNOLOGIES TO COMPREHENSIVELY DEFINE THE SURFACEOME CHANGES OF ALZHEIMER'S DISEASE MICROGLIA AND WILL THEREFORE PROVIDE THE FIRST HUMAN CELL-SURFACE PROTEIN MAP IN THIS CELL TYPE AND DISEASE CONTEXT. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022008F

NAME OF ORGANIZATION OR GOVERNMENT: MASSACHUSETTS GENERAL HOSPITAL.

(H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY HOANG LE, PHD, ENTITLED: (A2022009F) UNDERSTANDING THE IMPACT OF TREM2 T96K MUTATION IN THE LIGAND-BINDING DOMAIN ON ALZHEIMER'S DISEASE PATHOGENESIS.

INVESTIGATOR'S SUMMARY: ALZHEIMER'S DISEASE (AD) IS THE LEADING CAUSE OF DEMENTIA AFFECTING MORE THAN 5.8 MILLION PEOPLE IN THE UNITED STATES; HOWEVER, WE STILL DO NOT HAVE EFFECTIVE THERAPIES TO PREVENT OR DELAY THIS DEBILITATING DISEASE. THIS PROPOSED STUDY AIMS TO UNDERSTAND THE IMPACT OF THE AD-ASSOCIATED MUTATION TREM2 T96K ON AD PATHOGENESIS USING A NOVEL TREM2 T96K KNOCK-IN MICE CROSSED WITH THE 5XFAD MOUSE MODEL OF AD AS WELL AS IN VITRO MICROGLIAL MODELS. THE INSIGHTS OBTAINED SHOULD BE USEFUL FOR AD DRUG DISCOVERY AND DEVELOPMENT TARGETING TREM2. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022009F

SCHEDULE I, PART II, LINE 1, COLUMN (H), CONTINUED:

NAME OF ORGANIZATION OR GOVERNMENT: WASHINGTON UNIVERSITY IN ST. LOUIS.

(H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY ALEXANDRA LITVINCHUK, PHD, ENTITLED: (A2022010F) THE ROLE OF ABCA1 IN REGULATION OF GLIAL LIPID METABOLISM IN APOE4-INDUCED TAUOPATHY AND ALZHEIMER'S

DISEASE. INVESTIGATOR'S SUMMARY: APOE4 IS THE STRONGEST GENETIC RISK FACTOR FOR DEVELOPING LATE-ONSET AD AND WAS SHOWN TO MARKEDLY ELEVATE TAU PATHOLOGY AND NEURODEGENERATION IN THE P301S/APOE4 TAUOPATHY MICE. A DISRUPTION OF LIPID METABOLISM IN GLIA IS LINKED TO NEUROINFLAMMATION AND NEURODEGENERATION IN SEVERAL STUDIES; WE RECENTLY DETECTED A SIGNIFICANT BUILDUP OF LIPIDS IN GLIA OF AGED P301S/APOE4 ANIMALS. IN THIS STUDY, WE WILL ASSESS THE ROLE OF ABCA1 LIPID TRANSPORTER IN MODULATION OF GLIAL LIPID METABOLISM IN THE P301S/APOE4 MICE, THUS, PROVIDING NOVEL THERAPEUTIC AVENUES FOR TREATING TAUOPATHY AND AD. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022010F

NAME OF ORGANIZATION OR GOVERNMENT: MASSACHUSETTS GENERAL HOSPITAL.

(H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY CHAO LIU, PHD, ENTITLED: (A2022011F) DEVELOPING A NOVEL OPTICAL IMAGING METHOD TO INVESTIGATE THE RELATIONSHIP OF WHITE MATTER ABNORMALITY AND VASCULATURE IN CEREBRAL AMYLOID ANGIOPATHY. INVESTIGATOR'S SUMMARY: WHITE MATTER HYPERINTENSITY (WMH) IS A TYPICAL NEUROIMAGE MARKER FOR THE DIAGNOSTICS OF CEREBRAL AMYLOID ANGIOPATHY (CAA), HOWEVER, ITS ROLE IN NEURODEGENERATION IS NOT FULLY UNDERSTOOD. THE PROPOSED PROJECT AIMS TO ESTABLISH A VERSATILE TOOL, AUTOMATIC SERIAL 3D OPTICAL COHERENCE SCANNER (AS-3DOCS), WHICH WILL UNRAVEL THE SOURCES FOR WMH IN CLINICAL MRI. THE HIGH-RESOLUTION AS-3DOCS DATA WILL ENABLE ACCURATE QUANTIFICATION OF MYELINATION AND HAVE THE POTENTIALS TO GUIDE MRI IN DEVELOPING MORE SENSITIVE BIOMARKERS FOR EARLY-STAGE CAA AND TARGETED THERAPY. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022011F

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF PENNSYLVANIA. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY COURTNEY MARSHALL, PHD, ENTITLED: (A2022012F) IN VIVO CX-4945 INDUCED CK2 INHIBITION TREATMENT OF ALZHEIMER'S DISEASE PATHOLOGY AND COGNITIVE SYMPTOMS. INVESTIGATOR'S SUMMARY: ALZHEIMER'S DISEASE (AD) GENERATES PATHOLOGICAL CHANGES IN TAU IN ADDITION TO COGNITIVE DECLINE, YET AD RESEARCH HAS YET TO IDENTIFY A DISEASE MODIFYING TREATMENT. MEMANTINE IS CURRENTLY USED TO TREAT COGNITIVE IMPAIRMENT IN AD PATIENTS. THIS PHARMACEUTICAL TOOL SELECTIVELY INHIBITS EXTRASYNAPTIC NR2B ACTIVITY. PRIOR STUDIES HAVE ESTABLISHED THAT CASEIN KINASE 2 (CK2) REGULATES SYNAPTIC/EXTRASYNAPTIC NR2B LOCATION AND SUGGEST A POTENTIAL THERAPEUTIC EFFECT OF CK2 INHIBITION. WE PROPOSE USING A CLINICALLY APPROVED CK2 INHIBITOR TO TEST THIS EFFECT IN AN AD MOUSE MODEL. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022012F

NAME OF ORGANIZATION OR GOVERNMENT: WASHINGTON UNIVERSITY, SCHOOL OF MEDICINE. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY NICOLE MCKAY, PHD, ENTITLED: (A2022013F) INVESTIGATING HOW WHITE MATTER INTEGRITY AND TAUOPATHY UNDERPIN COGNITIVE DECLINE IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE. INVESTIGATOR'S SUMMARY: IN THE YEARS LEADING UP TO ALZHEIMER DISEASE DIAGNOSIS, THE BRAIN BEGINS TO DETERIORATE. SCIENTISTS BELIEVE THAT ABNORMAL FORMS OF THE TAU PROTEIN MAY BE PARTIALLY RESPONSIBLE FOR THESE CHANGES. THIS EXCESSIVE AND ABNORMAL TAU CAN SPREAD ALONG WHITE MATTER PATHWAYS CAUSING A BREAKDOWN IN THE WAY OUR BRAIN FUNCTIONS. UNFORTUNATELY, THESE WHITE MATTER PATHWAYS ARE CRITICAL FOR OUR ABILITY TO PERFORM MEMORY AND ATTENTION-BASED TASKS. OUR PROJECT AIMS TO UNDERSTAND HOW LEVELS OF TAU

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

IMPACT THE INTEGRITY OF OUR BRAIN'S PATHWAYS AND LEADS TO A DECLINE IN COGNITION. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022013F

NAME OF ORGANIZATION OR GOVERNMENT: WASHINGTON UNIVERSITY, SCHOOL OF MEDICINE. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY PETER MILLAR, PHD, ENTITLED: (A2022014F) MODELING BRAIN-PREDICTED AGE IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE. INVESTIGATOR'S SUMMARY: RECENT MACHINE LEARNING TOOLS CAN MEASURE HOW "OLD" A PERSON'S BRAIN APPEARS, COMPARED TO OTHER HEALTHY BRAINS. IN SYMPTOMATIC ALZHEIMER'S DISEASE (AD), BRAINS APPEAR OLDER THAN EXPECTED, E.G., A 75-YEAR-OLD AD BRAIN MIGHT RESEMBLE A HEALTHY 84-YEAR-OLD'S BRAIN. WE WILL STUDY PEOPLE WITH A RARE GENETIC MUTATION FOR EARLY-ONSET ALZHEIMER'S DISEASE, TO TEST IF THEIR BRAINS BEGIN TO APPEAR OLDER AS THEY APPROACH THEIR EXPECTED DEMENTIA ONSET. THESE ANALYSES WILL EVALUATE WHETHER CLINICIANS CAN USE THIS BRAIN-AGE APPROACH TO IDENTIFY PEOPLE WITH VERY EARLY AD PATHOLOGY AND PREDICT AD RISK. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022014F

NAME OF ORGANIZATION OR GOVERNMENT: INDIANA UNIVERSITY. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY MIGUEL MOUTINHO, PHRMD, PHD, ENTITLED: (A2022017F) CAN THE NIACIN RECEPTOR HCAR2 MODULATE MICROGLIA TO LIMIT THE PROGRESSION OF ALZHEIMER'S DISEASE? INVESTIGATOR'S SUMMARY: ALZHEIMER'S DISEASE (AD) IS THE MOST COMMON FORM OF DEMENTIA FOR WHICH THERE IS NO EFFECTIVE TREATMENT. INCREASED DIETARY NIACIN INTAKE HAS BEEN ASSOCIATED WITH REDUCED RISK OF AD. NIACIN IS ABLE TO CROSS THE BLOOD BRAIN BARRIER AND ACTIVATE THE NIACIN RECEPTOR HCAR2. THIS RECEPTOR INDUCES BENEFICIAL EFFECTS IN OTHER DISEASE MODELS BY

MODULATION OF BRAIN-RESIDENT IMMUNE CELLS (MICROGLIA). THUS, WE HYPOTHESIZED THAT HCAR2 REGULATES A PROTECTIVE RESPONSE OF MICROGLIA IN AD, WHICH CAN BE PHARMACOLOGICALLY STIMULATED WITH A CLINICAL FORMULATION OF NIACIN. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022017F

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, IRVINE. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY TATSUKI NAKAGAWA, PHD, ENTITLED: (A2022018F) UNDERSTANDING NEURAL CIRCUIT MECHANISMS FOR ASSOCIATIVE MEMORY IMPAIRMENT IN APP-KI MICE. INVESTIGATOR'S SUMMARY: ALZHEIMER'S DISEASE (AD) AFFECTS 6 MILLION PEOPLE IN THE US, BUT NO CURE EXISTS. ALTHOUGH MOLECULAR AND CELLULAR MECHANISMS OF AD BECOME CLEARER, IT IS STILL UNCLEAR WHAT TYPE OF NEURONAL BRAIN ACTIVITY IS LOST IN AD. IF WE UNDERSTAND THIS, WE MAY BE ABLE TO DEVELOP A THERAPY TO PREVENT MEMORY LOSS IN AD PATIENTS. IN THIS PROJECT, WE WILL IDENTIFY THE UNDERLYING CAUSES OF BRAIN CELL DYSFUNCTION, AND TEST IF ARTIFICIAL REACTIVATION OF BRAIN CELL ACTIVITY RESTORES ASSOCIATIVE MEMORY IN AD MICE. THESE STUDIES ARE EXPECTED TO LEAD TO A NEW METHOD FOR RESTORING MEMORY IN AD PATIENTS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022018F

NAME OF ORGANIZATION OR GOVERNMENT: MEMORIAL SLOAN KETTERING CANCER CENTER. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY SAHIL SHARMA, PHD, ENTITLED: (A2022020F) DEVELOPMENT OF EPICHAPEROME IMAGING PROBES FOR ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: MATCHING THE RIGHT PATIENT TO THE RIGHT MEDICINE IS A GOAL OF THE FUTURE IN MEDICINE. IN THIS PROPOSAL I AIM TO BUILD TOOLS THAT CAN BE USED TO IMAGE AND SELECT THOSE ALZHEIMER DISEASE (AD) PATIENTS THAT ARE MOST

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

LIKELY TO BENEFIT FROM A NEW EXPERIMENTAL MEDICINE WITH DISEASE-MODIFYING POTENTIAL. THIS MEDICINE, PU-AD, DEVELOPED BY MY LABORATORY, WORKS BY REBALANCING CELLULAR NETWORKS AND BRAIN CIRCUITS. IN MOUSE MODELS, IT REVERTED COGNITIVE DYSFUNCTION AND IS CURRENTLY IN CLINICAL EVALUATION IN AD AND RELATED DISORDERS. TOOLS I DEVELOP HERE THEREFORE HAVE IMMEDIATE TRANSLATIONAL POTENTIAL. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022020F

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, IRVINE.

(H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY LORENA SORDO, PHD, ENTITLED: (A2022021F) THE ROLE OF LEPTIN ON ALZHEIMER'S DISEASE PATHOGENESIS IN DOWN SYNDROME. INVESTIGATOR'S SUMMARY: PEOPLE WITH DOWN SYNDROME (DS) HAVE A HIGH RISK OF DEVELOPING ALZHEIMER'S DISEASE (AD). MID-LIFE OBESITY AND LATE-LIFE WEIGHT LOSS INCREASE THE RISK OF AD. SINCE PEOPLE WITH DS TEND TO BE OVERWEIGHT, THEY MAY HAVE AN EVEN GREATER RISK OF DEVELOPING AD. WE WILL MEASURE LEVELS OF LEPTIN (A HORMONE THAT REGULATES APPETITE AND FOOD INTAKE THAT IS RELEASED IN RESPONSE TO THE AMOUNT OF FAT TISSUE IN THE BODY) IN PEOPLE WITH DS, WITH AND WITHOUT AD, AND WILL ASSESS THE ASSOCIATION BETWEEN LEPTIN LEVELS AND ABNORMAL DEPOSITION OF AMYLOID-BETA (AB) AND TAU, MAJOR HALLMARKS OF AD, IN THE BRAIN. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022021F

SCHEDULE I, PART II, LINE 1, COLUMN (H), CONTINUED:

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, IRVINE.

(H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY LORENA SORDO, PHD, ENTITLED: (A2022021F) THE ROLE OF LEPTIN ON ALZHEIMER'S DISEASE

PATHOGENESIS IN DOWN SYNDROME. INVESTIGATOR'S SUMMARY: PEOPLE WITH DOWN SYNDROME (DS) HAVE A HIGH RISK OF DEVELOPING ALZHEIMER'S DISEASE (AD). MID-LIFE OBESITY AND LATE-LIFE WEIGHT LOSS INCREASE THE RISK OF AD. SINCE PEOPLE WITH DS TEND TO BE OVERWEIGHT, THEY MAY HAVE AN EVEN GREATER RISK OF DEVELOPING AD. WE WILL MEASURE LEVELS OF LEPTIN (A HORMONE THAT REGULATES APPETITE AND FOOD INTAKE THAT IS RELEASED IN RESPONSE TO THE AMOUNT OF FAT TISSUE IN THE BODY) IN PEOPLE WITH DS, WITH AND WITHOUT AD, AND WILL ASSESS THE ASSOCIATION BETWEEN LEPTIN LEVELS AND ABNORMAL DEPOSITION OF AMYLOID-BETA (AB) AND TAU, MAJOR HALLMARKS OF AD, IN THE BRAIN. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022021F

NAME OF ORGANIZATION OR GOVERNMENT: NORTHWESTERN UNIVERSITY - EVANSTON CAMPUS. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY XIAOJING SUI, PHD, ENTITLED: (A2022023F) COMPREHENSIVE IDENTIFICATION OF THE METASTABLE SUBPROTEOME DYSREGULATED IN AGING AND ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: ALZHEIMER'S DISEASE IS A LEADING CAUSE OF DEMENTIA AND AGING IS A STRONG RISK FACTOR. THIS STUDY WILL IDENTIFY THE PROTEINS THAT GO AWRY IN AGING AND ALZHEIMER'S DISEASE, USING AN ADVANCED TECHNOLOGY THAT CAN SCREEN THOUSANDS OF PROTEINS AT A TIME. THE ULTIMATE GOAL OF THE PROJECT IS TO IDENTIFY NEW PROTEIN BIOMARKERS OF AGING AND ALZHEIMER'S DISEASE AND PROVIDE NEW TREATMENT TARGETS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022023F

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF COLORADO, BOULDER. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY MEAGHAN VAN ALSTYNE, PHD, ENTITLED: (A2022025F) ROLES AND APPLICATIONS OF SRRM2 IN

THE ASSEMBLY AND DISASSEMBLY OF TAU AGGREGATES. INVESTIGATOR'S SUMMARY: A KEY HALLMARK OF ALZHEIMER'S DISEASE IS TAU AGGREGATION WHICH IS BELIEVED TO PLAY A ROLE IN NEURONAL DEGENERATION. WITH NO CURATIVE TREATMENTS AVAILABLE, IT IS CRITICAL TO BETTER UNDERSTAND DISEASE MECHANISMS TO DEVELOP EFFECTIVE TREATMENTS. WE RECENTLY IDENTIFIED TAU AGGREGATES CONTAIN A PROTEIN RELOCATED FROM NUCLEAR SPECKLES CALLED SRRM2. THIS RESEARCH PLAN WILL INVESTIGATE THE INTERACTION OF SRRM2 WITH TAU AND EVALUATE EFFECTS IN DISEASE CONTEXTS. FURTHER, I WILL REPURPOSE THIS KNOWLEDGE TO IDENTIFY FACTORS THAT CAN MITIGATE TAU AGGREGATION WITH BROAD THERAPEUTIC POTENTIAL. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022025F

NAME OF ORGANIZATION OR GOVERNMENT: BOSTON CHILDREN'S HOSPITAL. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY HUIXIN XU, PHD, ENTITLED: (A2022026F) HARNESSING THE CHOROID PLEXUS BARRIER AS A NEUROIMMUNE BARRIER IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: MY ULTIMATE GOAL IS TO ENABLE TREATMENTS FOR ALZHEIMER'S DISEASE (AD) THAT CURB BRAIN INFLAMMATION AT THE BARRIERS SEPARATING THE BRAIN FROM THE REST OF THE BODY, FOCUSING ON A TISSUE CALLED THE CHOROID PLEXUS. I WILL APPLY NEWLY DEVELOPED IMAGING TOOLS THAT ENABLE EXPLORATION OF BLOOD-BORNE IMMUNE CELLS ENTERING THE CHOROID PLEXUS IN AD MODELS AND TEST FOR BARRIER BREAKDOWN AND BLOOD VESSEL LEAKAGE. THE INNOVATION FROM MY RESEARCH WILL LAUNCH MY INDEPENDENT CAREER TO CONTINUE THIS INQUIRY, AND BENEFIT RESEARCHERS OF OTHER INFLAMMATORY BRAIN DISEASES. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022026F

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, SAN

FRANCISCO. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY ANDREW YANG, PHD, ENTITLED: (A2022027F) UNDERSTANDING HOW HUMAN BRAIN VASCULAR CELLS MEDIATE GENETIC RISK FOR ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: THE RISK FOR LATE-ONSET ALZHEIMER'S DISEASE (AD) INVOLVES DOZENS OF RISK VARIANTS OPERATING IN DIVERSE CELL TYPES. ELUCIDATING THE FUNCTIONS OF THESE RISK VARIANTS IS CRITICAL TO INFORM TREATMENTS BUT IS CHALLENGING, IN PART BECAUSE THE VASCULAR HALF OF HUMAN BRAIN CELL TYPES HAS ELUDED POWERFUL SINGLE-CELL ASSAYS. WE WILL USE OUR NEW VASCULAR-CAPTURING VINE-SEQ TECHNIQUE TO COMPREHENSIVELY DETERMINE THE CELLS AND GENES DYSREGULATED AD VARIANTS. WE WILL THEN USE OUR BIOORTHOGONAL LABELING APPROACHES TO DETERMINE HOW AD VARIANTS DYSREGULATE BRAIN VASCULAR TRANSPORT FUNCTIONS TO PROMOTE AD RISK. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022027F

NAME OF ORGANIZATION OR GOVERNMENT: MASSACHUSETTS GENERAL HOSPITAL. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY QIUCHEN ZHAO, PHD, ENTITLED: (A2022028F) SLEEP RESTORATION, MICROGLIA, AND ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: ALZHEIMER'S DISEASE (AD) IS ASSOCIATED WITH PROFOUND SLEEP DISTURBANCES THAT CONTRIBUTE TO THE DISEASE PROGRESSION, PARTICULARLY AT EARLY STAGES OF DISEASE. USING STATE-OF-THE-ART LABORATORY TECHNOLOGIES, WE WILL DEVELOP EFFECTIVE STRATEGIES TO RESTORE SLEEP AND ASSESS ITS EFFECT ON MEMORY FUNCTION AND PATHOLOGICAL PROGRESSION OF AD. ADDITIONALLY, WE WILL INVESTIGATE THE RESPONSES OF MICROGLIA TO SLEEP RESCUE USING A MULTI-PRONGED DESIGN ASSESSING THE MORPHOLOGICAL, FUNCTIONAL, AND GENETIC ASPECTS. THIS STUDY WILL PROVIDE THE BASIS FOR NOVEL THERAPEUTIC STRATEGIES FOR AD. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

WWW.BRIGHTFOCUS.ORG/GRANT/A2022028F

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, IRVINE. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY KEVIN BEIER, PHD, ENTITLED: (A2022031S) IDENTIFYING CIRCUIT DRIVERS OF EARLY AD PATHOGENESIS. INVESTIGATOR'S SUMMARY: WE AIM TO IDENTIFY BRAIN REGIONS AND CELL TYPES TO TARGET IN ORDER TO SLOW OR PREVENT THE DEVELOPMENT OF ALZHEIMER'S DISEASE BEFORE SYMPTOM ONSET. WE HAVE IDENTIFIED A CHANGE IN THE RETROSPLENIAL CORTEX THAT OCCURS EARLY IN AD PATHOGENESIS, AND NEXT PLAN TO VERIFY THESE RESULTS IN A DIFFERENT RODENT MODEL AND EXPLORE THE FUNCTIONAL CONSEQUENCES OF CHEMOGENETICALLY INHIBITING THESE CELLS. OUR GOAL IS TO USE THESE DATA TO IDENTIFY BIOMARKERS OF EARLY AD, AND POTENTIALLY CIRCUIT TARGETS FOR FUTURE AD THERAPEUTICS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022031S

NAME OF ORGANIZATION OR GOVERNMENT: WASHINGTON UNIVERSITY IN ST. LOUIS. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY THOMAS BRETT, PHD, ENTITLED: (A2022032S) STRUCTURAL BASIS AND MODULATION OF TREM2/OABETA42 SIGNALING. INVESTIGATOR'S SUMMARY: CURRENT STUDIES INDICATE THAT TREM2, A RECEPTOR MOLECULE FOUND IN THE BRAIN, PLAYS AN IMPORTANT ROLE IN NEURONAL HEALTH. IT HAS EMERGED AS A CRITICAL POTENTIAL DRUG TARGET TO DEVELOP TREATMENTS FOR ALZHEIMER'S DISEASE. TREM2 ENGAGES AND RESPONDS TO OTHER MOLECULES IN THE BRAIN. OUR PROJECT WILL DETERMINE HOW TREM2 ENGAGES AMYLOID BETA AND IDENTIFY HOW OTHER POTENTIAL DRUG MOLECULES MODULATE THIS INTERACTION. UNDERSTANDING AND MODULATING THIS INTERACTION WILL ENABLE THE DEVELOPMENT OF THERAPEUTICS FOR ALZHEIMER'S DISEASE THAT TARGET TREM2. FOR MORE INFORMATION, VISIT

THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022032S

NAME OF ORGANIZATION OR GOVERNMENT: NEW YORK UNIVERSITY SCHOOL OF MEDICINE. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY OMONIGHO BUBU, MD, PHD, ENTITLED: (A2022033S) MECHANISMS OF RACIAL DIFFERENCES IN THE RELATIONSHIP BETWEEN OBSTRUCTIVE SLEEP APNEA AND IN VIVO TAU DEPOSITION IN THE CONTEXT OF AMYLOID BURDEN. INVESTIGATOR'S SUMMARY: THIS PROPOSAL WILL EXAMINE WHETHER BLACKS WITH OBSTRUCTIVE SLEEP APNEA (OSA) EXHIBIT HIGHER TAU-PET AND GREATER NEURODEGENERATION FOR A GIVEN LEVEL OF AMYLOID BURDEN COMPARED TO WHITES. THE PROPOSAL WILL ALSO EXAMINE THE ROLE OF SOCIOECONOMIC STATUS, CUMULATIVE STRESS EXPOSURE AND VASCULAR RISK AS MEDIATORS OF ANY OBSERVED RACE-SPECIFIC EFFECTS IN MICRO-LEVEL SLEEP PHYSIOLOGY AND INFLAMMATION ON TAU-PET AND NEURODEGENERATION. LONG-TERM GOAL IS TO INCREASE SLEEP QUALITY, AND CONTROL VASCULAR RISK USING NON-INVASIVE AMBULATORY METHODS AS NOVEL THERAPEUTIC TARGETS FOR AD PREVENTION IN BLACKS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022033S

SCHEDULE I, PART II, LINE 1, COLUMN (H), CONTINUED:

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF KANSAS CENTER FOR RESEARCH, INC. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY LAN GUO, PHD, ENTITLED: (A2022036S) MITOCHONDRIAL DNA OXIDATIVE DAMAGES AND MICROGLIAL ACTIVATION IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: MICROGLIA-MEDIATED NEUROINFLAMMATION CONTRIBUTES TO THE PATHOGENESIS OF ALZHEIMER'S DISEASE (AD), THE MECHANISMS OF AD-RELATED MICROGLIAL ACTIVATION ARE NOT FULLY UNDERSTOOD. IN VIEW OF OUR PRELIMINARY DATA, WE AIM TO ESTABLISH A CAUSE-EFFECT RELATIONSHIP OF OXIDATIVE DAMAGE AND THE SUBSEQUENT LEAKAGE OF MITOCHONDRIAL DNA

(MTDNA) WITH INFLAMMATORY MICROGLIAL RESPONSE VIA ACTIVATION OF CYTOSOLIC DNA-SENSING SYSTEM IN AD-RELATED CONDITIONS. POSITIVE RESULTS WILL REVEAL A NOVEL MITOCHONDRIAL PATHWAY OF NEUROINFLAMMATION IN AD AND HOLD PROMISE TO DEVELOP INNOVATIVE THERAPY FOR AD TREATMENT. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022036S

NAME OF ORGANIZATION OR GOVERNMENT: BRIGHAM YOUNG UNIVERSITY. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY DAVID HANSEN, PHD, ENTITLED: (A2022037S) VALIDATING PILRA, AN IMMUNE CHECKPOINT AND AD-ASSOCIATED GENE, AS A THERAPEUTIC TARGET FOR ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: THE EMERGING LANDSCAPE OF ALZHEIMER'S THERAPEUTICS INCLUDES DRUGS INTENDED TO PROMOTE THE PROTECTIVE FUNCTIONS OF MICROGLIA, THE BRAIN'S IMMUNE CELLS. THE MAJORITY OF THESE THERAPEUTICS SEEK TO DIRECTLY ACTIVATE TREM2, A KEY RECEPTOR FOR MICROGLIAL ACTIVATION AND HEALTHY CNS TISSUE MAINTENANCE. IN THIS PROPOSAL, WE EXPLORE THE THERAPEUTIC POTENTIAL OF BLOCKING MICROGLIAL CHECKPOINT PROTEINS AS AN INDIRECT WAY OF ENABLING MORE ROBUST TREM2 FUNCTION AT SITES OF MICROGLIAL ACTIVATION, WHICH MAY BE SAFER THAN CHRONIC ACTIVATION OF ALL MICROGLIA (AND POSSIBLY OSTEOCLASTS/MACROPHAGES). FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022037S

NAME OF ORGANIZATION OR GOVERNMENT: WASHINGTON UNIVERSITY IN ST. LOUIS. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY KEITH HENGEN, PHD, ENTITLED: (A2022038S) ABERRANT NEURAL DYNAMICS IN EARLY LIFE WARN OF FUTURE DISEASE. INVESTIGATOR'S SUMMARY: SYMPTOMS OF ALZHEIMER'S DISEASE (AD) ONLY EMERGE AFTER TOXIC PROTEINS HAVE TAKEN A SIGNIFICANT

TOLL ON THE CIRCUITRY OF THE BRAIN. EFFECTIVE INTERVENTION IN AD IS BELIEVED TO BE STYMIED BY THE INABILITY TO DETECT THE DISEASE UNTIL IT IS TOO LATE TO MAKE A DIFFERENCE. HERE WE DEMONSTRATE A NOVEL METHOD TO PREDICT AD BEFORE SYMPTOMS APPEAR BY MEASURING BRAIN ACTIVITY IN BOTH HUMANS AND MOUSE MODELS OF DISEASE. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022038S

NAME OF ORGANIZATION OR GOVERNMENT: COLORADO STATE UNIVERSITY. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY SEONIL KIM, PHD, ENTITLED: (A2022039S) CO-ACTIVATION OF SELECTIVE NICOTINIC ACETYLCHOLINE RECEPTORS IMPROVES HIPPOCAMPAL ACTIVITY IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: CHANGES IN BRAIN RHYTHMS (SYNCHRONIZED ACTIVITY BETWEEN NERVE CELLS) IN THE HIPPOCAMPUS HAVE BEEN LINKED TO MEMORY IMPAIRMENTS ASSOCIATED WITH ALZHEIMER'S DISEASE (AD). IMPORTANTLY, THESE ALTERATIONS IN BRAIN RHYTHM CAN BE DETECTED BEFORE AD PATIENTS DISPLAY SIGNS OF MEMORY LOSS. AS A RESULT, THESE CHANGES COULD BE A PRECURSOR TO AD. KNOWING THIS, WE PLAN TO INVESTIGATE WHETHER ABERRANT BRAIN ACTIVITY AND MEMORY LOSS CAN BE PREVENTED OR PERHAPS REVERSED IN THE EARLY STAGES OF AD. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022039S

NAME OF ORGANIZATION OR GOVERNMENT: RICE UNIVERSITY. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY STEPHANIE LEAL, PHD, ENTITLED: (A2022040S) PRECISE NEUROBIOLOGICAL PROFILING OF THE LOCUS COERULEUS AND MEDIAL TEMPORAL LOBE FOR THE EARLY DETECTION OF ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: THE CAUSE OF ALZHEIMER'S DISEASE (AD) IS UNKNOWN. WE HAVE BEGUN TO UNDERSTAND WHICH BRAIN REGIONS ARE

IMPACTED DECADES BEFORE CLINICAL SYMPTOM ONSET. HOWEVER, CURRENT RESEARCH HAS NOT UTILIZED TASKS SENSITIVE ENOUGH TO DETECT THE EARLIEST CHANGES IN MEMORY THAT COULD PREDICT AD. IN THIS PROPOSAL, WE WILL USE SENSITIVE MEMORY TASKS THAT TARGET THE EARLIEST BRAIN REGIONS IMPACTED IN AD. PAIRED WITH STATE-OF-THE-ART BRAIN IMAGING TECHNIQUES, WE WILL IDENTIFY EARLY COGNITIVE AND BRAIN CHANGES IN AD BEFORE CLINICAL SYMPTOMS MANIFEST, WHICH COULD AID IN EARLIER INTERVENTIONS TO PREVENT OR SLOW AD. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022040S

NAME OF ORGANIZATION OR GOVERNMENT: SEATTLE INSTITUTE FOR BIOMEDICAL AND CLINICAL RESEARCH. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY NICOLE LIACHKO, PHD, ENTITLED: (A2022041S) MECHANISMS UNDERLYING SELECTIVE NEURON VULNERABILITY TO CO-MORBID TAU AND TDP-43 IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: OVER HALF OF ALZHEIMER'S DISEASE (AD) PATIENTS EXHIBIT NEURONAL AGGREGATES OF THE PROTEIN TDP-43 AS A CO-PATHOLOGY IN ADDITION TO AMYLOID PLAQUES AND NEUROFIBRILLARY TANGLES. THE PRESENCE OF TDP-43 PATHOLOGY CORRELATES WITH WORSE BRAIN ATROPHY, MORE SEVERE COGNITIVE IMPAIRMENT, AND MORE RAPID COGNITIVE DECLINE. THEREFORE, UNDERSTANDING ITS CONTRIBUTION TO NEURODEGENERATIVE DISEASE PROCESSES IS A CRITICAL NEED IN THE FIELD. THIS WORK WILL CHARACTERIZE MECHANISMS UNDERLYING NEURON VULNERABILITIES TO TDP-43 IN AD, AND IDENTIFY NEW THERAPEUTIC TARGETS AND STRATEGIES. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022041S

NAME OF ORGANIZATION OR GOVERNMENT: HEBREW REHABILITATION CENTER. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY BRAD MANOR, PHD,

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

ENTITLED: (A2022042S) MULTIFOCAL TRANSCRANIAL CURRENT STIMULATION FOR COGNITIVE AND MOTOR DYSFUNCTION IN OLDER ADULTS LIVING WITH DEMENTIA. INVESTIGATOR'S SUMMARY: MEMORY LOSS AND EXECUTIVE DYSFUNCTION ARE TWO HALLMARKS OF ALZHEIMER'S DISEASE (AD) THAT MAP ONTO DIFFERENT, SPATIALLY-DISTINCT BRAIN NETWORKS. THIS STUDY WILL COMBINE AND SIMULTANEOUSLY DELIVER TWO DIFFERENT TYPES OF TRANSCRANIAL CURRENT STIMULATION (TCS) TO PROVIDE MULTI-SYMPTOM RELIEF TO OLDER ADULTS WITH MILD AD. BY STIMULATING MORE THAN ONE BRAIN NETWORK AT THE SAME, AND STUDYING THE RELATIONSHIP BETWEEN THE ELECTRICAL FIELDS CREATED BY TCS AND INDIVIDUAL THERAPEUTIC BENEFIT, THIS TRIAL WILL HELP TO DEVELOP TCS INTERVENTIONS WITH MAXIMAL IMPACT ON DAILY LIFE FUNCTION FOR THIS POPULATION. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022042S

NAME OF ORGANIZATION OR GOVERNMENT: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY ALEJANDRO MARTIN TRUJILLO, PHD, ENTITLED: (A2022043S) COMPREHENSIVE STUDY OF TANDEM REPEAT VARIATION AS A CAUSE OF ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: TANDEM REPEATS (TRS) ARE STRETCHES OF DNA COMPOSED OF TWO OR MORE CONTIGUOUS COPIES OF A SEQUENCE ARRANGED IN HEAD-TO-TAIL PATTERN (EG. CAG-CAG-CAG), THAT, IN SOME CASES, GAIN ADDITIONAL COPIES AND BECOME EXPANDED. DUE TO TECHNICAL LIMITATIONS, TRS ARE USUALLY UNTRACEABLE USING STANDARD PROCEDURES, BEING LARGELY IGNORED IN STANDARD GENETICS STUDIES. HOWEVER, NEWLY BIOINFORMATICS TOOLS ARE NOW ABLE TO SCREEN THE WHOLE GENOME FOR REPEATS EXPANSIONS AND TR VARIANTS. USING THESE TOOLS, WE WILL SCREEN THE GENOMES OF THOUSANDS OF AD CASES AND CONTROLS FOR TR VARIANTS THAT ARE ASSOCIATED WITH AD RISK. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE:

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

WWW.BRIGHTFOCUS.ORG/GRANT/A2022043S

NAME OF ORGANIZATION OR GOVERNMENT: GEORGIA TECH RESEARCH CORPORATION.

(H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY ANNABELLE SINGER, PHD, ENTITLED: (A2022048S) DRIVING BRAIN RHYTHMS TO REDUCE CHRONIC STRESS-INDUCED SYNAPTIC LOSS AND ALZHEIMER'S DISEASE RISK.

INVESTIGATOR'S SUMMARY: CHRONIC STRESS LEADS TO A 2-FOLD OR MORE INCREASED RISK FOR ALZHEIMER'S DISEASE (AD). WE PROPOSE TO USE NOVEL NON-INVASIVE BRAIN STIMULATION TO PREVENT STRESS-INDUCED PATHOLOGY INCLUDING MEMORY IMPAIRMENT, ANXIETY, THE LOSS OF CONNECTIONS BETWEEN NEURONS, AND OVERACTIVE IMMUNE RESPONSES. BECAUSE THIS STIMULATION IS NON-INVASIVE, IT WILL READILY TRANSLATE TO HUMANS TO POTENTIALLY REDUCE THE RISK OF DEVELOPING AD. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022048S

SCHEDULE I, PART II, LINE 1, COLUMN (H), CONTINUED:

NAME OF ORGANIZATION OR GOVERNMENT: TRUSTEES OF BOSTON UNIVERSITY. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY JULIA TCW, PHD, ENTITLED: (A2022049S) MODULATION OF ASTROCYTE MATRISOME SIGNALS REPROGRAM MICROGLIA THAT CAN BE TARGETED TO MITIGATE ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: THE STRONGEST GENETIC RISK FACTOR FOR LATE-ONSET ALZHEIMER'S DISEASE (AD) IS APOLIPOPROTEIN E E4 (APOE4). WITH THE GOAL OF EXPLAINING HOW APOE4 INFLUENCES RISK OF AD, WE WILL SUPPRESS AN APOE4 RISK SIGNAL AND UNDERSTAND THE MECHANISM OF CELLULAR REPROGRAMMING TO PREVENT AD IN OUR "BRAIN-IN-A-DISH" MODEL. WE HOPE THIS APPROACH CAN IDENTIFY NEW DRUG TARGETS OF APOE4 AND OPEN DOORS TO NOVEL THERAPEUTIC MODALITIES. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022049S

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF MICHIGAN. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY PETER TESSIER, PHD, ENTITLED: (A2022050S) CD98HC BRAIN SHUTTLE FOR EFFICIENT DELIVERY OF A NEUROPROTECTIVE TRKB AGONIST ANTIBODY IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: MONOCLONAL ANTIBODIES ARE REVOLUTIONIZING THE TREATMENT OF HUMAN DISEASES. HOWEVER, AN ACHILLES HEEL OF THESE LARGE MOLECULES IS THAT THEY POORLY PENETRATE THE BLOOD-BRAIN BARRIER, WHICH GREATLY LIMITS THEIR USE FOR TREATING ALZHEIMER'S DISEASE (AD). WE HAVE DEVELOPED A NOVEL APPROACH FOR DELIVERING ANTIBODIES TO THE BRAIN BY ATTACHING A SMALL PROTEIN TO THEM TO MEDIATE ANTIBODY ENTRY INTO THE BRAIN. IN THIS PROPOSAL, WE SEEK TO EVALUATE THE THERAPEUTIC EFFICACY OF DELIVERING AN ANTIBODY TO THE BRAIN THAT STIMULATES NEUROPROTECTIVE SIGNALING AND PREVENTS NEURONAL DEATH IN ANIMAL MODELS OF AD. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022050S

NAME OF ORGANIZATION OR GOVERNMENT: MASSACHUSETTS GENERAL HOSPITAL. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY SUSANNE VAN VELUW, PHD, ENTITLED: (A2022051S) TARGETING APOE AS A TREATMENT STRATEGY IN CEREBRAL AMYLOID ANGIOPATHY. INVESTIGATOR'S SUMMARY: CEREBRAL AMYLOID ANGIOPATHY (CAA) IS A DISEASE IN WHICH AMYLOID BUILDS UP IN THE BLOOD VESSELS OF THE BRAIN, WHICH CAN CAUSE BLEEDING AND DEMENTIA. THERE ARE CURRENTLY NO TREATMENTS FOR CAA. REMOVING AMYLOID WITH IMMUNOTHERAPY IS NOT RECOMMENDED DUE TO A HIGH BLEEDING RISK. THIS RISK IS FURTHER INCREASED IN CAA PATIENTS WITH AN APOE4 GENOTYPE. A RECENT STUDY SUGGESTED THAT REMOVING APOE, WHICH IS CO-DEPOSITED WITH AMYLOID, COULD BE A SAFE ALTERNATIVE. HOWEVER, IT REMAINS UNCLEAR

WHETHER REMOVING APOE IMPROVES CAA AND PROTECTS BLOOD VESSELS. THIS PROJECT WILL TEST THIS IN A MOUSE MODEL. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022051S

NAME OF ORGANIZATION OR GOVERNMENT: PRESIDENT & FELLOWS OF HARVARD COLLEGE. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY LIMOR COHEN, PHD, ENTITLED: (A2022052F) SPATIAL TRANSCRIPTOMICS OF ISOFORM EXPRESSION IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: THE BRAIN IS A COMPLEX AND HIGHLY ORGANIZED TISSUE THAT CONSISTS OF DISTINCT FUNCTIONAL REGIONS. EACH BRAIN REGION CONSISTS OF MANY CELL TYPES THAT ARE SPATIALLY ORGANIZED IN A UNIQUE PATTERN THAT UNDERLIES BRAIN FUNCTION. HERE, I PROPOSE TO DEVELOP A NEW METHOD TO MAP THESE CELL TYPES IN HEALTHY AND ALZHEIMER'S DISEASE (AD) BRAINS. I WILL ALSO USE THIS METHOD TO UNDERSTAND WHICH CELL TYPES AND CELLULAR ENVIRONMENTS ARE VULNERABLE TO TAU PROPAGATION IN AD. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2022052F

NAME OF ORGANIZATION OR GOVERNMENT: MAYO CLINIC, JACKSONVILLE. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH ENTITLED: (CA2021010) MOLECULAR NEURODEGENERATION JOURNAL. INVESTIGATOR'S SUMMARY: THE AIM OF MOLECULAR NEURODEGENERATION (MN) JOURNAL (HTTPS://MOLECULARNEURODEGENERATION.BIOMEDCENTRAL.COM/) IS TO SERVE THE SCIENTIFIC COMMUNITY BY PUBLISHING HIGH-IMPACT, HIGH-QUALITY, AND FRONT-LINE RESEARCH DISCOVERIES IN DIVERSE AREAS OF NEURODEGENERATIVE DISEASES INCLUDING ALZHEIMER'S DISEASE AND EYE-RELATED DEGENERATIVE CONDITIONS. MN IS THE OFFICIAL JOURNAL OF THE BRIGHTFOCUS FOUNDATION. THE OPEN ACCESS PUBLISHING MODEL PROVIDES FREE ARTICLES TO THE GENERAL PUBLIC, AS WELL AS SCIENTISTS, CLINICIANS, AND OTHER HEALTHCARE

PRACTITIONERS. THE JOURNAL HAS SEEN FURTHER GROWTH IN RECENT YEARS IN PARTICULAR IN THE AREA OF SCIENTIFIC IMPACT AND REPUTATION. SOME OF THESE ARE REFLECTED IN THE FOLLOWING METRICS: 1) THE USAGE OF THE JOURNAL: 1,034,660 DOWNLOADS (AS OF APRIL 22, 2022); 2) THE CITATIONS TRACKED BY WEB OF SCIENCE: 4290 IN 2018, 5217 IN 2019, AND 6488 IN 2020.; 3) THE IMPACT FACTOR: 14.195 (AS OF APRIL 22, 2022); 4) THE RANKING BY JCR: MOLECULAR NEURODEGENERATION HAS BEEN RANKED AS THE NO. 1 OPEN-ACCESS JOURNAL IN THE NEUROSCIENCE CATEGORY FOR 10 YEARS IN A ROW (2013 PRESENT), AND RANKED NO. 15 AMONG ALL 272 NEUROSCIENCE JOURNALS (WITHIN THE TOP 5.5%).

NAME OF ORGANIZATION OR GOVERNMENT: INTERNATIONAL SOCIETY FOR MOLECULAR NEURODEGENERATION. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH ENTITLED: (CA2021011) INTERNATIONAL SOCIETY FOR MOLECULAR NEURODEGENERATION. INVESTIGATOR'S SUMMARY: THIS AWARD IS FOR THE CREATION, AND GROWTH OF, THE "INTERNATIONAL SOCIETY FOR MOLECULAR NEURODEGENERATION (ISMND) AND SUPPORT OF ITS BI-ANNUAL MEETINGS AND EDUCATIONAL AND SCIENTIFIC PURPOSES. IN ACCORDANCE WITH SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE AND THE PROVISIONS OF THE FLORIDA NOT FOR PROFIT CORPORATION ACT. THE INTERNATIONAL SOCIETY FOR MOLECULAR NEURODEGENERATION (ISMND) SHALL BE ORGANIZED AND OPERATED PRIMARILY AND EXCLUSIVELY FOR EDUCATIONAL AND SCIENTIFIC PURPOSES. THE INTERNATIONAL SOCIETY FOR MOLECULAR NEURODEGENERATION'S MISSION IS TO SERVE AS AN ACCELERATOR FOR THE CONTINUOUS IMPROVEMENT OF BRAIN AND EYE HEALTH AND WELL-BEING BY CREATING A MULTIDISCIPLINARY GLOBAL PLATFORM FOR SCIENTISTS, PHYSICIANS, AND THE PUBLIC FROM DIFFERENT FACETS AND SCIENTIFIC DISCIPLINES TO MORE READILY CONNECT, SHARE AND COMMUNICATE SCIENTIFIC DISCOVERIES, AND DEVELOP CURES FOR NEURODEGENERATIVE

DISEASES, IN THE HOPES OF A WORLD FREE OF BRAIN AND EYE DISEASES.

SCHEDULE I, PART II, LINE 1, COLUMN (H), CONTINUED:

NAME OF ORGANIZATION OR GOVERNMENT: MASSACHUSETTS GENERAL HOSPITAL.

(H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY BECKY CARLYLE, PHD, ENTITLED: (A2019182S) INTEGRATED MULTIMODAL *OMICS OF NEUROPEPTIDE PROTEOFORMS TO ASSESS THEIR SUITABILITY AS BIOMARKERS AND THERAPEUTIC TARGETS FOR ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: EMERGENCY RELIEF SUPPLEMENT DUE TO COVID-19. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2019128S

NAME OF ORGANIZATION OR GOVERNMENT: JOHNS HOPKINS UNIVERSITY. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY PETER ABADIR, PHD, ENTITLED: (A2019634S) CHARACTERIZING BRAIN ANGIOTENSIN SYSTEM. INVESTIGATOR'S SUMMARY: EMERGENCY RELIEF SUPPLEMENT DUE TO COVID-19. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/A2019634S

NAME OF ORGANIZATION OR GOVERNMENT: JOHNS HOPKINS UNIVERSITY. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY QUINCY SAMUS, PHD, ENTITLED: (CA2021001) DISSEMINATION OF MIND AT HOME DEMENTIA CARE MODEL TO DRIVE HEALTH CARE TRANSFORMATION AND GREATER VALUE. INVESTIGATOR'S SUMMARY: INFORMED BY DECADES OF DEMENTIA CARE CLINICAL EXPERTISE, BEST PRACTICE RECOMMENDATIONS, AND CLINICAL STUDIES, MIND AT HOME IS AN EFFECTIVE, COMPREHENSIVE, HOMEBASED DEMENTIA CARE COORDINATION MODEL THAT SYSTEMATICALLY ASSESSES AND ADDRESSES A BROAD RANGE OF DEMENTIARELATED CARE NEEDS THAT PLACE ELDERS AT RISK FOR HEALTH DISPARITIES, HOSPITALIZATIONS, UNWANTED LONG TERM CARE PLACEMENT, POOR

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

QUALITY OF LIFE AND FAMILY CAREGIVERS AT RISK FOR BURNOUT AND HEALTH IMPACTS. YET TRANSLATION INTO PRACTICE HAS BEEN SLOW PRIMARILY DUE LACK OF DATA ON ITS POTENTIAL FOR RETURN ON INVESTMENT AND ITS VALUE PROPOSITION TO HEALTH SYSTEMS, HEALTH PLANS, AND PROVIDERS, AS WELL LACK OF DATA ON HOW TO EFFECTIVELY REFINE THE MODEL TO INTEGRATE INTO EXISTING HEALTH CARE DELIVERY ENVIRONMENTS. THIS GRANT SUPPORTS A PARTNERSHIP WITH UNIVERSITY OF MARYLAND BALTIMORE COUNTY, JADE GONG & ASSOCIATES LLC, AND JOHNS HOPKINS HOME CARE GROUP, WITH THE SUPPORT OF MARYLAND PRIMARY CARE PROGRAM, MARYLAND MEDICAID, AND JOHNS HOPKINS ALLIANCE FOR PATIENTS TO STRATEGICALLY ADVANCE THE DISSEMINATION AND TRANSLATION OF JOHN HOPKINS UNIVERSITY'S EVIDENCEBASED MIND AT HOME MODEL, IN THE CONTEXT OF MARYLAND'S NEW PRIMARY CARE PROGRAM (MDPCP) AS A TRANSFORMATIVE TOOL TO ACHIEVE GREATER CARE COORDINATION AND VALUE FOR A VULNERABLE COGNITIVELY IMPAIRED POPULATION. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/CA2021001

NAME OF ORGANIZATION OR GOVERNMENT: FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH, ENTITLED: (CA2021012) PRE-COMPETITIVE ANALYTICAL VALIDATION OF SV2A PET IMAGING AS A BIOMARKER OF SYNAPTIC DENSITY. INVESTIGATOR'S SUMMARY: THE SV2A PET PROJECT AIMS TO DEMONSTRATE THE RELIABILITY OF SV2A PET IMAGING AS A BIOMARKER OF SYNAPTIC DENSITY IN ALZHEIMER'S DISEASE AND ACCELERATE THE APPLICATION OF SV2A PET AS A TREATMENT RESPONSE MARKER IN DISEASE-MODIFYING CLINICAL TRIALS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/CA2021012

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

NAME OF ORGANIZATION OR GOVERNMENT: BOSTON UNIVERSITY SCHOOL OF MEDICINE. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY BENJAMIN WOLOZIN, MD, PHD ENTITLED: (CA2020002) DEVELOPMENT OF SYNTHETIC GENE FEEDBACK CIRCUITS TO PREVENT TAU AGGREGATION. INVESTIGATOR'S SUMMARY: THIS PROPOSAL USES A RADICALLY NOVEL APPROACH TERMED "SYNTHETIC BIOLOGY", WHICH USES CONCEPTS FROM ELECTRICAL ENGINEERING TO DESIGN NEW TYPES OF GENETIC THERAPY FOR ALZHEIMER'S DISEASE (AD). WE WILL CREATE NEW SYNTHETIC GENE CIRCUITS THAT CAN DETECT AND THEN REMOVE HARMFUL TAU PATHOLOGY AS IT APPEARS IN THE BRAINS OF PATIENTS WITH AD. THESE NEW THERAPIES WILL SELECTIVELY TARGET ONLY THOSE NERVE CELLS THAT ACTUALLY HAVE PATHOLOGY, INCREASING THE EFFECTIVENESS WHILE REDUCING THE POTENTIAL FOR UNWANTED SIDE EFFECTS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/CA2020002

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF DENVER. (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY ANN CHARLOTTE GRANHOLM-BENTLEY, PHD, ENTITLED: (CA2018010) INTERNATIONAL BRAIN BANK FOR DOWN SYNDROME-RELATED ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: THE FOCUS OF THIS SPECIAL PROJECT IS TO DEVELOP A STRONG COLLABORATE NETWORK BETWEEN SIX DIFFERENT RESEARCH GROUPS FOCUSED ON PROVIDING MUCH-NEEDED INFORMATION ABOUT THE DOWN SYNDROME POPULATION, OF WHICH AS MANY AS 80 PERCENT HAVE ALZHEIMER'S PATHOLOGY BY THE TIME THEY ARE IN THEIR 50S AND 60S. ALTHOUGH THERE ARE MANY CENTERS AND RESEARCHERS THAT FOCUS ON ALZHEIMER'S IN THE GENERAL POPULATION, FEW OF THEM FOCUS ON PEOPLE WITH DOWN SYNDROME. THE INFORMATION GENERATED BY OUR PROJECT WILL BE OF GREAT HELP TO THOSE WITH DOWN SYNDROME AND THOSE WITH ALZHEIMER'S DISEASE. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS

WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/CA2018010

SCHEDULE I, PART II, LINE 1, COLUMN (H), CONTINUED:

NAME OF ORGANIZATION OR GOVERNMENT: INDIANA UNIVERSITY. (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY ALESSANDRA CARMICHAEL-MARTINS, PHD, ENTITLED: (G2022001F) ADAPTIVE OPTICS OPTICAL COHERENCE TOMOGRAPHY AND SCANNING LASER GONIOSCOPY OF THE HUMAN TRABECULAR MESHWORK IN VIVO. INVESTIGATOR'S SUMMARY: ELEVATED INTRAOCULAR PRESSURE, THE MAJOR RISK FACTOR IN GLAUCOMA, IS PRIMARILY CONTROLLED BY THE RATE OF AQUEOUS OUTFLOW THROUGH THE TRABECULAR MESHWORK AND SCHLEMM'S CANAL. IN POST-MORTEM HUMAN TISSUE, CHANGES TO THESE STRUCTURES ARE ASSOCIATED WITH GLAUCOMA, AND MANY GLAUCOMA TREATMENTS TARGET THIS REGION. THIS PROPOSAL WILL ENABLE RESEARCHERS AND CLINICIANS TO ACHIEVE THREE DIMENSIONAL IMAGES OF THE DRAINAGE STRUCTURES IN THE LIVING HUMAN EYE AT CELLULAR-LEVEL RESOLUTION, ALLOWING A DEEPER UNDERSTANDING OF CHANGES WITHIN THE TRABECULAR MESHWORK ASSOCIATED WITH AGE, GLAUCOMA, AND TREATMENT. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2022001F

NAME OF ORGANIZATION OR GOVERNMENT: INDIANA UNIVERSITY. (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY CATIA GOMES, PHD, ENTITLED: (G2022003F) THE ROLE OF REACTIVE ASTROCYTE-ASSOCIATED COMPLEMENT C3 IN GLAUCOMATOUS NEURODEGENERATION. INVESTIGATOR'S SUMMARY: GLAUCOMA IS CHARACTERIZED BY RETINAL GANGLION CELLS (RGCS) DYSFUNCTION AND LOSS. REACTIVE ASTROCYTES CLOSELY ASSOCIATE WITH RGCS IN THE OPTIC NERVE HEAD, WHERE THE INITIAL INSULT TO RGC AXONS OCCURS. A SPECIFIC NEUROTOXIC PHENOTYPE OF REACTIVE ASTROCYTES WAS RECENTLY IDENTIFIED. TO STUDY SUCH NEUROTOXIC EFFECTS, RGCS AND ASTROCYTES WILL BE

DIFFERENTIATED FROM HUMAN PLURIPOTENT STEM CELLS, AND MICROFLUIDIC PLATFORMS USED TO ALLOW THE SPECIFIC ANALYSIS OF RGC AXONS. IDENTIFYING REACTIVE ASTROCYTE-INDUCED AXONAL DEGENERATION PATHWAYS WILL ALLOW FOR THE DEVELOPMENT OF NOVEL THERAPEUTIC STRATEGIES. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2022003F

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH. (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY PRABHAVATHI MADDINENI, PHD, ENTITLED: (G2022004F) EFFECT OF OCULAR HYPERTENSION ON SYNAPTIC FUNCTION AND PLASTICITY IN GLAUCOMATOUS NEURODEGENERATION. INVESTIGATOR'S SUMMARY: GLAUCOMA IS AN EYE DISEASE THAT CAN CAUSES BLINDNESS BY DAMAGING THE OPTIC NERVE. THE JOB OF THE OPTIC NERVE IS TO TRANSFER VISUAL INFORMATION FROM EYE TO THE BRAIN VIA ELECTRICAL IMPULSES. IN GLAUCOMA, AN INCREASED OCULAR PRESSURE CAUSES OPTIC NERVE DEGENERATION. SINCE OPTIC NERVE IS THE PART OF CENTRAL NERVOUS SYSTEM AND CONNECTED TO THE BRAIN, PRESSURE INDUCED OPTIC NERVE DAMAGE MAY ALSO DAMAGE SURROUNDING CELLS AND NEURONS IN THE BRAIN. IN THIS PROPOSAL, WE WILL STUDY HOW NEURONS IN THE BRAIN COMMUNICATE WITH EACH OTHER IN RESPONSE TO PRESSURE INDUCED DAMAGE. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2022004F

NAME OF ORGANIZATION OR GOVERNMENT: JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE. (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY THOMAS JOHNSON, MD, PHD, ENTITLED: (G2022005S) IN VIVO ADAPTIVE OPTICS OPHTHALMOSCOPY TO CHARACTERIZE FUNCTIONAL RETINAL INTEGRATION OF TRANSPLANTED RGCS USING A NOVEL TRANSGENIC REPORTER PARADIGM. INVESTIGATOR'S SUMMARY: STEM CELL TRANSPLANTATION THERAPY HAS THE

POTENTIAL TO RESTORE VISION FOR TENS OF MILLIONS OF PEOPLE WORLDWIDE SUFFERING FROM OPTIC NERVE DISEASES SUCH AS GLAUCOMA. TO HELP USHER THIS NEW APPROACH TOWARDS TREATING HUMAN PATIENTS, WE PROPOSE TO DEVELOP A NOVEL, SENSITIVE, RAPID EXPERIMENTAL TOOL THAT LABELS SUCCESSFUL INTEGRATION OF TRANSPLANTED NEURONS IN THE RETINAS OF RECIPIENT EYES, AND TO RIGOROUSLY VALIDATE THE EXPERIMENTAL FRAMEWORK USING MULTIPLE COMPLIMENTARY TECHNIQUES THAT INCLUDE HIGH-RESOLUTION THREE-DIMENSIONAL MICROSCOPY AND MEASUREMENTS OF ELECTRICAL RESPONSES TO LIGHT. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2022005S

NAME OF ORGANIZATION OR GOVERNMENT: GOOD SAMARITAN FOUNDATION (LHS). (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY KAZUHIRO KUROKAWA, PHD, ENTITLED: (G2022006S) MULTIFUNCTIONAL CELLULAR-SCALE IMAGING IN THE LIVING RETINA TO STUDY GLAUCOMA PATHOPHYSIOLOGY. INVESTIGATOR'S SUMMARY: THE CURRENT APPROACH USED BY EYE DOCTORS TO DETECT GLAUCOMA AND ITS PROGRESSION IS BASED ON SIGNS THAT REPRESENT IRREVERSIBLE DAMAGE, NAMELY LOSS OF VISION AND CELLS OF THE OPTIC NERVE. NEW WAYS ARE NEEDED FOR DETECTING DAMAGE EARLIER, AT A POINT WHEN TREATMENT COULD PRESERVE VISION, AND EVEN RESTORE THE HEALTH OF THE EYE AND OPTIC NERVE BEFORE IRREVERSIBLE DAMAGE OCCURS. WE PROPOSE TO CONSTRUCT AND TEST A NEW ADVANCED MULTIFUNCTIONAL IMAGING SYSTEM CAPABLE OF REVEALING ASTOUNDING DETAILS IN THE LIVING EYE AS SMALL AS SINGLE CELLS AND TRANSFORMING THE FUTURE OF CLINICAL TESTING FOR GLAUCOMA. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2022006S

NAME OF ORGANIZATION OR GOVERNMENT: MICHIGAN STATE UNIVERSITY. (H)

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY ANDRAS KOMAROMY, DVM, PHD, ENTITLED: (G2022007S) TARGETING EXERCISE FOR NEUROPROTECTION IN GLAUCOMA. INVESTIGATOR'S SUMMARY: GLAUCOMA IS A LEADING CAUSE OF PERMANENT VISION LOSS DUE TO PROGRESSIVE DEGENERATION OF THE OPTIC NERVE THAT TRANSMITS VISUAL INFORMATION FROM EYE TO BRAIN. THE ONLY PROVEN METHOD TO TREAT GLAUCOMA AND SLOW VISION LOSS IS BY LOWERING EYE PRESSURE, BUT GLAUCOMA PROGRESSES DESPITE SUCH THERAPY. IN DOGS WITH NATURALLY-OCCURRING GLAUCOMA, WE WILL THUS DETERMINE IF REGULAR, MODERATE-INTENSITY EXERCISE CAN SLOW GLAUCOMA DISEASE PROGRESSION, AS SUGGESTED BY EXPERIMENTAL MODELS IN MICE AND RATS. EXERCISE WOULD PROVIDE AN EASY, LOW-COST, BENEFICIAL THERAPY AVENUE FOR GLAUCOMA PATIENTS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2022007S

SCHEDULE I, PART II, LINE 1, COLUMN (H), CONTINUED:

NAME OF ORGANIZATION OR GOVERNMENT: GOOD SAMARITAN FOUNDATION (LHS).

(H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY HONGLI YANG, PHD, ENTITLED: (G2022008S) NOVEL TECHNIQUES TO CORRELATE STRUCTURAL AND MOLECULAR ALTERATIONS IN NON-HUMAN PRIMATE EARLY GLAUCOMA. INVESTIGATOR'S SUMMARY: THIS PROPOSAL'S GOAL IS TO IDENTIFY THE CELLULAR AND MOLECULAR ALTERATIONS UNDERLYING LONGITUDINAL STRUCTURAL CHANGE IN AN EXPERIMENTAL GLAUCOMA MONKEY MODEL. WE PROPOSE TO DEVELOP AND OPTIMIZE NOVEL METHODS TO AUTOMATICALLY COLOCALIZE POST-MORTEM IMMUNOHISTOCHEMISTRY IMAGES TO IN VIVO OPTICAL COHERENCE TOMOGRAPHY (OCT) SCANS. OVERALL, THIS PROJECT WILL INFORM AND ENHANCE THE INTERPRETATION OF HUMAN OCT IMAGING, ADVANCE OUR UNDERSTANDING OF PATHOPHYSIOLOGIC MECHANISMS IN GLAUCOMA, AND PROVIDE GUIDANCE TO IMPROVE THERAPEUTIC OPTIONS BEFORE GLAUCOMATOUS DAMAGE BECOMES

PERMANENT AND UNTREATABLE. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2022008S

NAME OF ORGANIZATION OR GOVERNMENT: CEDARS-SINAI MEDICAL CENTER. (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY SHAOMEI WANG, MD, PHD, ENTITLED: (G2022009S) NEURAL PROGENITOR CELL ENGINEERED TO EXPRESS TROPHIC FACTOR FOR TREATING GLAUCOMA. INVESTIGATOR'S SUMMARY: ELEVATED INTRAOCULAR PRESSURE (IOP) IS A PROMINENT MANIFESTATION OF GLAUCOMA, A CHRONIC, PROGRESSIVE OPTIC NEUROPATHY CHARACTERIZED BY LOSS OF RETINAL GANGLION CELLS (RGCS) AND VISUAL FIELD DEFECTS. ACCUMULATING EVIDENCE HAS SHOWN THE SITE OF IOP INDUCED AXONAL DAMAGE IS THE OPTIC NERVE HEAD (ONH), WHERE ASTROCYTES RETRACT ITS PROCESSES AND FAIL TO PROVIDE ESSENTIAL METABOLIC AND TROPHIC SUPPORT TO RGCS. THE NOVEL APPROACH OF THIS STUDY IS TO DELIVER A COMBINED STEM CELL AND GENE THERAPY CLOSE TO THE SITE OF DISEASE TO PROTECT RGCS FROM SECONDARY DEGENERATION IN A RODENT MODEL OF GLAUCOMA. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2022009S

NAME OF ORGANIZATION OR GOVERNMENT: DUKE UNIVERSITY SCHOOL OF MEDICINE. (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY MYOUNGSUP SIM, PHD, ENTITLED: (G2022010S) AUTOPHAGY REGULATES ENDOTHELIAL NITRIC OXIDE (NO)SYNTHASE/NO IN SCHLEMM'S CANAL CELLS IN RESPONSE TO SHEAR STRESS. INVESTIGATOR'S SUMMARY: SEVERAL STUDIES HAVE SHOWN THAT NITRIC OXIDE (NO) LOWERS EYE PRESSURE. MORE, A NOVEL NO-DONATING DRUG (LATANOPROSTENE BUNOD) HAS BEEN RECENTLY APPROVED TO LOWER EYE PRESSURE IN PATIENTS WITH GLAUCOMA. HOWEVER, MOST OF THE NO-BASED DRUGS HAVE FAILED TO BE APPROVED BY FDA DUE TO SOME CHALLENGES RELATED TO THE EXOGENOUS DELIVERY OF NO, SUCH AS UNCONTROLLED NO RELEASE, SUGGESTING

THAT REGULATION OF ENDOGENOUS NO PRODUCTION COULD REPRESENT A BETTER STRATEGY FOR GLAUCOMA TREATMENT. HERE, WE SEEK TO INVESTIGATE HOW TO REGULATE ENDOGENOUS NO PRODUCTION TO IMPROVE THE CURRENT NO-BASED GLAUCOMA THERAPY. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2022010S

NAME OF ORGANIZATION OR GOVERNMENT: VANDERBILT UNIVERSITY MEDICAL CENTER. (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY MICHAEL RISNER, PHD, ENTITLED: (G2022011S) HARNESSING INTERCELLULAR MITOCHONDRIAL TRANSFER IN HUMAN-DERIVED RETINAL CELLS TO TREAT GLAUCOMA. INVESTIGATOR'S SUMMARY: GLAUCOMA IS AN AGE-RELATED NEURODEGENERATIVE DISEASE, CAUSING IRREVERSIBLE BLINDNESS THROUGH RETINAL GANGLION CELL DEATH. GLAUCOMA IS TYPICALLY TREATED BY LOWING INTRAOCULAR PRESSURE. HOWEVER, MANY PATIENTS DO NOT PRODUCE A ROBUST RESPONSE TO THIS TREATMENT AND CONTINUE TO LOSE VISION. FOR THESE PEOPLE, CELL REPLACEMENT THERAPY MAY BE THE ONLY OPTION. THE MOST IMPORTANT POINT OF THIS PROPOSAL IS UNDERSTANDING THE METABOLIC INTERACTION BETWEEN HEALTHY AND STRESSED CELLS IN THE CONTEXT OF CELL TRANSPLANTATION FOR THE TREATMENT OF GLAUCOMA. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2022011S

NAME OF ORGANIZATION OR GOVERNMENT: EMORY UNIVERSITY. (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY JIAXING WANG, PHD, ENTITLED: (G2022012S) GENETIC MUTATION ENHANCE OPTIC NERVE REGENERATION IN BXD29 MOUSE STRAIN. INVESTIGATOR'S SUMMARY: THE DAMAGE TO THE OPTIC NERVE LEADS TO BLINDNESS IN MANY DISEASES SUCH AS GLAUCOMA. WE ARE LOOKING FOR GENES THAT COULD MODULATE THE OPTIC NERVE REGENERATION TO SAVE VISION. WE HAVE FOUND A MOUSE MUTANT WITH ENHANCED REGENERATION

RESPONSE THAT IS CARRYING SUCH GENE AND WE ARE WORKING TO IDENTIFY IT. ONCE WE HAVE IT IDENTIFIED, WE WILL TEST THE FUNCTION OF THE GENE AND SEE HOW DOES IT ALTER THE REGENERATION RESPONSE. THIS MAY LEAD TO A CLINICAL INTERVENTION FOR THE TREATMENT OF BLINDNESS DUE TO OPTIC NERVE DAMAGE. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2022012S

NAME OF ORGANIZATION OR GOVERNMENT: TRUSTEES OF BOSTON UNIVERSITY. (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY HAIYAN GONG, MD, PHD, ENTITLED: (G2022013S) INVESTIGATIONS OF SEGMENTAL UVEAL AQUEOUS OUTFLOW. INVESTIGATOR'S SUMMARY: UVEAL OUTFLOW, ONE OF TWO ROUTES FOR FLUID DRAINAGE FROM THE EYE, PLAYS A ROLE IN MAINTAINING NORMAL PRESSURE INSIDE THE EYE (IOP). GLAUCOMA, A POTENTIALLY BLINDING DISEASE OFTEN ASSOCIATED WITH HIGH IOP, CAN BE TREATED BY IMPROVING FLUID DRAINAGE OUT OF THE EYE AND DECREASING IOP. PROSTAGLANDIN ANALOGUE DRUGS LOWER IOP IN GLAUCOMA BY INCREASING UVEAL OUTFLOW. OUR RECENT STUDIES FOUND THAT UVEAL OUTFLOW IS SEGMENTAL OR NON-UNIFORM AROUND EYE, THOUGH IT IS UNCLEAR WHAT FACTORS REGULATE IT. THIS STUDY AIMS TO FURTHER INVESTIGATE SEGMENTAL UVEAL OUTFLOW AND THE FACTORS THAT MAY REGULATE IT. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2022013S

SCHEDULE I, PART II, LINE 1, COLUMN (H), CONTINUED:
NAME OF ORGANIZATION OR GOVERNMENT: INDIANA UNIVERSITY. (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY JASON MEYER, PHD, ENTITLED: (G2022014S) EXPLORING THE ROLE OF THE APBB2 RISK VARIANT IN GLAUCOMA WITH HUMAN INDUCED PLURIPOTENT STEM CELLS. INVESTIGATOR'S SUMMARY: AFRICAN AMERICANS ARE AT A SIGNIFICANTLY HIGHER RISK FOR GLAUCOMA

COMPARED TO OTHER ETHNICITIES. RECENTLY, A VARIANT IN THE APBB2 GENE WAS IDENTIFIED TO BE SIGNIFICANTLY ASSOCIATED WITH GLAUCOMA IN AFRICAN AMERICANS, REPRESENTING A NOVEL OPPORTUNITY TO EXPLORE THE DEGENERATION OF RGCS ASSOCIATED WITH THIS INCREASED RISK. THE OVERALL GOALS OF THIS APPLICATION FOCUS UPON THE USE OF HUMAN INDUCED PLURIPOTENT STEM CELLS, AS WELL AS CRISPR/CAS9 GENE EDITING, AS AN IN VITRO MODEL TO STUDY THE EFFECTS OF THIS GENE VARIANT ON RGCS AND IDENTIFY HOW IT MAY LEAD TO GLAUCOMATOUS NEURODEGENERATION. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2022014S

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA DAVIS. (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY NICK MARSH-ARMSTRONG, PHD, ENTITLED: (G2022016S) LIVE IMAGING TO DETERMINE WHETHER MITOCHONDRIA AND AMYLOID BETA AXONAL RELEASES ARE LINKED. INVESTIGATOR'S SUMMARY: THIS PROPOSAL WILL USE LIVE IMAGING OF THE OPTIC NERVE IN YOUNG TADPOLES TO DETERMINE WHETHER AN AGENT BELIEVED TO BE CENTRAL TO ALZHEIMER'S DISEASE MIGHT BE BEING RELEASED FROM AXONS TOGETHER WITH MITOCHONDRIA. IF ITS RELEASE IS LINKED TO THAT OF MITOCHONDRIA, IT WOULD HAVE PROFOUND IMPLICATIONS FOR BOTH ALZHEIMER'S DISEASE AND GLAUCOMA. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2022016S

NAME OF ORGANIZATION OR GOVERNMENT: THE UNIVERSITY OF IOWA. (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY MICHAEL ANDERSON, PHD, ENTITLED: (G2022017S) TESTING THE INFLUENCE OF PODOSOMES ON INTRAOCULAR PRESSURE. INVESTIGATOR'S SUMMARY: THERE ARE ONGOING NEEDS FOR IMPROVED GLAUCOMA THERAPIES. ONE APPROACH IS TO FIND NEW WAYS TO DECREASE AQUEOUS HUMOR OUTFLOW RESISTANCE AND THEREBY LOWER INTRAOCULAR

PRESSURE. HERE, WE TEST THE ROLE OF SMALL FINGERLIKE PROTRUSIONS OF CELLS CALLED "PODOSOMES". OUR EXPERIMENTS USE MICE TO MANIPULATE PODOSOMES AND ASSESS WHETHER THIS CHANGES INTRAOCULAR PRESSURE. THIS WORK WILL LEAD TO IMPORTANT INFORMATION ABOUT THE CELL BIOLOGY OF GLAUCOMA, PERHAPS IDENTIFYING THE PRECISE MOLECULAR LOCATION OF OUTFLOW RESISTANCE, AND MAY POINT TO COMPOUNDS ALTERING PODOSOMES AS POTENTIAL NEW GLAUCOMA THERAPIES. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/G2022017S

NAME OF ORGANIZATION OR GOVERNMENT: STANFORD UNIVERSITY. (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY JEFFREY GOLDBERG, PHD, ENTITLED: (CG2022001) A RANDOMIZED, SHAM CONTROLLED, MASKED PHASE II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF DUAL INTRAVITREAL IMPLANTATION OF NEUROPROTECTIVE CELL THERAPY FOR THE TREATMENT OF GLAUCOMA. INVESTIGATOR'S SUMMARY: THE PROPOSED PROJECT IS AN EXTENSION OF THE CURRENT PHASE 2 CLINICAL TRIAL, TO ASSESS AND VALIDATE THE USE OF DUAL NT-501 CNTF ENCAPSULATED CELL THERAPY (ECT) ON VISUAL IMPAIRMENT RELATED TO GLAUCOMA, IN HUMAN SUBJECTS. THE PROPOSED STUDY IS DESIGNED TO EXPAND OUR KNOWLEDGE OF THE DOSE-DEPENDENT EFFECT OF CNTF IN GLAUCOMA THROUGH DUAL IMPLANTATION OF NT-501 ECT. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/CG2022001

NAME OF ORGANIZATION OR GOVERNMENT: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY YONGSU KWON, PHD, ENTITLED: (M2022001F) NANOCERIA-COATED MELANIN NANOPARTICLES AS A NOVEL ANTIOXIDANT FOR AGE-RELATED MACULAR DEGENERATION. INVESTIGATOR'S SUMMARY: THIS STUDY AIMS TO DEVELOP A

COMBINATION OF A NEW ANTIOXIDANT SYSTEM TO SCAVENGE FREE RADICALS (TOXIC WASTE PRODUCTS THAT GRADUALLY BUILD UP IN THE CELLS OVER TIME), WHICH CAN POTENTIALLY ACHIEVE LONG-TERM EFFECTS AND REDUCE THE DAMAGE IN AMD. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2022001F

SCHEDULE I, PART II, LINE 1, COLUMN (H), CONTINUED:
NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF WASHINGTON. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY DANIEL HASS, PHD, ENTITLED: (M2022003F) DISINHIBITION OF FATTY ACID OXIDATION TO DISPOSE OF DRUSEN COMPONENTS. INVESTIGATOR'S SUMMARY: THIS STUDY DETERMINES THE EFFECT OF A SMALL MOLECULE ON FATTY ACID METABOLISM, CELL FUNCTION, AND DEPOSIT LEVELS IN MULTIPLE CELL CULTURE AND MOUSE MODELS OF AMD. THIS SMALL MOLECULE HAS BEEN TESTED IN HUMANS IN CLINICAL TRIALS AND IS SAFE, SO IF IT IS ALSO EFFECTIVE AT DECREASING DEPOSIT LEVELS THE TRANSITION TO CLINICAL USE MAY BE MORE RAPID THAN FOR UNTESTED TREATMENTS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2022003F

NAME OF ORGANIZATION OR GOVERNMENT: THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY STEFFI DANIEL, PHD, ENTITLED: (M2022005F) IDENTIFYING PHARMACEUTICS FOR AMD ASSOCIATED PATHOPHYSIOLOGY. INVESTIGATOR'S SUMMARY: THIS STUDY WILL EMPLOY NOVEL "DISEASE-IN-A-DISH" SYSTEM, TO SCREEN FOR MORE THAN 1500 FDA APPROVED DRUGS FOR THEIR ABILITY TO REVERSE DISEASE. LEAD DRUGS FROM THIS SCREEN WILL ALSO BE EXTENSIVELY AND RIGOROUSLY TESTED IN A PRE-CLINICAL MODEL SYSTEM. IF SUCCESSFUL, THE RESULTS FROM THIS STUDY WILL CONTRIBUTE

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

TOWARDS TRANSFORMING AMD THERAPEUTICS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2022005F

NAME OF ORGANIZATION OR GOVERNMENT: SEATTLE CHILDREN'S HOSPITAL. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY LEAH VANDENBOSCH, PHD, ENTITLED: (M2022006F) MOLECULAR AND MACHINE LEARNING APPROACHES TO NON-CODING RISK IN AGE-RELATED MACULAR DEGENERATION. INVESTIGATOR'S SUMMARY: THIS STUDY WILL APPLY MACHINE LEARNING TO HUMAN RETINAL AND RETINAL PIGMENTED EPITHELIUM GENOMIC DATA TO PREDICT THE EFFECT OF VARIATIONS IN THE NON-CODING REGIONS, THE REGIONS OF DNA WITH NO KNOWN FUNCTION TO CONTRIBUTE DIRECTLY TO AMD. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2022006F

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF ROCHESTER. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY KRISTEN BOWLES JOHNSON, PHD, OD, ENTITLED: (M2022007F) CELLULAR SCALE CHARACTERIZATION OF THE RPE-PHOTORECEPTOR COMPLEX IN PENTOSAN-ASSOCIATED MACULOPATHY; A MODEL FOR GEOGRAPHIC ATROPHY PROGRESSION. INVESTIGATOR'S SUMMARY: IN THIS STUDY, RESEARCHERS WILL USE A CAMERA CALLED AN ADAPTIVE OPTICS OPHTHALMOSCOPE (AOO) TO TAKE PICTURES OF FLUORESCENT CLUMPS IN RPE CELLS AND MEASURE HOW SICK PHOTORECEPTORS AS THE DISEASE PROGRESSES. COMPLETION OF THIS STUDY COULD IDENTIFY BIOMARKERS TO HELP IDENTIFY PATIENTS MOST LIKELY TO BENEFIT FROM A TREATMENT AND DETERMINATION OF TREATMENT EFFICACY. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2022007F

NAME OF ORGANIZATION OR GOVERNMENT: THE REGENTS OF THE UNIVERSITY OF MICHIGAN. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

THOMAS WUBBEN, PHD, ENTITLED: (M2022008N) METABOLIC UNCOUPLING AND AMD: ASSESSING THE ROLE OF PKM2 IN THE BIOENERGETIC CRISIS OF THE OUTER RETINA. INVESTIGATOR'S SUMMARY: AGE-RELATED MACULAR DEGENERATION (AMD) IS A LEADING CAUSE OF VISUAL IMPAIRMENT IN THE ELDERLY. IT AFFECTS NEARLY 200 MILLION PEOPLE WORLDWIDE, AND THIS NUMBER IS EXPECTED TO CONTINUE TO INCREASE IN THE COMING DECADES. WHILE THE EXACT CAUSE OF AMD REMAINS UNKNOWN, DEREGULATION OF CELLULAR METABOLISM IS BELIEVED CRITICAL TO ITS PATHOGENESIS. THIS PROJECT WILL REVEAL THE SIGNIFICANCE OF MODULATING METABOLIC TARGETS IMPORTANT IN MACULAR DEGENERATION, WHICH MAY HAVE IMMEDIATELY TRANSLATABLE APPLICATIONS TO CLINICALLY TREAT PATIENTS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2022008N

NAME OF ORGANIZATION OR GOVERNMENT: OREGON HEALTH & SCIENCE UNIVERSITY. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY YIFAN JIAN, PHD, ENTITLED: (M2022009N) MAPPING OF PHOTORECEPTOR NUCLEAR LAYER USING VOLUMETRIC DIRECTIONAL OCT: APPLICATIONS IN AGE-RELATED MACULAR DEGENERATION. INVESTIGATOR'S SUMMARY: AGE-RELATED MACULAR DEGENERATION (AMD) IS THE MOST COMMON CAUSE OF VISION LOSS IN THE ELDERLY POPULATION. HOWEVER, THERE IS NO TREATMENT OPTION AND VERY LIMITED UNDERSTANDING OF NON-EXUDATIVE AMD, THAT ACCOUNTS FOR MORE THAN 90% OF PATIENTS DIAGNOSED WITH AMD. WE ARE DEVELOPING A NOVEL RETINA IMAGING DEVICE CALLED VOLUMETRIC DIRECTIONAL OPTICAL COHERENCE TOMOGRAPHY WHICH CAN MEASURE A NEW BIOMARKER, THE TRUE THICKNESS OF OUTER NUCLEAR LAYER (ONL). THE ABILITY TO MEASURE ONL COULD LEAD TO IMPROVED UNDERSTANDING OF THE RETINAL DEGENERATION IN AMD, AND THE EFFECTS OF THERAPEUTIC INTERVENTIONS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2022009N

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

SCHEDULE I, PART II, LINE 1, COLUMN (H), CONTINUED:

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF NEVADA, RENO. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY ALBERT GONZALES, PHD, ENTITLED: (M2022010N) LIGHT-DEPENDENT CONSTRICTION OF CHOROID VASCULATURE. INVESTIGATOR'S SUMMARY: THE CURRENT PROPOSAL CHALLENGES THE COMMONLY HELD VIEW THAT CAPILLARY NETWORKS ARE PASSIVE STRUCTURES WHOSE SOLE PURPOSE IS TO PROVIDE A CONDUIT INFRASTRUCTURE FOR BLOOD FLOW. WE WILL EXAMINE THE HOW BLOOD VESSELS CAN RESPOND TO LIGHT AND CHANGE BLOOD FLOW IN THE EYE. THIS PROCESS IS NOT ONLY IMPORTANT FOR THE DELIVERY OF VITAL OXYGEN AND NUTRIENTS FOR CELL SURVIVAL, BUT ALSO FOR THE REMOVAL OF WASTE DEPOSIT THAT CAN LEAD TO DISEASES LIKE AGE-RELATED MACULAR DEGENERATION. COMPLETION OF THE PROPOSAL WILL PROVIDE INSIGHTS INTO THE ACTIVE PHYSIOLOGICAL ROLE OF CAPILLARIES IN CHOROID VASCULATURE. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2022010N

NAME OF ORGANIZATION OR GOVERNMENT: THE REGENTS OF THE UNIVERSITY OF MICHIGAN. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY LEV PRASOV, PHD, ENTITLED: (M2022011N) THE ROLE OF MYRF IN TRANSCRIPTIONAL REGULATION OF RETINAL PIGMENT EPITHELIAL MAINTENANCE. INVESTIGATOR'S SUMMARY: THE RETINAL PIGMENT EPITHELIUM (RPE) IS A SUPPORTING TISSUE THAT IS CRITICAL FOR VISION AND IS IMPLICATED IN THE EARLY PATHOLOGY OF AGE-RELATED MACULAR DEGENERATION (AMD). WE IDENTIFIED A NEW GENE, MYRF, THAT CONTROLS EXPRESSION OF OTHER GENES IN THE RPE AND LEADS TO DYSFUNCTION. OUR PROPOSAL EVALUATES THE ROLE OF THIS GENE IN MAINTAINING ADULT RPE FUNCTION AND ITS ABILITY TO PROTECT AGAINST STRESSES THAT LEAD TO AMD. UNDERSTANDING THIS MAY OPEN NEW AVENUES FOR

TREATMENT OF AMD BY TARGETING THIS GENE OR ITS DOWNSTREAM TARGETS. IT WILL ALSO IMPROVE OUR KNOWLEDGE OF RPE BIOLOGY. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2022011N

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF SOUTH FLORIDA. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY MANAS BISWAL, PHD, ENTITLED: (M2022012N) INVESTIGATING RETINAL PIGMENT EPITHELIUM (RPE) INJURY RESPONSE IN AFRICAN SPINY MICE (ACOMYS). INVESTIGATOR'S SUMMARY: DEGENERATION OF THE NEURAL RETINA AND IN THE RETINAL PIGMENT EPITHELIUM (RPE) IS ASSOCIATED WITH THE ADVANCED ATROPHIC FORM OF DRY-AMD. SINCE PHOTORECEPTORS IN THE NEURAL RETINA AND RPE ARE POSTMITOTIC, THEY CANNOT BE REPLACED ONCE THEY DIE. THEREFORE, THE TREATMENTS BOOSTING THE ENDOGENOUS FACTORS TO STIMULATE RETINAL TISSUE REGENERATION COULD BE A NOVEL THERAPEUTIC STRATEGY. OUR GOAL IS TO STUDY OCULAR REGENERATION FOLLOWING TISSUE INJURY IN AN ANIMAL MODEL THAT COULD FACILITATE STUDIES TO DEVELOP POTENTIAL TREATMENTS FOR DRY-AMD IN HUMANS. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2022012N

NAME OF ORGANIZATION OR GOVERNMENT: JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY SRINIVASA RAO SRIPATHI, PHD, ENTITLED: (M2022014N) SCREENING FOR MOLECULES THAT MODULATE RPE EPITHELIAL-MESENCHYMAL TRANSITION AND RESPONSE TO AMD-RELATED STRESSORS AS LEADS FOR THE TREATMENT OF AMD. INVESTIGATOR'S SUMMARY: AN EARLY EVENT ASSOCIATED WITH AMD IS DAMAGE TO THE RETINAL-PIGMENTED EPITHELIUM (RPE), THE CELLS THAT HELP MAINTAIN PHOTORECEPTOR CELL HEALTH AND FUNCTION. MULTIPLE FACTORS, INCLUDING CIGARETTE SMOKE, HAVE BEEN IDENTIFIED AS BEING IMPORTANT IN INITIATING

AND PROMOTING RPE INJURY. ONE OF THE WAYS THE RPE RESPONDS TO INJURY IS BY A PROCESS KNOWN AS EPITHELIAL-MESENCHYMAL TRANSITION (EMT), WHERE RPE LOSES ITS INTEGRITY. TO DEVELOP NOVEL TREATMENTS FOR AMD, WE PROPOSE TO UTILIZE HUMAN STEM CELL-DERIVED RPE CELLS TO SCREEN FOR MOLECULES (POTENTIAL DRUGS) THAT INHIBIT RPE DAMAGE AND REDUCE EMT. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2022014N

NAME OF ORGANIZATION OR GOVERNMENT: THE JACKSON LABORATORY. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY PATSY NISHINA, PHD, ENTITLED: (M2022016I) TRANSLATIONAL VISION RESEARCH MODELS FOR SUBRETINAL FIBROSIS. INVESTIGATOR'S SUMMARY: TISSUE DAMAGE IN THE BACK OF THE EYE MAY LEAD TO FORMATION OF SCAR TISSUE OR FIBROSIS THAT CAUSES VISION IMPAIRMENT. WE DESCRIBE HERE TWO NEW GENETIC MODELS THAT DEVELOP SUBRETINAL FIBROSIS, A COMMON COMPLICATION OF WET AMD. WE AIM TO DETERMINE HOW CHANGES IN FUNCTION/STRUCTURE AND CELL SIGNALS LEAD TO THE DISEASE USING CLASSIC GENETIC AND MOLECULAR METHODS. WE WILL ALSO TEST VARIOUS DRUGS TO DETERMINE THEIR EFFECTS ON THE DISEASE. AT THE END OF THIS STUDY, WE WILL HAVE ROBUST, WELL CHARACTERIZED SUBRETINAL FIBROSIS MOUSE MODELS AND INSIGHTS INTO PATHWAYS THAT MAY UNDERLIE THE DISEASE. FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/M2022016I

NAME OF ORGANIZATION OR GOVERNMENT: DRUSOLV THERAPUTICS, INC. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY JOHN G. EDWARDS, MS/MBA, ENTITLED: (CM2022001) OCUSTATIN FOR TREATMENT OF INTERMEDIATE AMD. INVESTIGATOR'S SUMMARY: DRUSOLV IS DEVELOPING A HIGH-DOSE ORAL STATIN FOR EARLY INTERVENTION IN A BLINDING EYE DISEASE CALLED

Name of the organization
BRIGHTFOCUS FOUNDATION

Employer identification number
23-7337229

AGE-RELATED MACULAR DEGENERATION (AMD). FOR MORE INFORMATION, VISIT THE BRIGHTFOCUS WEBSITE: WWW.BRIGHTFOCUS.ORG/GRANT/CM2022001

SCHEDULE R (Form 990)

Department of the Treasury
Internal Revenue Service

Related Organizations and Unrelated Partnerships

▶ Complete if the organization answered "Yes" on Form 990, Part IV, line 33, 34, 35b, 36, or 37.

▶ Attach to Form 990.

▶ Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2021

Open to Public Inspection

Name of the organization

BRIGHTFOCUS FOUNDATION

Employer identification number

23-7337229

Part I **Identification of Disregarded Entities.** Complete if the organization answered "Yes" on Form 990, Part IV, line 33.

(a) Name, address, and EIN (if applicable) of disregarded entity	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Total income	(e) End-of-year assets	(f) Direct controlling entity
NATIONAL DEVELOPMENT, LLC - 23-7337229 22512 GATEWAY CENTER DRIVE CLARKSBURG, MD 20871	PROPERTY RENTAL AND MANAGEMENT	MARYLAND	542,987.	3,871,939.	BRIGHTFOCUS FOUNDATION
AMERICAN HEALTH ASSISTANCE, LLC - 23-7337229 22512 GATEWAY CENTER DRIVE CLARKSBURG, MD 20871	OWNER OF BRIGHTFOCUS HEADQUARTERS	MARYLAND	0.	3,319,296.	BRIGHTFOCUS FOUNDATION

Part II **Identification of Related Tax-Exempt Organizations.** Complete if the organization answered "Yes" on Form 990, Part IV, line 34, because it had one or more related tax-exempt organizations during the tax year.

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Exempt Code section	(e) Public charity status (if section 501(c)(3))	(f) Direct controlling entity	(g) Section 512(b)(13) controlled entity? Yes	(g) No

Part III **Identification of Related Organizations Taxable as a Partnership.** Complete if the organization answered "Yes" on Form 990, Part IV, line 34, because it had one or more related organizations treated as a partnership during the tax year.

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(e) Predominant income (related, unrelated, excluded from tax under sections 512-514)	(f) Share of total income	(g) Share of end-of-year assets	(h) Disproportionate allocations? Yes	(h) No	(i) Code V-UBI amount in box 20 of Schedule K-1 (Form 1065)	(j) General or managing partner? Yes	(j) No	(k) Percentage ownership

Part IV **Identification of Related Organizations Taxable as a Corporation or Trust.** Complete if the organization answered "Yes" on Form 990, Part IV, line 34, because it had one or more related organizations treated as a corporation or trust during the tax year.

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(e) Type of entity (C corp, S corp, or trust)	(f) Share of total income	(g) Share of end-of-year assets	(h) Percentage ownership	(i) Section 512(b)(13) controlled entity? Yes	(i) No

Part V **Transactions With Related Organizations.** Complete if the organization answered "Yes" on Form 990, Part IV, line 34, 35b, or 36.

Note: Complete line 1 if any entity is listed in Parts II, III, or IV of this schedule.		Yes	No
1 During the tax year, did the organization engage in any of the following transactions with one or more related organizations listed in Parts II-IV?			
a Receipt of **(i)** interest, **(ii)** annuities, **(iii)** royalties, or **(iv)** rent from a controlled entity	1a		
b Gift, grant, or capital contribution to related organization(s)	1b		
c Gift, grant, or capital contribution from related organization(s)	1c		
d Loans or loan guarantees to or for related organization(s)	1d		
e Loans or loan guarantees by related organization(s)	1e		
f Dividends from related organization(s)	1f		
g Sale of assets to related organization(s)	1g		
h Purchase of assets from related organization(s)	1h		
i Exchange of assets with related organization(s)	1i		
j Lease of facilities, equipment, or other assets to related organization(s)	1j		
k Lease of facilities, equipment, or other assets from related organization(s)	1k		
l Performance of services or membership or fundraising solicitations for related organization(s)	1l		
m Performance of services or membership or fundraising solicitations by related organization(s)	1m		
n Sharing of facilities, equipment, mailing lists, or other assets with related organization(s)	1n		
o Sharing of paid employees with related organization(s)	1o		
p Reimbursement paid to related organization(s) for expenses	1p		
q Reimbursement paid by related organization(s) for expenses	1q		
r Other transfer of cash or property to related organization(s)	1r		
s Other transfer of cash or property from related organization(s)	1s		

2 If the answer to any of the above is "Yes," see the instructions for information on who must complete this line, including covered relationships and transaction thresholds.

	(a) Name of related organization	**(b)** Transaction type (a-s)	**(c)** Amount involved	**(d)** Method of determining amount involved
(1)				
(2)				
(3)				
(4)				
(5)				
(6)				

Part VI **Unrelated Organizations Taxable as a Partnership.** Complete if the organization answered "Yes" on Form 990, Part IV, line 37.

Provide the following information for each entity taxed as a partnership through which the organization conducted more than five percent of its activities (measured by total assets or gross revenue) that was not a related organization. See instructions regarding exclusion for certain investment partnerships.

(a) Name, address, and EIN of entity	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Predominant income (related, unrelated, excluded from tax under sections 512-514)	(e) Are all partners sec. 501(c)(3) orgs.? Yes	(e) No	(f) Share of total income	(g) Share of end-of-year assets	(h) Disproportionate allocations? Yes	(h) No	(i) Code V-UBI amount in box 20 of Schedule K-1 (Form 1065)	(j) General or managing partner? Yes	(j) NO	(k) Percentage ownership

Part VII Supplemental Information

Provide additional information for responses to questions on Schedule R. See instructions.